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ABSTRACT
Bovine papillomavirus type 4 (BPV 4) infects the upper alimentary canal 
of cattle causing benign papillomas which can progress to squamous carcinomas 
in cattle grazing on bracken fern (BF). A single treatment with quercetin, a well 
characterised and potent mutagen found in BF, can cause full oncogenic 
transformation of cells partially transformed by BPV-4. Quercetin elevates the 
activity of the BPV-4 enhancer/promoter element (LCR) by up to four fold but this 
cannot fully explain the observed effect as the timing of quercetin exposure is 
critical for full transformation of the cells. We show that quercetin exposure 
arrests normal PalF cells in the G1 phase of the cell cycle, and this G1 arrest 
correlates with an increase in p53 protein levels and transcriptional activity.
Cells transformed by expression of either BPV 4 E7 and Ha-ras or the 
BPV4 genome and Ha-ras, fail to arrest in G1 after subsequent quercetin 
treatments. In these cells which are transformed but non-tumorigenic, p53 protein 
is elevated and transcriptionally activated in response to quercetin exposure. Yet 
the lack of cell cycle arrest is probably due to the viral protein E7 inhibiting
p2iW afl/C ipl
In the transformed tumorigenic cells the failure to arrest in the G1 phase of 
the cell cycle is also evident. p53 protein is still present and even its stabilisation 
in response to quercetin can be observed in some cell lines, however p53 
transcriptional activity is inhibited, probably as a result of p53 mutation. 
Additionally the protein which mediates p53 dependent cell cycle arrest, 
p21Wafl/Cipl, js aiSo absent from all the tumorigenic cells lending further evidence 
to the loss of p53 as a transcriptional activator.
Here we propose a model in which in normal cells quercetin induces G1 
arrest, mediated by p53. Abrogation of this arrest by BPV-4 E7 allows the cell to 
proliferate allowing the accumulation of inheritable damage, including mutations
XVIII
of the p53 gene at later stages. The net effect of this is full tumorigenic 
transformation of the cell.
XIX
Chapter One Introduction
CHAPTER ONE 
INTRODUCTION
1.1 Multistage Nature of Cancer
Along with heart disease and strokes, cancer is one of the major causes of 
death in the western world, indeed 1 in 5 humans will develop cancer (Franks and 
Teich, 1991). There is a considerable international effort to seek understanding of 
the nature and causes of this disease in a hope to discover means to cure and 
prevent the different types of cancer.
It is believed that cancer arises through a complex series of interactions 
between environmental and genetic factors (Pike and Forman, 1991; Henderson et 
al, 1991, for review), resulting in genetic lesions in the cell. As the cell 
accumulates successive genetic lesions the regulation and function of more key 
cellular regulator genes is altered. The cell will then develop the ability to override 
the normal checkpoints and the ability to penetrate the basement membrane and to 
invade surrounding tissues and resulting in an expanding population of cells 
which has the ability to metastasise to other regions of the organism.
The hypothesis of clonal expansion (Nowell, 1976) puts forward the 
notion that a single progenitor cell begins to proliferate abnormally. Further 
damage is then caused which permits further clonal expansion and so the cycle 
continues. Thus after sufficient genetic lesions have occurred the checkpoints that 
regulate cellular proliferation are over-ridden and a malignant tumour is formed.
The number of genetic lesions required were estimated to be anywhere 
from three to seven independent lesions (Renan, 1993). Recent work in human 
primary cells has demonstrated that as little as 3 initial changes to the cell 
(impacting on multiple cellular signalling pathways) can cause full transformation 
(Hahn et al., 1999).
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Evidence for this multi-stage nature of cancer comes from initial 
epidemiological analysis of colon and cervical cancer. There is clear evidence in 
the case of colon cancer that the condition comes from an evolution of benign 
adenomas which progress to become malignant tumours (Sugerbaker et al, 1985). 
This kind of morphological evolution is also seen in cancer of the cervix which is 
classified according to the degree of cellular disruption (CIN 1-3, in increasing 
severity) (Richart, 1968).
The features taken into account when making a diagnosis of O N  grade
are:
1. Differentiation (maturation, stratification)
a) Present or absent
b) Proportion of epithelium showing differentiation
2. Nuclear abnormalities
a) Nucleus : Cytoplasmic ratio
b) Hyperchromasia
c) Nuclear pleomorphism and anisokaryosis
3. Mitotic activty
a) Number of mitotic figures
b) Height of mitosis in the epithelium
c) Abnormal configurations
The different grade of CIN may be characterised in the following way:
CIN 1:
Maturation in upper two thirds of epithelium 
Slight nuclear atypia to surface
Most nuclear abnormalities and mitotic figure in basal third and are slight 
CIN 2: (As CIN1 except)
Nuclear atypia persists to surface but is more marked 
Maturation present in upper half of epithelium 
Mitotic figures found in basal half of epithelium 
Abnormal configurations may also be seen
2
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CIN3:
No maturation, or confined to superficial third of epitheliumm 
Marked nuclear abnormalities and mitotic figure throughout 
Abnormal mitotic figures are frequent
This morphological evolution of this cancer was backed up by molecular 
analysis discovering the activation of cellular genes during malignant progression 
(Roiu et al, 1985).
There are thought to be 3 main stage of carcinogenesis: Initiation, 
promotion and progression. This model was observed easily in the mouse skin 
model (Hecker et al, 1982) which proved useful for study due to it being well 
documented and easily controlled.
The initiation step involves the accumulation of a series of genetic lesions 
caused by genotoxic agents. This DNA damage was triggered by treatment of the 
mouse skin, with the drug DMBA (7-12-dimethylbenz[a]anthracene). The drug 
causes DNA damage and leads to mutation in the c-Ha-ras gene (Quintanilla et al,
1986). In the initiation stage the resultant DNA damage causes genetic lesions and 
cell proliferation. In the second stage of carcinogenesis, promotion, the 
transformed cells proliferate resulting in benign tumours (papillomas). In the 
mouse skin model multiple treatments of the papillomas with another chemical 
agent TPA (12-o-tetradecanoylphorbol-13-acetate), which does not cause DNA 
damage, allows growth and persistence of the altered cells. This may be due to the 
control of epigenetic mechanisms such as activation of protein kinase C (Castagna 
et al, 1982), a Ser/Thr kinase involved in signal transduction.
The final stage is progression. This stage involves the accumulation of 
further genetic lesions. This was evidenced by the fact that genotoxic agents 
increase the rate at which malignant tumours develop, yet non-genotoxic agents 
have no affect on the rate of tumour formation (Hennings et al, 1983).
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1.2 Risk Factors
These can be broadly classified into three main categories.
1. Physical Agents e.g. UV and X-rays
2. Chemical Agents (carcinogens and mutagens)
3. Infectious Agents e.g. tumour viruses
Exposure to ultraviolet light from the sun has been demonstrated to have a 
causal relationship with cancers of the lip and skin. However studies carried out 
generally involved exposure to sunlight, rather than ultraviolet light alone. 
However UV is presumed to be the active component due to its known tissue 
damaging and mutagenic effects (Cole et a l, 1986).
Ionising radiation, classed as ionising when it has the capacity to accelerate 
electrons in matter directly or indirectly, is ubiquitous. The most important natural 
sources are radioactive nucleotides in the environment and cosmic rays. The 
discovery of X-rays and nuclear fission have led to further exposure to ionising 
radiation, however natural sources still provide the greatest contribution to the 
radiation exposure of the human population. A key study into the effects of 
ionising radiation exposure upon cancer risk was carried out after the atomic 
bombing of 1945 by the Atomic Bomb Casualty Commission. Studies showed that 
survivors were at higher risk of leukaemia, multiple myelomas and cancers of the 
lung, breast, thyroid and gasterointestinal tract (Tomatis et al, 1990 and 
references therein)
A good example of the risk conferred by exposure to chemical agents is 
that of cigarette smoking. Many studies over a past few decades have proven that 
smokers are well known to be at high risk of lung cancer. Doll & Hill in 1952 
proved beyond doubt that cigarette smoking increased the chance of developing 
lung cancer. Smokers are also at higher risk of cervical neoplasia (Trevethan et al, 
1983; Reeves et al, 1987; Cuzick et al, 1990; Basu et al, 1991). Different 
carcinogens contained within the smoke, some of which are proven to be more 
carcinogenic after metabolic activation and have electrophilic properties would
4
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cause them to react with and damage DNA, RNA and protein e.g. Polycyclic 
aromatic hydrocarbons and nitrosamines (Miller, 1978; Pasquini et al, 1988). 
Carcinogens in the diet may also play a role in the development of cancer such as 
alchohol consumption which is linked to increased risk of oro-pharyngeal cancer, 
oesophagus cancer and primary liver cancer (IARC, 1988).
In the category of infectious agents many different agents have been 
implicated in various cancers including viruses, parasitic animals, fungi and 
bacteria. Whilst viruses have been the most studied in their relation to tumour 
formation, examples of other infectious agents being correlated to cancer have 
been noted. One such example is that of Helicobacter pylori which is thought to 
be a co-factor in the development of stomach cancer (Forman et al, 1990; 
Nomura e ta l, 1991 and Parsonnet e ta l, 1991).
Viruses these been shown to have both a direct effect on the development 
of cancer e.g. Hepatitis B virus (HBV) or Epstein Barr Virus (EBV) (see later) or a 
more indirect effect e.g. Human Immuno-deficiency Virus (HIV). This latter case 
can been seen by the fact that HIV patients have an increased risk of developing 
B-cell lymphomas (Zur Hausen et al, 1991b) and an increased risk of developing 
other rare cancers such as Kaposi’s sarcoma (Fauci, 1988).
Apart from these environmental factors there are of course genetic factors 
involved. Genetic predisposition is also a risk factor in such diseases as ataxia 
telangiectasia (AT), breast cancer, Retinoblastoma and Wilms tumour. In such 
diseases there would be a displayed family history of occurrence of the cancer. 
This family history would be due to inheritance of cell regulator genes with an 
altered activity.
1.3 Oncogenes and Tumour Suppresser Genes
1.3.1 Oncogenes
Oncogenes are activated cellular proto-oncogenes. These proto-oncogenes 
are genes involved in the proliferation and growth of the cell. Normally the
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activity of said genes is tightly controlled only permitting the cell to undergo DNA 
synthesis and mitosis, along with cellular growth, under specific signals.
Oncogenes were first described in rapidly transforming retroviruses such 
as the Rous sarcoma virus, where genes were discovered that were not required for 
viral replication but were involved in viral pathogenesis (Weiss et al, 1985). 
These genes were likely to have been picked up from cellular DNA sometime 
during their evolution (Bishop and Varmus, 1982). This cellular DNA includes 
gene controlling growth factors (e.g. c-sis) and their receptors (e.g. c-erb-B, c- 
fms), signal transduction protein (e.g. c-src, ras, c-abt), and transcription factors 
(e.g. c-myc, c-fos, c-myb). Hence oncogenes can be derived from a range of proto- 
oncogenes that are involved in the normal growth factor related signalling (Teich, 
1991).
The proto-oncogenes will have undergone alterations in order to render 
them abnormally active, such as:
1. Point Mutation
2. Amplification
3. Chromosomal translocation
4. Viral transduction
For example the ras proto-oncogene can suffer point mutation by exposure 
to carcinogens such as DMBA in codons 12, 13 and 61 (Balmain and Brown, 
1988; Brown et a l, 1990) in mammalian cells and animal models. Neu (a 
transmembrane protein with homology to the epidermal growth factor receptor) is 
also frequently activated in tumours of the nervous system in rats by a single point 
mutation resulting in a valine to glutamic acid causing the transforming properties 
of the protein product (Bargmann et al, 1986).
N-myc can suffer amplification in many neuroblastomas (Brodeur et al, 
1984). There is also increasing evidence to suggest that amplification of c-erb-B 
may be a useful prognostic marker for the development of breast cancer (Barnes, 
1989).
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An example of translocation is that of c-myc in Burkitts’s lymphoma 
(Dalla-Favera et al, 1983) which occurs between chromosomes 2 and 8. The 
condition of Chronic myeloid leukaemia (CML) results from the generation of a 
specific chromosomal abnormality called the Philadelphia chromosome which 
normally results from a translocation between chromosome 9 (which contains the 
c-abl gene) and 22 (at 9q34 and 22qll). The breakpoint region on chromosome 22 
involved in this translocation is quite small (5.8Kb) and therefore this region was 
termed the breakpoint cluster region (bcr). This results in a protein derived from 
the fusion between c-abl and bcr genes (Hermans et al., 1987; Dreazen et al, 
1988).
The transforming gene of the Rous sarcoma virus (v-src) is an example of 
viral transduction, where the virus at one point in its history acquired the c-src 
gene which encodes a receptor tyrosine kinase (Schwartzberg, 1998 for review). In 
fact c-src was first isolated as the cellular homologue of the transforming gene of 
the Rous sarcoma virus v-src (Stehelin et al, 1976). The v-src transforming 
protein is mutated and encodes a truncated version of c-src (lacks the COOH 
terminus) resulting in the loss of a critical amino acid residue (Y527) causing 
constitutive activation of the kinase
1.3.2 Tumour Suppresser Genes
In contrast to the oncogenes, this class of genes suppress cellular 
proliferation. These genes contribute to cell transformation by being de-activated. 
Evidence for these genes first came from when tumour cell to normal cell fusions 
were carried out. These fusions lead to non-tumourigenic hybrids (Harris et al, 
1969 and Harris, 1988) indicating that the normal cells contained genetic 
information capable of suppressing the transformed phenotype of their tumor cell 
partner. However it was also observed that these hybrids had unstable karyotypes 
and would revert to tumorigenicity upon loss of specific chromosomes. These lost 
chromosomes therefore were presumed to contain critical growth regulatory 
genes.
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Development of single chromosome studies by microcell transfer (Fournier 
& Ruddle, 1977) allowed a more detailed analysis of the chromosomes. This 
technique showed that introduction of chromosome 11 to HeLa cells and Wilms 
tumour cells (Saxon et al, 1986 and Weissman et al, 1987 respectively) 
suppressed growth. Since these initial discoveries other chromosomes have been 
associated with tumour suppresser genes.
The use of techniques such as cytogenetic chromosome banding and 
restriction enzyme fragment length polymorphism (RFLP) analysis has allowed 
researchers to home in on specific chromosome regions of interest, due to the fact 
that areas of the chromosome that contain tumour suppresser gene(s) suffer a 
phenomenon known as loss of heterozygosity (LOH). This is where these regions 
suffer large scale chromosome re-arrangements and/or deletions resulting in only 
one copy of the tumour suppresser gene at that locus.
The use of LOH studies has identified several tumour suppresser genes 
over the years of study such as those involved in Retinoblastoma and Wilms 
tumour.
Retinoblastoma is a cancer where ocular tumours form in young children 
(Knudson, 1971). Both sporadic and hereditary forms of the disease occur with a 
world wide incidence of about 1 in 20,000 and 10% of cases prove to be 
inheritable (Evans, 1993). Knudson in 1971 postulated that this cancer of the eye 
whether associated with development by familial or sporadic means, was due to 
two successive lesions in the cell genome. In sporadic retinoblastoma, where there 
is no family history, there would be lesions within the same somatic cell. However 
in familial retinoblastoma one of the lesions would be inherited during 
gametogenesis and the second would occur somatically. Karyotype analysis 
displayed that some retinoblastomas had deletions in chromosome 13ql4 
suggesting that this area may be important (Godbout et al, 1983; Sparkes et al, 
1983). The ultimate isolation and identification of the Rb-1 gene showed that it 
encoded a 105 KDa protein (pl05Rb) (Friend et al, 1986; Lee et al, 1987). This 
protein may be one of the most critical tumour suppressers involved in the cell
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cycle (Wang et al., 1994; Dyson, 1998; Mittnancht, 1998 for reviews). 
Hypophosphorylated, the pl05Rb protein associates with the E2F family of 
transcription factors that promote expression of genes required for DNA synthesis 
(Helin, 1998 for review). Hyperphosphorylation of the pl05Rb protein by the 
family of cyclin dependent kinases causes the release of free E2F which is then 
capable of activating transcription and allowing entry in S phase of the cell cycle. 
In addition there have also been associations of this protein to differentiation in a 
study where the induction of differentiation in several leukemic cell lines by 
treatment with phobol esters or retinoic acid resulted in dephosphorylation of the 
pl05Rb protein which preceded the cell cycle arrest associated with differentiation 
(Chen et al, 1989).
Wilms Tumour is a cancer that is responsible for 85% of all childhood 
kidney cancers (Matsungaga, 1981). This cancer also develops sporadically and 
more rarely familial. Studies of Wilms tumour cells isolated an area on 
chromosome l lp l3  with LOH (Koufas et al., 1984). However the situation may 
be more complex than that as there is also an area at position pl5 on chromosome 
11 which may be involved independently in Wilms tumour (Mannes et al, 1988; 
Reeve et al., 1989).
Possibly one of the best examples of a tumour suppresser protein is that of 
p53. p53 is negative regulator of cell proliferation as with other tumour 
suppressers and has been mapped to chromosome 17q31.1 (Mcbride, 1986). In 
addition to its control on the cell cycle, by causing arrest in response to a plethora 
of signals such as DNA damage and hypoxia, it is important in apoptosis and 
activation of DNA repair (for reviews see Ko & Prives, 1996; Agarwal et al, 
1998; Giacca & Kastan, 1998). Its importance to the control of the cell is 
underpinned by the fact that it is estimated to have lost activity in half of all 
cancers. In addition the germline mutation of p53 results in the Li-Fraumeni 
Syndrome. This syndrome results in pre-disposition to a variety of cancers such as 
breast carcinoma, soft tissue sarcoma, osteosarcoma and leukaemia at a young age 
(Malkin et al., 1990; Srivasatva et al., 1990).
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Whilst the study of the role of the oncogenes and tumour suppresser genes 
in the context of a whole animal remains difficult due to the nature of the myriad 
complex interactions involved in a whole organism, the development of tissue 
culture systems has permitted easily controlled assays to be developed and 
provided detailed insight into the cellular functions of these regulator genes.
Tissue culture assays have again demonstrated the multi-stage nature of 
cancer with the expression of oncogenes or tumour-suppresser genes causing 
transformation of the cell but not conversion to full tumourigenicity, e.g. 
conferring the ability to grow in low serum conditions or independent of substrate 
but not form tumours in nude mice. However the results obtained from such in 
vitro systems are only ever an approximation of the proteins function and must be 
backed up with in vivo studies where possible.
One such in vivo study is the use of transgenic mice. The gene of interest is 
introduced, often by injection, into the pronuclei of fertilised mouse eggs. Then 
the DNA is incorporated into the mouse genome and expressed in every cell. Such 
studies permit the analysis of this expression pattern in the whole transgenic 
organism. One such experiment involved the over-expression of the c-myc gene 
under the control of a strong inducible promoter of the mouse mammary tumour 
virus (MMTV) long terminal repeat (Stewart et al., 1984). The transgenic mice 
developed mammary carcinomas after a latent period of several months, thus 
confirming the role of myc as an oncogene. However as not all the mammary 
glands of the mouse developed carcinomas (1 out of 10 on average) and there was 
the long latency period before the cancer developed it indicated that the myc 
expression was not the only factor involved in the carcinoma development.
Interest in the Rb and p53 genes increased upon the discovery that virally 
encoded oncoproteins can bind to these proteins. Human adenovirus, Human 
papillomavirus and SV40 all encode proteins, namely E1A, E7 and large T antigen 
respectively, that bind and inactivate Rb, mimicking hyperphosphorylation of the 
tumour suppresser. The same viruses also encode protein that result in abrogation 
of p53 function, namely E1B, E6 and large T antigen (same protein that binds Rb).
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The evolution of the viruses to overcome the cellular controls carried out 
by these tumour suppresser proteins implicates their important role in maintaining 
normal cell proliferation.
1.4 Viruses and Virally Associated Cancer
Viruses are thought to be associated with 15% of all human cancers world­
wide (Zur Hausen, 1991b) and as such represent a major target for cancer 
prevention. As mentioned earlier viruses can be implicated with cancer risk by 
indirect effects, such as those described for HIV compromising the immune 
system, or direct effects which probably account for the majority of virally 
associated cancer. Examples of direct effects viruses can have on the development 
of cancer include those of viruses such as Hepatitus B virus (HBV) which is 
associated with hepatocellular carcinoma as evidenced by epidemiological 
(Trichopoulos et al, 1976) and DNA analysis (Nagaya et al, 1987) of liver 
tumours. The human T cell leukaemia virus (HTLV-1), a retrovirus, is associated 
with adult T cell leukaemia and lymphomas (Zur Hausen, 1991b) and the Epstein 
Barr Virus (EBV) is linked to several cancers including Burkitt’s lymphoma, 
nasopharyngeal cancer and Hodgkins disease (Zur Hausen 1991b). However it is 
the papillomaviruses and their contribution to cancer that will be focused on in 
this thesis.
1.4.1 Papillomaviruses
Papillomaviruses, member of the papovavirus family, are widespread in 
the animal kingdom and there are examples of many different types that infect a 
wide range of species including dogs, sheep, birds, cattle and humans (Sundberg,
1987). They have a small double stranded circular genome of roughly 8 kilobases. 
The DNA is condensed into nucleosomes and encapsulated into a icosahedral 
virion without a lipid containing membrane envelope.
All the open reading frames (ORF) overlap to a large extent and are 
located one strand of the genome. Their position and sequence though are
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conserved between papillomavirus species. Viral transcription is uni-directional 
and the mRNA is derived from splicing mechanisms. The genome can be divided 
into roughly three main regions. The long control region (LCR) which controls the 
expression of the viral genes with the combination of cellular and viral 
transcription factors. The early region which encodes the proteins involved in viral 
replication and transcription and the late region which encodes the structural 
proteins (Fuchs & Pfister, 1996).
Despite their genome organisation which is roughly comparable between 
species of papillomaviruses, they are normally highly species and anatomical site 
specific (Broker & Botchan, 1986). Papillomaviruses infect either the mucosal 
surfaces or the skin. Virus replication occurs in generally benign proliferations 
(papillomas) which form upon viral infection. Some types of papillomas will 
remain benign, with no invasion of the basement membrane, however others can 
progress to malignancy (Broker & Botchan, 1986).
The most commonly studied papillomaviruses are the cottontail rabbit 
(CRPV), human (HPV) and the bovine (BPV) viruses, and as such will be 
discussed below.
1.4.1.1 Cottontail Rabbit Papillomavirus (CRPV)
CRPV was the first model used to examine viral oncogenesis in mammals 
(Shope, 1933; Rous & Beard, 1935). The virus normally infects the hairy 
epithelium (Kidd & Parsons, 1936) inducing papillomas which can regress. 
However in 25% of rabbits the papillomas progress to squamous skin carcinoma 
(Kidd & Rous, 1940; Syverton, 1952), several months after viral infection 
(Syverton et al, 1950a.b; Syverton 1952) implying the requirement for other 
factors. CRPV was demonstrated to synergise with chemical carcinogens e.g. tar 
(Rous et al, 1936; Kidd & Rous, 1937) to induce malignant conversion of the 
papilloma in a much shorter time than with either carcinogen or virus alone (Rous 
& Beard, 1935; Rous & Friedewald, 1941; 1944).
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1.4.1.2 Human Papillomavirus (HPV)
The HP Vs are epitheliotropic agents that infect the mucosal surfaces or the 
skin. Infection by HPV induce warts, localised lesions with different 
morphological and histological manifestations (Croissant et al., 1985). Some types 
of wart remain benign, with the dividing cells failing to invade the basal 
membrane. However some infections can progress and become dysplastic to 
varying degrees. Some of the papillomavirus lesions can develop to carcinoma in 
situ. Of the mucosotropic HPVs there is a subset strongly linked with the 
development of various forms of genital cancer especially HPVs 16 and 18. These 
types are classed as ‘high risk’ due to their association with carcinoma. Other high 
risk HPVs include types 31, 33, 35 and 39 all of which display high correlation to 
genital and oral carcinomas and therefore have received the most study. Other 
HPV types such as 6 and 11 (best studied in this group) produce genital warts, 
these lesions are usually benign and are only rarely associated with malignant 
cancer and as such are termed Tow risk’.
As stated above infection of the anogenital tract by HPVs results in genital 
warts. These warts can be of two distinct types. First they may be exophytic 
(condylomata acuminata) or flat (condylomata plana). The former is normally 
found around the penis and anus in males and occasionally on the scrotum. In 
females they are located to the entrance of the vagina and on the vulva, anus, 
perineum and occasionally on the cervix. The flat type of wart can be located to 
the cervix in women and is the type of wart that can progress to carcinoma which 
first suggested the link between papillomaviruses and genital cancer (Zur Hausen, 
1977)
The first evidence between papillomaviruses and cervical cancer was due 
to the detection of HPV DNA in tumour cells (Gissmann & Schneider, 1986). 
Samples world-wide were then assayed and in each study HPV DNA was 
detected in the majority of the cancer biopsies (Ikenburg, 1990). The most 
common HPV type was HPV 16 which was found in roughly 50-70% of biopsies, 
with HPV 18 being the next most prevalent with 5-20% of the biopsies. This
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correlation between HPV and cervical cancer has been strengthened by analysis of 
yet more invasive squamous cervical carcinomas, cervical adenocarcinomas and 
cell lines derived from these tumours for presence of HPV specific sequences. 
These studies have demonstrated that greater than 90% of these cases display 
presence of HPV DNA (Munoz & Bosch, 1996; Zur Hausen, 1991a for reviews). 
In fact in the majority of cases the HPV DNA has integrated into the host genome 
and is actively transcribed (Wettstein, 1990). This integration often occurs within 
the 3’ part of the early region of the genome, and may cause disruption of the E2 
reading frame (see section 1.4.2 for further details on E2). Therefore removal of 
the transcriptional repressor E2 would presumably lead to elevated levels of the 
viral transforming proteins E6 and E7. In support of this notion it was reporter that 
elevated levels of E6 and E7 expression were detected, by in situ hybridisation, in 
high grade cervical lesion when compared to undifferentiated keratinocytes of low 
grade cervical lesions (Stoler et al, 1992; Durst et al, 1992).
Further indirect supportive evidence for the association between 
papillomavirus and genital cancer is due to the fact that the disease displays the 
characteristics of a sexually transmitted disease. For example nuns and virgins did 
not display the disease (Rigoni-Stern, 1842) and women whose partners had first 
wives with the disease were at higher risk (Gross et al, 1985; Kessler, 1986).
Risk factors for the development of cervical cancer include (Broker & 
Botchan, 1986 and references therein):
1. Early onset of sexual activity
2. Sexual promiscuity
3. Use of oral contraceptives
4. Lower socio-economic class
5. Smoking
6. History of infection and of different HPV types
With just cervical cancer alone accounting for around 450,000 cases per 
annum (Broker & Botchan, 1986) with a 45% mortality even with medical
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intervention there is an obvious need for research to attempt discover means to 
reduce this figure.
1.4.1.3 Bovine Papillomavirus (BPV)
Due to the infection of human beings with HPV for the purpose of 
experimentation being unethical, the study of animal papillomaviruses as a model 
for their action is a useful substitute. Both bovine and human papillomaviruses 
share certain features such as:
1. Specificity of anatomical site of infection.
2. Certain viral types associated with malignant progression.
3. Requirement of interaction between viral, cellular and environmental co­
factors
There are six types of BPV which are divided into 2 sub-groups (Campo et 
al. 1980; 1981; Jarret et al, 1984). Group A includes BPV 1, 2 and 5 which cause 
fibropapillomas. Group B includes BPV 3, 4 and 6 which are purely 
epitheliotropic.
Of these six types BPV-1 was one of the first to be studied and a lot of the 
early work on the papillomaviruses used this virus to dissect the ORF functions 
(see earlier). BPV 2 and 4 are associated with urinary bladder cancer (Campo et 
al, 1992) and alimentary canal cancer (Campo et al, 1994b). In both cases 
bracken consumption by the animals was identified as a co-factor. Bracken fern 
(Pteridium aquilinum) which contains carcinogens (Evans I. A. et al, 1982) and 
immunosuppressants (Evans W.C. et al, 1982) are thought to allow persistence of 
the papillomas through the immunosupression, and the carcinogens working with 
viral transforming proteins to cause conversion of the lesions to squamous 
carcinomas.
Note though that the BPV DNA is often lost on the progression to 
malignancy (Campo et al, 1985), additionally when bovine palatine tissue was 
infected with BPV 4 DNA in vitro and placed in the renal capsule of nude mice, 
malignant cells developed. However those same cells when assayed for the
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presence of the viral DNA were found to be negative (Gaukroger et al, 1991). 
Hence a ‘hit and run’ hypothesis was generated (Smith and Campo, 1988) for the 
transformation of the cell by BPV 4. This is in contrast to the transformation 
incurred by HPV 16 or 18 where the viral DNA persists in the transformed cell.
1.4.2 Papillomavirus Transforming Genes
A lot of the early work on the identification of the papillomavirus 
ORF functions was carried out using BPV 1. In the case of this virus the 8Kb 
genome consists of:
1.LCR
Region of roughly lOOObp containing the sequences which bind viral and 
cellular factors to control transcription and replication.
2. Early region.
Originally defined as a 69% fragment of the genome sufficient for 
transformation in rodent cells in vitro (Lambert et al, 1988). The region encodes 
the transforming proteins E5, E6 and E7 (DiMaio, 1991). In addition this region 
encodes the E l protein which is involved in DNA replication (Lambert, 1991). 
The E l protein binds an AT rich palindrome sequence at the region of replication 
(Chow & Broker, 1994; Howley, 1996). The E2 ORF encodes for 3 proteins: 
E2TA (full length), E2TR (carboxy terminus) and E8/E2TR (carboxy terminus of 
E2 ORF fused to 10 amino acids from the E8 ORF), the former acts as 
transcriptional activator and the latter two repress (Choe et al, 1989; Lambert et 
al, 1987; Spalholz et al, 1985). In fact subsequent work has shown that the E2TA 
protein binds the E l protein (Mohr, 1990) and a DNA helicase (Seo et al, 1993; 
Yang et al, 1993) and due to this is thought to aid viral replication by increasing 
E l ’s occupancy at the BPV 1 origin. In comparison the E2 protein in the high risk 
HPV’s is a repressor of transcription (Romanczuk et al, 1990) and in BPV 4 the 
E2 protein acts to activate transcription at low dosage levels and repress 
transcription at high dosage levels (Jackson & Campo, 1995; Morgan e ta l, 1998).
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The control of the expression of the viral transforming genes in BPV 1 is 
further complicated by the discovery that expression of E l has been shown to 
repress E2 transactivated transcription from the BPV 1 major early promoter 
(Sandler et al, 1993).
The E4 ORF is though to be involved in particle maturation (Doorbar et 
al., 1991; Doorbar, 1996). This may be due to altering keratinocyte differentiation 
in order to favour viral particle production and release.
3. Late region
Encodes the 2 structural capsid proteins LI and L2. LI is the major capsid 
protein and L2 the minor capsid protein. They form icosahedral virions into which 
the viral DNA is packaged.
The general function of several of the BPV 1 proteins will likely be very 
similar to that in other papillomavirus types, even if the mechanism in which the 
functions are carried out do vary slightly e.g. E2 is involved in transcriptional 
control but in differing ways in the different viral types.
However it is the viral transforming proteins that have probably received 
the most attention in order to underpin the mechanisms by which they over-ride 
normal cellular controls on proliferation. This study in turn has shed alot of 
understanding on these controls in normal cell biochemistry.
The mechanism by which each of the viruses causes transformation in the 
cell is likely to differ as not all the viruses share the same complement of 
transforming genes as can be seen in table 1.1.
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Table 1.1 List of Oncogenes Found in Different Papillomaviruses
E5 E6 E7 E8
BPV 1 Yes Yes No No
BPV 4 No No Yes Yes
CRPV Yes Yes Yes Yes
HPV 16 Yes Yes Yes No
HPV 8 No Yes No No
( adapted from Campo, 992)
The properties and functions of these transforming proteins will be 
discussed in further detail below from studies mostly of the high risk HPV 
proteins.
1.4.2.1 E7
The E7 protein is a nuclear protein of roughly 18 kilodaltons (Howley,
1996). The expression of the E7 protein alone in the absence of other transforming 
viral gene products leads to the immortalisation of rodent fibroblasts
There have been several domains identified in the E7 protein: a pocket
protein binding domain, a casein kinase II domain and two zinc finger motifs
(Cys-X-X-Cys) (Dyson et al, 1989; Zerfass et al., 1995; Barbosa et al,
1989;1990). The ability of the E7 protein to bind to the pocket protein, p l05R b is 
central to the viral protein’s ability to transform cells as defined by mutational 
analysis (Vousden, 1994). In normal cells the retinoblastoma gene product, 
pl05R b, is in a hypophosphorylated state in early G1 phase of the cell cycle. 
Hypophosphorylated it forms a complex with the E2F family of transcription 
factors. This results in transcriptional repression of genes that contain E2F binding 
sites in their promoters. Entry into S phase is associated with cyclin/cdk
complexes which phosphorylate p!05Rb, namely cyclin D/cdk4/6 and cyclin 
E/cdk2. This phosphorlyation results in p l0 5  assuming a hypcrphosphorylated 
state and causing the release of the transcription factor E2F, this in turn promotes 
transcription from E2F dependent promoters. The ability of E7 to bind to the
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pocket proteins and cause dissociation of E2F from hypophosphorylated pl05Rb 
causes constitutive expression from the E2F responsive promoters (Chellappan et 
al, 1992). In addition it has been recently shown that pl05Rb binds a histone 
deacetylase through its conserved pocket domain, and this association is important 
for its ability to repress E2F regulated transcription (Magnaghi-Jaulin et al, 1998; 
Brehm et al, 1998). E7 also interferes with this association between the histone 
deacetylase and pl05Rb (Brehm et al, 1998). One further effect on pl05Rb by E7 
is to reduce the stability of the protein (Boyer et al, 1996; Jones et al, 1997). 
Thus through the ability to directly bind and inactivate pl05Rb, to reduce the 
stability of the pl05Rb protein and interference with the association between the 
histone deacetylase and pl05Rb E7 efficiently abrogates the pl05Rb growth 
suppression ability.
In addition to this central role of E7 other interactions with cellular 
proteins have been reported. E7 has been shown to bind to cyclin E via interaction 
with the pl05Rb related pocket protein pi 07 (McIntyre et al, 1996) and also to 
cyclin A although at this point it is unclear whether this is a direct interaction with 
the cyclin or not (Arroyo et al, 1993; Tommasino et al, 1993). Interestingly the 
first E7 responsive gene B-Myb, which plays an essential role in cell cycle 
progression, has had its de-regulated expression correlated to E7’s interactions 
with pl07/E2F complexes (Lam et al, 1994). In addition to binding these cyclins 
E7 has also been shown to deregulate expression of cyclin E (Martin et al, 1998; 
Vogt et al, 1999) and cyclin A in suspension cells (Schulze et al, 1998).
Another family of protein involved in the regulation of the Gl/S 
checkpoint the cyclin dependent kinase inhibitor (CKIs), has also been implicated 
as targets of E7. The CKIs function by binding and inhibiting cyclin/cdk activity. 
They fall into two categories: Kip/Cip family which affect the activities of cyclin 
D, E and A complexes e.g. p21Wafl/Qpl, p27Kipl and p57Kip2 and the INK family 
which inhibit only D cyclin complexes e.g. p l6 INK4a, p l5 INK4b and p l8 INK4c (Sherr 
& Roberts, 1995; 1999). Note that the Kip/Cip family are potent inhibitors of
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cyclin E and A complexes but recent work suggests that they are in fact positive 
regulators of cyclin D complexes (Sherr & Roberts, 1999 for review).
It was shown that E7 can bind p21 directly and abrogate the inhibitor. This 
binding not only inhibits p21’s effect on the cyclin/cdk complexes but also p21’s 
ability to inhibit DNA replication by binding PCNA (Jones et al, 1997; Funk et 
al, 1997). The related CKI, p27, is also bound by E7 which results in abrogation 
of its inhibitory activity on cyclin/cdk complexes (Zerfass-Thome et al, 1996).
E7 has also been shown to interact with and fra/zs-activate the AP-1 family 
of transcription factors, including c-Jun, JunB, JunD and c-fos. The ability of E7 
to bind to c-Jun was demonstrated by immunoprecipitation and yeast two hybrid 
systems and locates to amino acids 224 to 286 of c-Jun. Additionally the ability of 
E7 to trans-activate c-Jun induced transcription was observed using a reporter 
construct responsive to c-Jun (Antinore et al, 1996).
As well as interacting with the retinoblastoma gene product there have 
been reports of an indirect interaction between E7 and the tumour suppresser 
protein p53. E7 was reported to repress p53 transcriptional activity via binding of 
the TATA box binding protein (TBP), which in turn is elevated following caesin 
kinase II phosphorylation (Massimi et al, 1997; Massimi & Banks, 1997).
These interactions are the probable cause of Gl/S checkpoint abrogation in 
cells expressing E7 (Hickman et al, 1994; Slebos et al, 1994; Demers et al,
1994). In these cells although DNA damage may induce p53 to initiate a cell cycle 
arrest, the combination of the afore-mentioned events would permit the 
transcription of genes required for DNA synthesis.
In addition to the abrogation of the Gl/S checkpoint there have been 
reports of an ability of E7 to disrupt the mitotic spindle checkpoint at the G2/M 
boundary. In the presence of mitotic spindle inhibitors expression of E7 allowed 
multiple rounds of DNA synthesis in a p53 independent manner (Di Leonardo et 
al, 1997; Thomas &Laimins, 1998).
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1.4.2.2 E6
E6 primarily alters the normal regulation of the cell cycle through its 
interaction with the p53 protein. E6, via the association of a cellular protein (a 
component of the ubiquitin proteolytic pathway), termed E6-AP, causes the rapid 
turnover of the p53 protein (Scheffner et al, 1994). Additionally E6 can inhibit 
p53’s ability to bind DNA, therefore inhibiting the protein’s capacity as a 
transcriptional regulator (Vousden, 1994). E6 in complex with the E6-AP protein 
can also targets the transcriptional co-activator CBP/p300 which involves the C 
terminal zinc finger of E6 and amino acids 1808 to 1826 in CBP. E6 does not 
require E6-AP to bind CBP/p300 as an E6 mutant incapable of binding E6-AP is 
still capable of binding CBP/p300 (Zimmermann et al, 1999)
As p53 is involved in G1 cell cycle arrest (Agarwal et al, 1995) due to 
DNA damage caused by chemical agents or y-irradiation (Kastan et al, 1991; 
Kuerbitz et al, 1992) or due to ribonucleotide depletion (Linke et al, 1996) loss 
of function due to E6 expression results in loss of G1 arrest in response to the 
DNA damaging stimuli (Vousden, 1994). As p53 is also involved in the mitotic 
spindle checkpoint (Di Leonardo et al, 1997; Taylor et al, 1999) E6 also impacts 
on this function. Expression of the E6 protein results in abrogation of this 
checkpoint (Di Leonardo et al, 1997; Thomas & Laimins, 1998; Thompson et 
al, 1997). Additionally another function of p53 is the regulation of apoptosis in 
certain cell types e.g. those of hematopoietic origin (Oren, 1994 and references 
therein). Stimuli such as DNA damage (Clarke et al, 1993), adenovirus E1A 
expression (Debbas & White, 1993) and withdrawal of growth factors (Johnson et 
al, 1993) can induce p53 dependent apoptosis. The ability of E6 to promote 
degradation of p53 was shown to establish resistance to such p53 mediated 
apoptosis (Haupt et al, 1995). E6 has also been implicated in resistance to 
apoptosis in cells lacking p53 (Steller et al, 1996) and E6, through interaction 
with E6-AP, is able to inhibit Bak induced apoptosis, in a p53 independent 
manner, by mediating degradation of the Bak protein (Thomas & Banks, 1998).
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Cancers which contain p53 mutation often contain amplifications and 
aneuploid chromosomes (Hollstein et al., 1991), which leads to the hypothesis that 
p53 plays a role in the genomic integrity maintenance of the cell. Loss of genomic 
stability in E6, but not E7, immortalised human uroepithelial cells was observed 
(Reznikoff eta l, 1994).
Other cellular proteins observed to bind to E6 include E6-BP (Chen et al.,
1995). E6-BP sequence is identical to a putative calcium binding protein, however 
as of yet its normal function has not been elucidated. Another E6 interacting 
protein is paxillin, a focal adhesion protein (Tong & Howley, 1997). Both E6-BP 
and paxillin would help explain the nuclear and cytoplasmic distribution of E6 in 
the cell (Scheffner et al, 1994). Additionally it was shown that only E6 from BPV 
1 and HPV 16, but not low risk types bound paxillin.
Another protein observed to interact with E6 is the disc large tumour 
suppresser protein (hDLG) (Kiyono et al., 1997). In common with paxillin and 
E6-BP, mutants of E6 which were unable to bind to the hDLG protein lost 
transformation activity. Again in common with paxillin, only E6 from high risk 
types bound the hDLG protein. These results suggest that as binding to these 
proteins correlates to transformation ability they may play a functional role in the 
transforming ability of the papillomaviruses.
In another study, another interaction of an E6 protein was demonstrated, 
between the BPV-1 E6 protein and AP-1, the TGN (trans-Golgi network)-specific 
clathrin adapter complex. AP-1 is a four-subunit protein complex required for 
clathrin-mediated cellular transport from the TGN. It was proposed that BPV-1 
E6, through its interaction with AP-1, could affect cellular processes involving 
clathrin-mediated trafficking pathway (Tong et al, 1998).
Other functions of the E6 protein include inhibition of human keratinocyte 
differentiation (Sherman & Shlegel, 1996) and the activation of telomerase 
(Klingelhutz et al, 1996) an enzyme involved in the maintenance of the structures 
at the end of the chromosome called telomeres, which under normal conditions 
shorten with each round of cell division (Engelhardt & Martins, 1998 for review).
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Telomerase activation in somatic cells, where it is normally inactive, is linked to 
cell immortalisation. This feature of the E6 protein may be linked to the 
observations that expression of the E6 protein led to immortalisation of p53 null 
mouse fibroblasts (Scobie et al, 1997) and primary mouse fibroblasts 
(independent of any interaction with p53) (Pirn et al, 1994).
1.4.2.3 E5 & E8
The BPV 4 E8 protein shows a significant resemblance to the E5 protein 
of BPV 1, in so far as they both are very hydrophobic and have a high leucine 
content in addition to similar hydrophobicity profiles (Jackson et al, 1991; Banks 
& Matlashewski, 1993). The E8 ORF encodes a polypeptide 42 amino acids in 
length which is located, like E5, in the Golgi and endoplasmic reticulum 
(occasionally in the plasma membrane) of transformed cells (Campo, 1992; 
Pennie et al, 1993; Faccini et al, 1996). It is also known that BPV 4 E8 is only 
expressed in the basal and superbasal regions of the papilloma (Anderson et al,
1997)
E8 expression, along with E7 and ras, results in anchorage independent 
growth of primary bovine fibroblasts. E8 expression together with ras is lethal to 
the cell, unless expressed with E7, or in the context of the BPV 4 genome 
(Campo, 1992; Pennie et al, 1993). Recent work has shown that E8 expression 
can also induce anchorage independent growth of the murine cell line NIH3T3 
(O’Brien & Campo, 1998).
In common with the BPV 1 and HPV 16 E5 proteins, BPV 4 E8 can 
complex with the 16K ductin protein in vitro (Banks & Matlashewski, 1993; 
Faccini et al, 1996; Oelze et al, 1995). The ductin protein has been identified as a 
component of the gap junctions and of the vacuolar ATP-ase (Finbow et al, 1991) 
and this may explain the observation that HPV 16 E5 or BPV 4 E8 expressing 
cells have reduced levels of gap junction intercellular communication (Faccini et 
al, 1996; Oelze et al, 1995). This may contribute to the virus transforming ability 
as cells released from the control of the surrounding environment (i.e. of non­
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transformed cells) would be permissive for proliferation and consequently form an 
expanding transformed clone (Campo, 1992). The complexing of the E5/E8 with 
the vacuolar ATP-ase could result in prolonged receptor signalling due to an 
alteration in pH of the endosomes reducing the efficiency at which the receptors 
are deactivated and recycled (Straight et a l, 1995).
BPV 1 E5 has also been shown to bind to and activate the membrane 
receptors EGF and PDGF (Martin et al, 1989; Petti et al, 1991; Cohen et al,
1993) thus likely to contribute to a proliferative signal in the transformed cell.
However it has been observed that mutations in the transmembrane 
domain of E5, which still permit binding to ductin, cause loss of transforming 
ability (Sparkowski et al, 1996) and BPV1 E5 that remains in the endoplasmic 
reticulum can still activate the PDGF receptor but not transform cells (Sparkowski 
et al, 1995). Hence maybe both functions of the protein are required in order to 
facilitate transformation, or indeed neither of these activities may be necessary for 
transformation and other, as yet unidentified, functions are necessary.
The HPV 16 E5 gene is less likely to play an important role in the 
maintenance of cell transformation, as it is often lost as a consequence of viral 
integration (Howley, 1996). This also applies to the BPV 4 E8 gene whose 
expression is also often lost due to the loss of the BPV 4 genome during 
progression to malignancy (Campo et al, 1985). The role for the E5 and E8 
protein functions in the early stages of transformation of the cell and the viral life 
cycle however may be more significant i.e. by promoting cell proliferation and 
reducing cell-cell communication.
The studies of the E5 and E8 ORFs in CRPV have also demonstrated their 
transforming function (Han et al, 1998). Both E8 and E5 stimulated C127 and 
BALB/c A31 (A31) cell proliferation and affected cell cycle transition. The E8 
and E5 transfectants lost cell contact inhibition. E8-C127 transfectants formed 
colonies in soft agar in the presence of platelet-derived growth factor (PDGF) 
while E5-C127 transfectants formed colonies without the requirement for PDGF. 
E8-C127 transfectants were highly tumorigenic whereas E5-C127 transfectants
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showed weak tumorigenicity in nude mice. However both E5 and E8 A31 
transfectants failed to display anchorage independent growth or form tumours in 
nude mice with or without the presence of PDGF. These results showed that 
CRPV E8 and E5 may well be oncoproteins and that the PDGF beta-receptor 
signalling pathway may be involved in E8-mediated C127 cell transformation. 
The difference observed with the two cell lines indicates there may be additional 
factors involved in E5 or E8 expressing cells to progress to full transformation.
1.4.3 Bovine Papillomavirus Type 4 (BPV 4)
BPV 4 is a transforming papillomavirus, which induces papillomas 
of the mucosal epithelium of the upper gastrointestinal tract of cattle (Campo et al,
1994). In healthy cattle, the papillomas develop and persist for approximately one 
year and are then rejected by a cell mediated immune response (Knowles et al,
1996). However, in cattle grazing on bracken fern the papillomas can progress to 
squamous cell cancer (Campo and Jarrett, 1986). Bracken fern contains 
immunosuppressants (Evans W.C. et al, 1982) and mutagens (Evans I. A. et al., 
1982). Bracken-eating cattle become chronically immunosuppressed and 
incapable of mounting an appropriate immune response against the virus or virus 
infected cells (Campo, 1997b). The progression of papillomas to carcinomas has 
also been experimentally reproduced in bracken-fed cattle (Campo et al, 1994b) 
thus confirming the epidemiological studies conducted in the field.
Activation of ras (Campo et al, 1990), mutation of p53 (Scobie, 1996) 
and increase in epidermal growth factor receptor (Smith et al, 1987) have all been 
found in naturally occurring bovine alimentary cancers which may be due to the 
exposure of the papillomas to the bracken carcinogens. These multiple 
independent events support the hypothesis of the multistage nature of cancer 
again.
Another interesting note, as mentioned earlier, on the BPV 4 associated 
carcinogenesis is that unlike HPV 16 or 18, the BPV 4 DNA is commonly lost on 
the progression to malignancy (Campo et al, 1985) which has also been
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demonstrated to occur in xenografts of BPV 4 infected bovine tissue 
(Gaukroger et al., 1991).
1.4.3.1 BPV Genome
The BPV 4 genome is a double stranded DNA circle of 7.265Kb (Jackson 
& Campo, 1995). The genome can, as with the other papillomaviruses, be divided 
into 3 main sections (see figure 1):
1. Long Control Region (LCR)
2. Early Region which encode protein for replication and transcription
3. Late Region which encodes the structural capsid proteins
DNasel footprinting of the BPV 4 LCR (nucleotides 6710-331) revealed 
16 sites which were protected from the DNAase by binding of nuclear factors 
(Jackson & Campo, 1991). Among these site were 3 consensus E2 binding sites at 
nucleotides 7050 [E2(l)], 175 [E2(2)] and 267 [E2(4)], with an additional 
degenerate (one base pair difference from consensus site) fourth site termed E2(3) 
at nucelotide 252. Mutational analysis of these E2 sites showed that E2(l) and 
E2(3) are involved in transcriptional activation and E2(2) and E2(4) led to 
transcriptional repression (Jackson & Campo, 1995). The E2(2) is an important 
ds-regulatory element that may bind several nuclear factors which includes 
PEBP2, in addition to the E2 protein (Jackson & Campo, 1995), implying that 
there is competition for this site. There are likely to be other factors that may bind 
to this region of the LCR as deletion or mutation result in a 60 to 85% drop in 
LCR activity (Jackson & Campo, 1991,1995). Analysis of the LCR has shown the 
presence of three, E2 independent, positive (CE 1-3) and negative regulatory (NR 
1-3) elements (Jackson & Campo, 1991). These are arranged so that each positive 
element is paired with a negative element, also each of these elements (except 
NR2) has binding sites for one or more nuclear factors as determined by DNAase I 
footprinting. However the NR2 site is in fact bound by a nuclear factor, C/EBP 
capable of positive and negative activities (Pei &Shih, 1990)
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At low concentrations E2 transactivates the LCR but at higher 
concentrations repression occurs (Jackson & Campo, 1995). The stability of the 
E2 complexes to E2(l) and E2(2) is greater than that of E2(3) and E2(4), so that at 
low E2 concentrations only the E2(l) site is occupied but at higher E2 
concentrations all the E2 sites become occupied and consequently less positive 
cellular factors may be able to bind or become displaced (Jackson & Campo,
1995)
Note that there is a pair of E2 sites separated by 3 bp that lie 3bp upstream 
of the TATA box which is an arrangement found in the E6/E7 promoter of HPVs 
such as 6b, 11,16,18, 31 and 33 (Gloss & Bernard, 1990) implying that there may 
be a common mechanism of E2 action upon these sites. The binding of E2 to the 
promoter proximal E2 site in HPV 18 has been shown to interfere with the 
preinitiation complex (Dostanti et al, 1991)
The two major transcriptional promoters have been identified: P l (late 
promoter at nucleotides 777 to 902) and PE (early promoter at the TATA box 
nucleotide 283) (Stamps & Campo, 1988; Jackson & Campo, 1995). The viral 
transcripts all are generated from one strand of the genome and several transcripts 
have been identified, which show a complex pattern of splicing between the ORFs 
(Stamps &Campo, 1988; Smith et al, 1986) (see figure 1). These and the 
individual ORF functions will be sequentially detailed below:
1. E l. Has several different mRNA species, however the one that actually encodes 
the functional protein is not known. The E l protein in BPV-1 is a phosphoprotein 
that is found located in the nucleus of infected cells (Sun et al, 1990). It binds the 
viral origin of replication (Ustav et al, 1991) and has helicase and DNA 
unwinding activities. It also interacts with the DNA polymerase alpha (Lentz et 
al, 1993).
2. E2. The E2 ORF is transcribed into large mRNAs that cover several of the 
BPV-4 ORFs. Another viral transcript termed Q, possesses sequences from the
3’parts of the E2 and E4 ORFs, hence it may encode an N terminally truncated E2
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protein which could act as a transcriptional repressor. As in BPV 1, this protein is 
a transcriptional regulator in BPV 4 (Jackson and Campo, 1991) and binds to the 
viral LCR to activate viral transcription along with other cellular factors. There are 
four E2 binding sites located in the BPV 4 LCR. Mutational analysis displayed 
that two E2 binding sites (located at nucleotides 7050 and 252) caused activation 
of the LCR when E2 was bound, and the other two sites (located at nucleotides 
175 and 267) mediated repression of the LCR under conditions of high level E2 
expression (Jackson and Campo, 1995; Morgan etal., 1998).
3. E4. Again this ORF has several mRNA species including it (Stamps and 
Campo, 1988). The transcript known as the 7E11 transcript (initiated at multiple 
sites between 777 and 902) is the most likely to encode the functional protein, an 
E1AE4 fusion protein analogous to that found in HPV 1 (described by Doorbar et 
al, 1988) with the 5 N-terminal residues of El fused to 118 amino acids of E4. 
However the 1.6Kb transcript also encodes another potential E1-E4 fusion protein, 
using a different part of El. The majority of E4 is located the in differentiating 
layers of the papilloma, coincident in time and in location with the vegetative 
replication of viral DNA (Anderson e ta l, 1997; Campo e ta l, 1994a). Exact 
function of the E4 ORF has not been identified in BPV-4 but it is likely to be 
similar to the homologue in HPVs, where the protein interferes with the 
cytokeratin assembly (Doorbar e ta l,  1991). This could result in upsetting the 
differentiation programme of the cell and favouring the production of the viral 
progeny instead.
4. E3 & E5. In BPV-4 they have no ATG codon and as such are assumed to have 
no function.
5. E7 & E8. These are the primary transforming genes of BPV-4 and are 
transcribed into a 3.0Kb RNA. These will be described in greater detail later.
6. LI & L2. These are the structural proteins of the virus where LI is the major 
capsid protein and L2 the minor capsid protein. They are encoded by a 2.8Kb 
RNA capable of encoding the LI protein, and by a 4.2Kb RNA that has the 
potential to encode both the LI and the L2 protein. The LI and L2 capsid proteins
29
Chapter One Introduction
are found in papillomas but not transformed cells. These proteins are effective 
prophylactic vaccines which can prevent infection (Campo et al., 1997; Campo, 
1997a, b)
7. L3 & L4. These have an ATG codon but have unknown function in BPV 4.
1.4.3.2 BPV 4 Transformation Studies in Established and Primary cells
Initial studies of the transforming properties of the virus were carried out 
using murine fibroblast cell lines, namely NIH3T3 and C127 cells. These cells 
were transfected with the virus genome in vitro which transformed both cell lines. 
Additionally several subclones were capable of inducing tumours in nude mice 
(Campo & Spandidos, 1983; Smith & Campo, 1988). However complete 
transformation of the C127 cells required co-operation with the tumour promoter 
12-o-tetradecanoylphorbol-13-acetate (TPA).
Work on the C127 cell line also lead to the discovery that a fragment of the 
viral genome which contained the E7 and E8 ORFs retained the ability to 
transform (Smith & Campo, 1988). This provided the first evidence that these two 
genes were the main transforming genes of BPV 4. Subsequent work on E8 in the 
NIH3T3 cells has shown that this protein is capable of inducing anchorage 
independent growth in these cells (O’Brien & Campo, 1998). Continued work on 
the E7 and E8 ORFs in primary cells has confirmed their role as the major 
transforming genes of BPV 4 (see below).
As with observations of the in vivo tumours the experiments with the C127 
cells again showed loss of the viral genome (Smith and Campo, 1988). Of the 60 
cell line tested only 9 retained the viral genome, thus reinforcing the notion that 
the expression of the viral genome, while required for initial transformation of the 
cell, is not required for the maintenance of the transformed state.
However work in the established murine cell line is removed from the cell 
type of the natural site of infection which is the mucous epithelium of the 
alimentary canal. Therefore work with cells established from this site was 
undertaken to examine the transforming properties of the virus under which
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conditions. BPV 4 was able to transform primary bovine fibroblasts only in 
association with another oncogene such as ras (Jaggar et al, 1990). Note that 
although keratinocytes are the natural target for BPV infection primary bovine 
fibroblasts (PalF) still remain a closer experimental system to study BPV than the 
murine established fibroblasts, and are easier to culture than the keratinocytes in 
vitro. The transfection of the BPV 4 genome together with an activated ras 
oncogene causes morphological transformation, anchorage independent growth 
and extended lifespans of the PalF cells (Jaggar et al., 1990). However these cells 
are neither immortal or tumorigenic (Jaggar et al., 1990; Pennie et al., 1993).
Subgenomic fragment of the BPV 4 genome were also transfected into the 
PalF cells with activated ras in order to determine the transforming properties of 
the ORFs. Transfection of the E7 ORF resulted in morphological transformation 
of the cell resulting in a more ‘spindle-like’ cell morphology (Pennie et al., 1993). 
The E7 protein is located in the cytoplasm and the nucleus (Pennie et al., 1993; 
Campo et al, 1994b) and in vivo E7 is expressed in all layers of the papilloma 
(Anderson et al., 1997). In common with other E7 proteins it contains two Cys-X- 
X-Cys zinc binding fingers and a potential pl05Rb binding domain (Jaggar et al., 
1990). Note though that this study also demonstrated that the protein lacked the 
casein kinase II site present in the E7 proteins of the high risk HPV 16 and 18. 
Mutation of either the zinc binding domains or the pocket protein binding site 
however did abolish the transforming properties of the protein (Campo et al, 
1994b; Jackson et al, 1996) showing that these domains where necessary for the 
transforming properties of the protein.
Addition of the E8 ORF to the transfection caused the cells to be 
morphologically transformed as with the E7 transfectants but also conferred 
anchorage independent growth (Pennie et al, 1993). These cells are still not 
immortal nor tumorigenic in nude mice. It is not known whether the E8 ORF, with 
ras, alone can confer anchorage independent growth as this combination proved 
lethal to the transfected cells. As detailed earlier though, E8 alone can confer 
substrate independence to the NIH3T3 cells (O’Brien & Campo, 1998). In
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addition to this function, E8 also downregulates gap junction intercellular 
communication in PalF cells (Faccini et al., 1996) thought to be due to binding of 
E8 to ductin, a component of the gap junctions (Finbow et al., 1991)
E8 is localised to the nuclear membrane, endoplasmic reticulum, Golgi 
apparatus and sometime to the plasma membrane (Pennie et al., 1993). The 
protein could be classed as a true early protein due to its expression pattern in 
vivo. It is only expressed in the basal and superbasal areas of the papilloma and 
therefore separated from region of vegetative viral DNA replication (Anderson et 
al, 1997)
As with the other group B BP Vs, the BPV 4 genome does not contain an 
E6 ORF (Jackson et al., 1991). E6 is a crucial transforming gene for the HPV 16 
and 18 viruses, and it is as yet unknown whether the proteins encoded by BPV 4 
can replace the E6 protein either singly or in combination. However the addition 
of the HPV 16 E6 ORF to the transfection of PalF cells, causes the cells to 
become immortal (Pennie et al., 1993). This result does suggest that BPV 4 does 
not support this phenotype with its own encoded proteins.
These studies showed that even with the addition of the HPV 16 E6 and 
activated ras, the transforming proteins of BPV 4, namely E7 and E8, still could 
not fully transform the PalF cells to achieve tumorigenic status (Pennie et al, 
1993). Further addition to the transfection of mutant p53 was required to allow 
full transformation (Scobie et al, 1997). Interestingly though the addition of the 
chemical co-factor quercetin to the cells containing the BPV 4 genome, or sub- 
genomic fragments, could cause full transformation of the cell (Pennie & Campo, 
1992; Caimey & Campo, 1995).
1.4.3.3 Co-Factors Associated with BPV 4 Transformation
BPV 4 can co-operate with the tumour promoter TPA or the initiator 
DMBA to induce carcinomas. BPV 4 infected palate tissue was implanted into the 
renal capsule of nude mice with pellets which released TPA or DMBA (Gaukroger
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et al, 1993). Papillomas formed from the implants (11/33 for virus and TPA, 
10/20 for virus and DMBA), with neoplasias forming from implants with the virus 
and either of the chemicals (4/33 for virus and TPA, 13/20 for virus and DMBA). 
However TPA or DMBA alone failed to induce either papillomas or neoplasias in 
any of the implants. The fact that the virus can synergise with either chemical 
suggests that it can induce transformation of the cell by working with a variety of 
different cellular pathways i.e. those involved in proliferation or DNA damage.
As briefly mentioned before in section 1.4.3 and 1.4.1.3, the co-factor for 
BPV 4 in causing alimentary canal cancer is the bracken fern (Pteridium 
aquilinum). Naturally occurring cases of alimentary canal cancer were found to 
occur at high frequencies in specific areas such as the Nasampolai Valley of 
Kenya and the Western Highlands of Scotland where the cattle were grazing on 
bracken infested lands (Jarret et al, 1978; Plowright et al, 1971). Cattle feeding 
on bracken fern become immunosuppressed, probably due to the sesquiterpene 
pterosins and pterosides found in bracken (Evans W.C. et al, 1982), develop 
enzootic hematuria and cancer of the bowels and upper alimentary canal (Campo 
et al, 1992; Campo et al, 1994a). Cattle also show signs of a high level of 
chromosomal abnormalities (Moura et al, 1988).
The experimental reproduction of the association between BPV 4 and 
bracken in the alimentary canal cancer confirmed their involvement (Campo et al, 
1994b). Cattle infected in the palate with the BPV 4 virus and kept on a bracken 
free diet developed papillomas but none of these progressed to carcinomas. Cattle 
fed on bracken fern without BPV 4 exposure developed neither papillomas or 
carcinomas of the alimentary canal. However those animals exposed to BPV 4 and 
bracken diets did develop cancer of the upper alimentary canal and lower bowels 
(2 out of 6 animals). An additional group of animals that were immunosuppressed 
with the drug azathioprine, with BPV 4 infection in addition, developed 
papillomas but not cancer. Thus this latter group indicated that other co-factors in 
the bracken must be required to cause the progression of the papilloma to 
carcinoma. The immunosuppression which is important for the persistence of the
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papilloma is likely to give a greater target pool of partially transformed cells that 
could be acted upon by the carcinogens. In addition the immunosuppression would 
allow a greater duration of exposure to permit accumulation of genetic lesions and 
would increase the probability of transformed cells to evade the immune 
surveillance
The synergism between BPV 4 and bracken is not an isolated case of this 
form of interaction. Another example would be smoking and HPV in a similar 
interaction. Smokers are more at risk of laryngeal papillomatosis (Lindeburg et al, 
1986), or cervical neoplasia (Trevethan et al, 1983; Reeves et al, 1987; Cuzick et 
al, 1990; Basu et al, 1991). This is thought to be because there are several 
different carcinogens contained within the smoke some of which are proven to be 
more carcinogenic after metabolic activation e.g. Polycyclic aromatic 
hydrocarbons and nitrosamines (Miller, 1978; Pasquini et al, 1988). Indeed the 
cervical mucus of smokers was shown to be mutagenic in the S.typhimurium 
microsomal test system (Kier et al, 1974) at an elevated frequency when 
compared to the cervical mucus of non smokers (Holly et al, 1986), thus the 
mutagens are probable present throughout the body. In addition smoking has been 
shown to reduce the immune response of smokers causing reduced killer cell 
activity and suppression of T-cell function as well as reduced levels of IgA, IgG 
and IgM (review, Holt 1987)
1.4.3.4 Quercetin as a Co-Factor for BPV 4 Transformation
Quercetin (3, 3’, 4’, 5, 7-pentahydroxyflavone) (see figure 2) is a 
ubiquitous bioflavonoid found in a range of edible plants e.g. fruits, vegetables, 
wine and tea (Herrmann, 1976).
Figure.2
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C hem ical Structure o f  Q uercetin
OH
It has been shown to exhibit a wide range of biological effects on 
the cell. Quercetin has been demonstrated to induce cell cycle arrest in various 
stages of the cell cycle in different cell lines including a variety of tumorigenic cell 
lines (Yoshida et al,. 1990, Hosokawa et a l, 1990, Gong et al, 1994, Scambia et 
al, 1990, Ranelletti et al, 1992, Avila et al, 1994, Plaumann et al, 1996). 
Quercetin also has the ability to scavenge free radicals (Bors & Saran, 1987; 
Negre-Salvayre & Salvayre, 1992). However in addition to some of these 
potentially beneficial functions of quercetin there has been a wealth of literature 
providing evidence for more deleterious functions of quercetin. The flavonoid can 
induce the formation of DNA adducts (Rahman et al, 1990) and is mutagenic in 
both prokaryotic and eukaryotic cells (Bjieldanes & Chang, 1977; Amacher et al, 
1979; Maruta et al, 1979; Nakayasu et al, 1986; Ishikawa et al, 1987). It also 
causes clastogenic damage (Ishidate et al, 1988) and can act as an initiator in a 
two stage transformation protocol in vitro with TPA as a promoter (Sakai et al, 
1990). Quercetin induces recombinational mutations in cultured cells (mouse 
mammary tumour cells and mouse fibrosarcoma cells) as detected by DNA 
fingerprinting (Suzuki et al, 1991). Also the activity of quercetin in the mouse 
lymphoma L5178Y TK+/" mutation assay, the DNA single strand break assay (also 
in the L5178Y cells) and the Balb/c 3T3 chemical transformation assay shows that 
it can form single-strand DNA breaks (Meltz & Mac Gregor, 1981).
This single strand scission damage caused to DNA by quercetin in itself 
requires co-factors, namely Cu2+ and oxygen (Rahman et al, 1990). It seems that 
quercetin reduces oxygen to superoxide, and in the presence of Cu a hydroxyl 
radical is formed. Strand scission experiments of DNA were done with quercetin,
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oxygen or hydrogen peroxide and Cu2+ (Fazal et al, 1990). They showed that the 
superoxide was not a necessary intermediate, but the reaction did involve the 
hydroxyl radical and a radical intermediate.
In the presence of Cu2+, quercetin also leads to the fragmentation of BSA 
(Ahmed et al, 1994) which involves the binding to tryptophan residues in the 
protein, however this effect is not universal for all tryptophan containing proteins.
Quercetin may inhibit kinase activity by competitive inhibition of ATP 
binding (Graziani et al, 1983). This would lead to gross overall alterations in the 
control of the signal transduction pathways evidenced by the fact that quercetin 
inhibits various cellular enzymes such as Calmodulin (Nishino et al, 1984), 
pp60vsrc, cAMP independent protein kinase, cAMP or cGMP Phosphodiesterases, 
Phosphorylase kinase, Ca2+/phospholipid-dependent kinase, ATP-ases, 5’ 
nucleotidase (Glossman et al, 1981; Graziani et al, 1983; Graziani et al, 1981; 
Gschwendt et a l, 1984; Srirastava, 1985; Lang & Racker, 1974; Shoshan & 
MacLennan, 1981; Beretz et al, 1978; Ruckstuhl et al., 1979). Further evidence 
of this impact on the signalling pathways within the cell comes from the study 
where Tosyl-phenylalanine-chloromethyl ketone (TPCK) and quercetin were 
shown to act synergistically, with vanadate, to increase protein-tyrosine 
phosphorylation in avian cells (Van Wart-Hood et al, 1989).
Singhal et al, in 1995, discovered that quercetin also impacted on the 
signal transduction activity in the human breast cancer cell line MDA-MB-435, as 
well as causing cytotoxicity and growth inhibition. The signal transduction activity 
was elevated in cancer cells as measured by increased activity of the enzymes 
utilising 1-phosphotidylinositol (PI), for the production of the second messenger 
inositol 1,4,5-triphosphate (IP3). In these breast cancer cells quercetin inhibited PI 
kinase activity with minor inhibition of PIP kinase. IP3 concentration dropped 
accordingly to 6% of the control level.
Another second messenger, cAMP, was shown to increase in level, after 
quercetin treatment (Graziani et al, 1979) and of course as already mentioned 
quercetin affects several cAMP substrate enzymes. This sum of experimental data
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proves that quercetin has a significant capacity for affecting the signalling 
pathways in cells as well as being capable of inducing damage to DNA and 
proteins.
Due to the role that bracken fern plays in carcinogenesis in cattle, the study 
of potential factors involved from the bracken and their cellular targets is of 
considerable importance. One of the factors from the bracken fern likely to play an 
important role is quercetin. Previous studies have shown its ability to synergise 
with the transforming genes of BPV 4 in transformation of PalF cells in vitro.
With an exposure to quercetin close to the time of transfection (20pM for 
48 hours initiated 24 hours after transfection), BPV 4 E7 and Ha-ras alone (or 
BPV 4 genome and Ha-ras) can induce full transformation of the cell including 
the ability to grow independent of anchorage and tumorigenicity in nude mice. 
Thus the exposure of the cells to quercetin substitutes for BPV 4 E8, HPV 16 E6 
and mutant p53 (Pennie & Campo, 1992; Caimey & Campo, 1995; Scobie et al.,
1997). BPV 4 E7 and E8 along with Ha-ras however fail to form clones, 
displaying some sort of antagonism between E8 and quercetin in this system. 
However under the control of the viral LCR in the whole BPV 4 genome this 
antagonism is not observed suggesting the control of expression of E8 may be 
critical.
Recent studies of the LCR have demonstrated that quercetin exposure, 
again just after transfection of an reporter gene under the control of the LCR, 
causes a 3 to 4 folds elevation of its activity (Connolly et al., 1998) which was 
mapped to an initiator like sequence downstream of the TATA box. Thus one of 
the effects of quercetin action on the cells may be elevated expression of the viral 
oncogenes.
Other effects of quercetin on the PalF cell have also been observed which 
may have an impact on the synergy between virus and chemical. Exposure of the 
PalF cells to quercetin caused an alteration in the phosphostyrosine status in 
several proteins (Connolly et al., 1998) indicating that quercetin is affecting the 
signalling pathways. This may of course lead to critical alterations in gene
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expression, or responses to stimuli depending on the protein involved. Exposure to 
quercetin was also demonstrated to induce cell cycle arrest in the PalF cells in 
both the G1 and G2/M phases of the cell cycle (Connolly et al, 1998) maybe due 
to quercetin’s impact on the signalling pathways and/or induced DNA damage.
1.5 Project Aims
Previous work has demonstrated the synergy between the oncogenes of 
BPV 4 and quercetin in the transformation of PalF cells. Quercetin exposure in 
close connection to transfection of BPV 4 E7 and Ha-ras results in full 
transformation of the cell without the need for the expression of BPV 4 E7, HPV 
16 E6 or mutant p53 (Pennie & Campo, 1992; Caimey & Campo, 1995; Scobie et 
al, 1997). Additionally quercetin also elevates the activity of the viral LCR which 
would lead to an increase in the expression of the viral proteins and as such may 
contribute to the transformation of the cell (Pennie & Campo, 1992; Connolly et 
al, 1998). The elevated expression of the BPV 4 E7 oncogene would be then 
hypothesised to increase the inhibition of the cyclin dependent kinase inhibitors 
p2 ]Wafi/ciPi ancj p2 7 KiP1? thus permitting greater levels of pl05Rb phosphorlyation 
and therefore it’s inactivation, additionally to the inactivation caused by direct 
binding of the pl05Rb protein by E7. This would therefore lead to a greater level 
of release from the negative effect of the pl05Rb protein on the cell cycle.
However as the timing of quercetin exposure is critical to the chemical’s 
effectiveness in the transformation of PalF cells this is unlikely to be the only 
function of quercetin important in the process.
Thus the initial aim of the project was to establish cell lines derived from 
the transfection of BPV 4 E7 and Ha-ras with or without quercetin exposure. 
Subsequent analysis of the resultant cell lines would permit a study of alterations 
in the tumorigenic and non-tumorigenic transformed cells. This would then lead to 
greater insight as to the nature of the transformation of the primary cell and the 
potential targets of quercetin exposure.
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Additionally, study of the quercetin induced cell cycle arrest observed in 
PalF cells (Connolly et al., 1998) and the effect of BPV 4 E7 and Ha-ras, on this 
arrest of the cell, was to be undertaken. The cell cycle arrest caused by quercetin 
may seem contradictory to the hypothesis of synergy between quercetin and virus. 
However there are reasons why this may in fact be important to the transformation 
of the PalF cell. Under normal conditions the cells would arrest due to quercetin 
exposure, however under conditions where E7 is expressed the signal to arrest 
could be abrogated and the cells allowed to cycle. Precedent for this would be the 
evidence displaying that HPV 16 E7 can abrogate p53 induced cell cycle arrest 
resultant from DNA damage (Demers et al., 1994; Hickman et al, 1994). This 
abrogation of arrest would then permit accumulation of genetic lesions which may 
promote the cells progression to full transformation.
Cell cycle analysis would allow testing of the hypothesis that abrogation of 
the cell cycle arrest, induced by quercetin, by the transfected genes would be an 
important step in the progression to tumorigenic status.
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CHAPTER TWO 
MATERIALS AND METHODS
2.1 Materials
2.1.1 Antibodies
SUPPLIER ANTIBODY
CalbioChem- Novabiochem corporation 
San Diego, USA
Anti-mouse IgM horseradish peroxidase 
linked whole antibody (raised in goat)
CalbioChem- Novabiochem corporation 
San Diego, USA
Anti-Actin (Ab-1). Mouse monoclonal IgM 
antibody (clone JLA20).
Amersham International pic, 
Amersham, Bucks, England
Anti-rabbit IgG horseradish peroxidase 
linked whole antibody (raised in sheep)
Amersham International pic, 
Amersham, Bucks, England
Anti-mouse IgG horseradish peroxidase 
linked whole antibody (raised in sheep)
Dako, Bucks, England Anti-CD20. FITC conjugated whole mouse 
monoclonal IgG antibody (clone B-Lyl)
Dako, Bucks, England Anti-BrdU. Mouse monoclonal IgG 
antibody, (clone Bu20a)
Sigma, Poole, Dorset, England Anti-mouse IgG. FITC conjugated whole 
antibody (raised in goat)
Transduction Laboratories, Lexington, 
USA
Anti-Ha-ras. Mouse monoclonal IgG 
antibody (clone 18)
Santa Cruz Biotechnology, Inc. 
California, USA
Anti-p21. Rabbit polyclonal IgG antibody 
(clone C-19).
Santa Cruz Biotechnology, Inc. 
California, USA
Anti-p53. Mouse monoclonal IgG antibody 
(clone Bp53.12).
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2.1.2 Bacterial Hosts
SUPPLIER BACTERIAL HOSTS
Gibco Europe Life Technologies Ltd., 
Paisley, Scotland
E. coli DH5a competent cells
2.1.3 Buffers
TE lOmM Tris-HCl pH 8.0, ImM EDTA pH 
8.0
TEG 25mM Tris-HCl pH 8.0, lOmM EDTA pH 
8.0, 50mM Glucose
5x TBE buffer 40mM Tris base, 16mM acetic acid, ImM 
EDTA, pH8.0
1 x ligase buffer 50mM Tris HCL pH7.6, lOmM MgCl2, 
ImM ATP, ImM DTT, 5% (w/v) 
polyethylene glycol-8000
Phosphate buffered saline (PBS) 137mM NaCl, 44mM KC1,1.4 mM 
KH2P 04, 8.5 mM Na2HP04
10 x loading buffer 0.45% (w/v) Bromophenol blue, 1% (w/v) 
SDS, lOOmM EDTA, 2.5% (w/v) Ficoll 
400 in TE
SDS-PAGE Lysis buffer 1M Tris-HCl (pH 6.8), 10% (w/v) SDS, 
20% (v/v) glycerol
SDS-PAGE Resolution gel buffer 0.5M Tris (pH8.8), 0.4% (w/v) SDS
SDS-PAGE Stacking gel buffer 0.5M Tris (pH6.8), 0.4% (w/v) SDS
Tris-glycine electrophoresis buffer 25mM Tris, 250mM glycine and 0.1% 
(w/v) SDS
2x SDS gel loading buffer 4% (w/v) SDS, 0.2% (w/v) bromophenol 
blue, 20% (v/v) glycerol and lOOmM Tris, 
pH6.8
Hypotonic Buffer (Buffer A) lOmM HEPES/ KOH (pH7.9), 1.5mM 
MgCl2, lOmM KC1, 0.5mM DTT, 0.2mM 
PMSF.
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High Salt Buffer (Buffer B) 20mM HEPES/ KOH (pH7.9), 25% 
Glycerol, 420mM NaCl, 1.5mM MgCL, 
0.2mM EDTA, 0.5mM DTT, 0.2mM 
PMSF
Dephosphorylation buffer 50mM Tris HC1, O.lmM EDTA. pH 8.0
2.1.4 Cells
Name Transfected Plasmids Quercetin Exposure Population
PalF None No n.a.
E7R pZipneo E7 and pT24Ras No pool
E7Q pZipneo E7 and pT24Ras Yes clone
E7Qb pZipneo E7 and pT24Ras Yes clone
E7QT2 pZipneo E7 and pT24Ras Yes clone
E7QPa pZipneo E7 and pT24Ras Yes pool
E7QP|3 pZipneo E7 and pT24Ras Yes pool
E7QPy pZipneo E7 and pT24Ras Yes pool
QOD pBV4 and pT24Ras No clone
Q2D pBV4 and pT24Ras Yes clone
Raji None n.a. n.a
88529B None n.a. n.a.
Note:
1. 88529B was derived from an in vivo transforming papilloma (Campo et al., 
1985)
2. Raji cells were derived from a Human Burkitt Lymphoma (Positive from CD20 
antigen expression)
2.1.5 Cell Culture Materials
SUPPLIER MATERIAL
Cadisch and Sons, Finchley, UK 70pm filter nylon gauze
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(i).Globerpharm Ltd., Esher, Surrey, 
England
(ii). Harlan Sera-Lab ltd., Crawley Down, 
England
Foetal Calf Serum 
Foetal Calf Serum
Gibco Europe Life technologies Ltd., 
Paisley, Scotland
10% Dulbecco s Modified Eagles Medium
lOx F10 (Ham) Medium
200 mM glutamine
Geneticin. G418 sulphate
MEM amino acids solution (50x)
7.5% sodium bicarbonate 
100 mM sodium pyruvate 
2.5% Trypsin
2.1.6 Chemicals & Enzymes
Supplier- Amersham International pic. Amersham. Bucks. England 
ECL Western detection agent 
Redivue [a32P]dATP
Supplier- BDH Chemicals Ltd.. Poole. Dorset. England.
Calcium chloride
D-glucose
Glycerol
Repelcote silicone treatment
Supplier- Beta Lab.. East Mosley. Surrey, England.
Yeast Extract
Supplier- Biogenesis Ltd.. Bournemouth. England.
RNAzolB
Supplier- Boehringer Mannheim UK Ltd.. Lewes. East Sussex. England. 
Caesium chloride
43
Chapter Tw o M aterials & M ethods
DOTAP (N-[l-(2, 3-Dioleoyloxy) propyl]-N, N, N- 
trimethylammoniummethylsulfate)
DNase 1, RNase-free 
Protease K
Supplier- Difco laboratories, Detroit, Michigan, USA.
Bacto-Agar
Bactotryptone
Supplier- Fisons Scientific Equipment. Loughborough. England.
Acetic acid
Butan-l-ol
Chloroform
di-potasium hydrogen orthophosphate anhydrous 
Ethylene diamine tetra acetate (EDTA) disodium salt 
Dimethyl sulfoxide (DMSO)
Hydrochloride acid 
Magnesium chloride 
Magnesium sulphate 
Methanol
Potassium chloride
Potassium dihydrogen orthophosphate 
Propan-2-ol
Sodium acetate
Sodium carbonate
Sodium chloride
Sodium dodecyl sulphate (SDS)
Sodium hydroxide
Supplier- Fluka AG. Chemisch Fabrik CH-9470 Buchs. 
Methocel MC 4000
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Supplier- Gibco Europe Life technologies Ltd., Paisley, Scotland.
All DNA restriction enzymes and appropriate buffer concentrates were obtained 
from Gibco Life Technologies (BRL) unless otherwise stated. The following 
reagents were also obtained from Gibco:
Agarose (ultrapure electrophoresis grade)
Tris Base
Supplier- James Burrough Ltd.. Witham. Essex. England.
Ethanol
Supplier- Kramel Biotech Ltd., Cramlington, Northumberland. England. 
Ribonuclease A
Supplier- NBL Gene Sciences 
Alkaline phosphatase 
T4 DNA ligase
Supplier- Pharmacia-Biotech Ltd
poly(dl-dC)
poly(dA-dT)
Supplier- Promega, Southampton, England 
Ribonuclease Inhibitor
Supplier-Sevem Biotech Ltd., Kidderminster, Worchester. England.
30% (w/v) acrylamide:0.8% (w/v) bis-acrylamide 
40% (w/v) acrylamide:2.1% (w/v) bis-acrylamide
Supplier- Sigma Chemical Co., Ltd., Poole, Dorset England.
P -mercaptoethanol 
Acetly Coenzyme A 
Benzamidine
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Bicinchoninic Acid solution 
Bleomycin Sulphate 
Bovine Serum Albumin 
Bromophenol Blue 
Coomassie Brilliant Blue R
Copper(II) sulphate (pentahydrate 4% (w/v) solution) 
DEPC
Dithiothreitol (DTT)
Ethidium Bromide 
Ficoll (type 4000)
HEPES
Leupeptin
Lysozyme
Nonidet P-40 (NP40)
ONPG
Phenol:Chloroform:Isoamyl Alcohol (25:24:1 (v/v)) 
PMSF
Ponceau S solution
Quercetin (3,3’,4’,5,7-pentahydroxyflavone)
Salmon testes DNA (sodium salt)
TEMED (N,N,N’,N’-tetramethylethylenediamine) 
Tween-20 (Polyoxyethylene sorbitan nonolaurate)
Supplier-Oiagen. Dorking, Surrey, England 
Superfect Transfection Reagent™
Supplier- Vector Laboratories. Burlingame, USA. 
VECTASHEILD™ Mounting Medium
2.1.7 Equipment and Plasticware
SUPPLIER EQUIPMENT
Alpha Laboratories Ltd., Eastleigh, Microfuge tube
46
Chapter Two M aterials & M ethods
Hampshire, England Pastettes
Amersham International pic, Amersham, 
Bucks, England
Hybond-C extra
Becton Dickinson Labware, Plymouth, 
England
Falcon 1059 polypropylene tubes 
Falcon 2059 polypropylene tubes 
Falcon 2097 polypropylene tubes 
Falcon 2098 polypropylene tubes 
Sterile Plastipak syringes 
18 gauge sterile syringe needles 
60, 90 and 140 mm tissue culture dishes
Bibby sterilin Ltd., Stone, Staffs, England. 60 and 90 mm bacteriological petri dishes 
Sterile plastic universal containers
Costar Corporation, High Wycombe, 
Bucks, England
24 well tissue culture plates 
96 well tissue culture plates 
Disposable Cell scrapers
Dupont Uk Ltd., Stevenage, Hertz, 
England
Polyallomer ultracentrifuge tubes
Eastman Kodak Co., Rochester, New 
york, USA
X-ray film (XAR-5)
Gelman Sciences, Northampton, England Sterile 0.2 pm acrodisc filters
Ilford Ltd., Mobbrrley, Cheshire, England Ilford PANF 50 black and white film
Nunc, Roskilde, Denmark T25, 80, and 175 cm2 tissue culture flasks 
Cryotubes
Sartorius AG, 37070 Goettingen, Germany Collodium Bags
Technical Photo Systems., Cumbernauld, 
Scotland
Fuji RX medical X-ray film
Whatman International Ltd., Maidstone, 
Kent, England
Whatman 3MM filter paper
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2.1.8 Kits
SUPPLIER KIT
Perkin Elmer Cetus, Norwalk, USA. GeneAmp PCR core kit 
GeneAmp thinwalled reaction tubes 
BigDye™ Terminator Cycle Sequencing
Promega ltd., Chilworth Research Centre, 
Southampton, England
Luciferase Assay System 
Reporter Lysis 5 X Buffer
Qiagen ltd., Dorking, Surrey, England QLA prep Spin plasmid miniprep kit 
QLA quick gel extraction kit 
RNeasy Mini RNA purification kit 
Omniscript RT Kit 
HotStar Taq PCR Kit
Invitrogen, Groningen, Netherlands S.N.A.P Total RNA Isolation Kit
2.1.9 Molecular Weight Markers
SUPPLIER MARKER
Amersham International pic, Amersham, 
Bucks, England
Rainbow™ coloured protein molecular 
weight markers
Gibco Europe Life Technologies Ltd., 
Paisley, Scotland
Bacteriophage X DNA (Hindlll digested) 
lOObp DNA ladder 
1Kb DNA Ladder
2.1.10 Other Materials
SUPPLIER MATERIALS
Beatson Institute Central Services Amphotericin B
LB-Medium (Luria-Bertani Medium)
Kanamycin
Penicillin
Sterile distilled water 
Sterile glycerol
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Sterile phosphate-buffered saline (PBS) 
Sterile phosphate-buffered saline + 
EDTA (PE)
Merck Ltd., Poole, England Silicone grease
Johnson and Johnson Medical Limited, 
Berks, UK
PRESEPT* effervescent disinfectant 
tablets
Premier Beverages., Adbaston, Stafford, 
UK
Marvel (Dried Skimmed milk)
2.1.11 Plasmids
pBV4 contains the whole BPV-4 genome (7.265 kb) cloned into the Bam H I site 
of pAT153 (Campo & Coggins, 1982).
pT24 is a pUC13 derived plasmid containing the 6.6 kb activated human c-Ha-ras 
oncogene from the T24 human bladder carcinoma line originally cloned in 
pBR322 (Santos et al, 1982). This plasmid construct was a gift from M. O’Prey 
(Beatson Institute, Glasgow).
pZipneoSV (XI) (referred to as pZipneo throughout the text) consists of a 
Moloney murine leukaemia virus (MoLV) transcriptional unit, including the long 
terminal repeats (LTRs), and pBR322 sequences. This construct has a unique 
BamH I cloning site and also contains DNA sequences derived from the 
transposon Tn5, which encodes G418-resistance (neomycin resistance) in 
mammalian cells (Cepko et al., 1984).
pZipneoE7 contains nucleotides (nts) 652-1250 of the BPV-4 genome cloned into 
the BamH I site of pZipneo SV (XI) (Pennie et al, 1993). In pZipneoE7 the BPV- 
4 E7 gene is under the transcriptional control of the Moloney leukaemia virus 5 
long terminal repeat (MoLV LTR).
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pRGCfosLuc carries two p53-binding sites from the ribosomal gene cluster 
promoter upstream of the murine c-fos promoter linked to a firefly luciferase 
reporter gene.. This was a kind gift from Dr J.D.Zhu, (Cyclacell)
pFosLuc This is the control plasmid for pRGCfosLuc. It lacks the p53-binding 
sites, thus only contains the murine c-fos promoter linked to the firefly luciferase 
reporter gene. This was also a kind gift from Dr J.D.Zhu, (Cyclacell)
pCB6wtp53 This plasmid expresses wild type human p53 from the CMV 
promoter in the pCB6+ plasmid. This was a kind gift from Dr Kevin Gaston 
(University of Bristol)
pCB6mtp53 This plasmid expresses a mutant form of human p53 from the CMV 
promoter in the pCB6+ plasmid. This was a kind gift from Dr Kevin Gaston 
(University of Bristol)
pGL2NA(mdm2) This plasmid utilises the human mdm2 gene promoter linked to 
a firefly luciferase reporter gene. This was a kind gift from Dr Kevin Gaston 
(University of Bristol)
WWP-Luc This plasmid utilises the human p2iWafl/Cipl gene promoter linked to a 
firefly luciferase reporter gene. This was a kind gift from Dr Bert Vogelstein (John 
Hopkins Hospital, Baltimore)
pCHllO is a control vector for eukaryotic transfection assays, which contains a 
functional ZacZ gene which is expressed either from the SV40 early promoter in 
eukaroytes or from the E.coli gpt promoter in prokaroytes. This vector was 
commercially obtained from Pharmacia..
pCMVCD20 is an eukaryotic expression plasmid, pCMV-neo-BamHl (Baker et 
al, 1990), of the cell surface epitope CD20. Expression is driven by the CMV 
promoter. This plasmid was a kind gift of Dr D.Johnson (Beatson Institute, 
Glasgow)
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pEGFPNl is a eukaryotic expression plasmid for the Green Flourescent Protein 
(GFP). Expression is driven by the CMV promoter. This plasmid was a kind gift 
from Dr R.Nibbs (Beatson Institute, Glasgow)
2.1.12 Water
Distilled water for the preparation of buffer stocks was obtained from a Millipore 
MilliRQ 15 system, and for protein, enzyme, RNA or recombinant DNA 
procedures was further purified on a Millipore MilliQ System to 18MQ/cm. 
Sterile distilled water for making up tissue culture media was supplied by the 
Beatson Institute for Cancer Research Technical Service.
2.2 Methods
2.2.1 Molecular biology
2.2.1.1 Oligonucleotide Synthesis and Purification
Oligonucleotides were synthesised by Beatson Institute technical services 
staff on an applied Biosystems model 381A DNA Synthesiser or 392 DNA/RNA 
Synthesiser using the manufactures protocols and Cruachem reagents. The final 
primers were synthesised with or without trityl group protection. All primers were 
firstly deprotected after synthesis by incubating in a 55°C water bath overnight.
“Trityl on” primers were detritylated using a Cruachem oligonucleotide 
purification (COP) cartridge according to manufacturers instructions. Each 
oligonucleotide was ultimately eluted from COP cartridge minus the trityl group 
using 1 to 2ml of 20% (v/v) acetonitrile. The acetonitrile was evaporated off and 
the primer dissolved in 0.5ml sterile distilled water or TE pH 8.0. Primers were 
stored at -20°C.
“Trityl o ff’ oligonucleotides were provided in ammonia. The 
oligonucleotides were deprotected by heating to 55°C overnight then purified by 
precipitation with butan-l-ol. 1ml butan-l-ol was added to 150pl oligonucleotide 
solution and microcentrifuged at 14000 for 20 minutes at room temperature.
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Excess butanol was removed by centrifugation under vacuum and the primer 
dissolved in an appropriate volume of sterile distilled water or TE pH 8.0. Primer 
concentration was determined as described in section 2.2.1.4.
2.2.1.2 Denaturation of Double-Stranded DNA Template
The double stranded DNA (dsDNA) was alkali-denatured by using the 
following alkaline denaturation reaction. The reaction was carried out in a final 
volume of 20pl comprising of 0.5pmol of dsDNA template, 0.2M NaOH, 0.2mM 
EDTA and sterile, deionized water to final volume 20pi. This was incubated for 5 
minutes at room temperature
The DNA was precipitated by adding one tenth of 2M ammonium acetate, 
pH 4.6 and 3.5 volume of ethanol and standing at -70°C for 30 minutes followed 
by centrifugation (14000 rpm) in a microcentrifuge for 15 minutes at 4°C. The 
pellet was washed with 70% ethanol before drying under vacuum for 5 minutes to 
remove all traces of ethanol. The pellet was dissolved in appropriate volume of 
sterile distilled water and stored at -20°C.
2.2.1.3 DNA Extraction with Organic Solvent and Ethanol Precipitation
DNA samples were purified by extraction with phenol:chloroform in 
order to remove contaminants, such as residual enzyme activities from a 
restriction reaction or detergent which might otherwise interfere with subsequent 
cloning steps. In the first round of extraction the DNA sample was mixed with an 
equal volume of phenol:chloroform. Phenol:chloroform was freshly prepared 
from an equal volume of 1M Tris-HCl pH8.0, saturated phenol and 
chloroform.'isoamyl alcohol (24:1 v/v). The aqueous DNA and organic phase 
were mixed thoroughly by vortexing, then separated by centrifugation in a 
microcentrifuge at 14000 rpm for 5 minutes at room temperature. The upper 
aqueous phase was transferred in a clean eppendorf tube, care was taken not to 
transfer any of the interphase to the tube, and the extraction process repeated. The 
aqueous phase was then extracted with an equal volume of chloroform 
(chloroform:isoamyl alcohol, 24:1 v/v) by vortexing and centrifugation as 
described above. This was repeated to remove any traces of phenol from the
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aqueous phase. The aqueous phase was transferred to a fresh eppendorf for 
ethanol precipitation.
Ethanol precipitation was used to concentrate DNA samples and also to 
remove solute contaminants such as salt. The aqueous DNA solution was mixed 
with one tenth volume of 3M sodium acetate pH 5.2 and 2-2.5 volumes of ice 
cold ethanol. The sample was then mixed well by inversion several times and 
then stored at -20°C or, alternatively, placed on dry ice for 15-30 minutes to 
facilitate DNA precipitation. The precipitated DNA was collected by 
centrifugation in a microcentrifuge at 14000 rpm for 15 minutes at 4°C. The 
supernatant was discarded, and the pellet was washed with 70 % ethanol to 
remove any trace of salt, dried under vacuum before resuspension in distilled 
water at an appropriate concentration. The DNA concentration was determined as 
described below.
2.2.1.4 Quantitation of Nucleic Acids
The concentration of nucleic acid in a solution was determined 
spectrophotometrically in a Beckman DU 650 spectrophotometer. Samples were 
diluted in TE and transferred to a quartz cuvette with a pathway of 1cm. The 
spectrophotometer was initially calibrated using TE buffer only as a blank. The 
optical density reading were obtained at 260nm and 280nm; an O.D. reading of 1 
at 260nm (A260 = 1) corresponds approximately to a concentration of 50pg/ml of 
double stranded DNA, for oligonucleotides an A260 of 1 was taken to correspond 
to ~35pg/ml, and for RNA an A260 of 1 was taken to correspond to 40^ig/ml. The 
ratio between readings at 260nm and 280nm (A26o-A28o) provided an estimate of 
the sample purity; a ratio of -1.8 indicated that preparations contained essentially 
no protein or phenol contamination.
2.2.1.5 Restriction Enzyme Digestion of DNA
Restriction digests were carried out in small reaction volumes using 
enzymes and their appropriate concentrated buffer solutions according to the 
manufacturers.
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Plasmid DNA was incubated with 5-10 units enzyme/^ig DNA in a 
buffered solution ensuring that the total volume of enzyme added did not 
exceeded one tenth of the final reaction volume. Small quantities of plasmid 
DNA (<5pg ) were routinely digested in a 20pl reaction volume as specified by 
the manufacturer for 2 hours at 37°C. Large digests were carried out in 
proportionally larger reaction volumes. The digestion fragments were analysed by 
agarose gel electrophoresis as described below.
2.2.1.6 Agarose Gel Electrophoresis
Horizontal gel cast apparatus from Pharmacia was used. In general, 1% 
(w/v) agarose gels were used, but smaller fragments (100-400) were separated on 
2-4% gels. Low melting point agarose was used at a concentration of 1% (w/v) in 
order to isolate and purify required DNA restriction fragments. Gel mixes 
containing the appropriate amount of agarose were dissolved in 0.5 x TBE buffer 
by heating the solution in a glass conical flask in a microwave until all the 
particles of agarose gel had dissolved. The gel was poured when the agarose was 
hand hot and a comb with the required number and size of teeth placed 
immediately into the gel to form the sample wells. The gel was submerged in 0.5 
x TBE buffer. The samples containing 1 x loading buffer were loaded in each 
well along with an appropriate size marker (e.g. 100b ladder, 1Kb ladder) into the 
first and/or last well in the gel and run at 70-100 constant voltage usually until the 
samples’ blue dye front was 1-3 cm from the end of the gel. Once run, the DNA 
fragments were visualised by staining the gel in running buffer containing 
0.5pg/ml ethidium bromide with gentle agitation for 10 minutes at room 
temperature. The separated DNA was visualised by illumination with short wave 
(312nm) UV light and photographed through a red filter onto videoprint paper 
using an Appligene Imager.
2.2.1.7 Isolation and Purification of DNA Restriction Fragment from 
Agarose Gel
The DNA fragment to be used for cloning was recovered from low melting 
point agarose gel and visualised as described in section 2.2.1.6. The fragment was
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cut out of the gel with a clean scalpel blade and,the gel slice placed in an 
eppendorf tube. Extraction of the DNA fragment from the agarose was achieved 
using a Qiagen Qiaquick gel extraction kit following the manufacturer’s 
instructions.
2.2.1.8 Ligation of DNA Fragments
Both vector DNA and the DNA fragment to be inserted into the vector 
were separately digested and purified as described above and then isolated by gel 
electrophoresis as described in section 2.2.1.6.
The vector DNA was dephosphorylated at its termini to prevent re-ligation. 
After the vector DNA had been linearized by digestion, the reaction mixture was 
adjusted by adding dephosphorylation buffer and 1 unit of Calf Intestinal Alkaline 
Phosphatase (CLAP) was added to the reaction mixture and incubated at 37°C for 
30 minutes. The reaction was stopped by heating to 90°C for a further 5 minutes. 
Another 1 unit of CLAP was added to the reaction mixture and incubated at 37°C 
for 15 minutes. All enzyme activity in the reaction was finally stopped by heating 
to 90°C for further 5 minutes.
The DNA was phenolxhloroform extracted, ethanol precipitated and then 
resuspended in appropriate volume of distilled water and stored at -20°C.
The DNA fragment was inserted into dephosphorylated vector (lOOng) at a 
ratio of 3:1 respectively. The vector and inserted DNA were incubated together in 
a reaction containing 1 x ligase buffer and 1 unit of T4 ligase at 22°C for 1 hour or 
overnight. Dilutions of this reaction volume were used to transform competent 
bacterial cells (section 2.2.1.9).
2.2.1.9 Transformation of Bacterial Hosts
All plasmids were propagated in commercially available E. coli DH5a 
competent cells supplied as frozen stocks (Gibco) kept at -70°C until use. 
Bacteria were transformed following manufacturer s instructions. Competent cells 
were thawed slowly on ice, and 100 pi of aliquots put into a prechilled 
polypropylene culture tube (Falcon 2059) and 1-2 ng of the appropriate plasmid 
DNA added and mixed by gently moving the pipette tip trough the cells while 
dispensing. The cells were then incubated on ice for 30 min before being heat
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shocked for 60 seconds at 42°C. The tube was then immediately placed on ice for 
5 min. 100 pi of room temperature SOC Media (2% Bactotryptone, 0.3% Yeast 
Extract, lOmM NaCl, 2.5mM KC1, 20mM Mg2+ Stock (equimolar ratio of 
MgCl2.6H20 & MgS0 4 .7 H2 0 ) and 20mM Glucose) was then added to each 
transformation reaction. The tube was then transferred to a shaking 37°C 
incubator (approximately 225rpm) for 1 hr to allow expression of the antibiotic 
resistant marker. Following this, cells were spread on an L-agar plate containing 
the appropriate antibiotic. The plate was inverted and incubated overnight at 37°C 
to allow colony formation.
2.2.1.10 Glycerol Stocks
Host strains, and their derivatives containing useful plasmids, were stored 
as glycerol stocks for future retrieval. 850 pi of an overnight culture was mixed 
gently with 150 pi sterile glycerol in a 1.5 ml Nunc Cryotubes and stored at -70°C. 
A sterile plastic loop was used to retrieve an aliquot of cells as and when required.
2.2.1.11 Small Scale Preparation of Plasmid DNA (Miniprep)
Small amounts of plasmid DNA were extracted from transformed bacterial 
colonies to identify correct clones.
Single colonies of bacteria carrying the required plasmid were picked 
using a sterile yellow pipette tip and grown in 5 ml culture of L-Broth (1% w/v 
Bactotryptone, 0.5% w/v yeast extract, 1% w/v NaCl) containing antibiotic 
(lOOpg/ml Ampicillin) at 37°C in a shaking incubator (225rpm) overnight. 10 
separate colonies were generally picked for screening at any one time. Bacteria 
were pelleted from 1.5ml of overnight culture by spinning in a microcentrifuge 
(14000rpm) for 30 seconds at room temperature. DNA was prepared using the 
QLA prep Spin plasmid miniprep kit following the manufacture’s instructions.
2.2.1.12 Large Scale Preparation of Plasmid DNA
Bacteria containing the plasmid of interest were streaked onto an L-agar 
plate containing the appropriate antibiotic and the plate inverted and incubated 
overnight at 37°C to allow colony formation. A single colony was picked, using a
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sterile yellow tip, from this plate and used to inoculate a sterile universal tube 
containing 5 ml of L-Broth medium and the appropriate antibiotic (100p,g/ml 
Ampicillin) which was then put in a shaking incubator at 225rpm overnight at 
37°C. This culture was then added to 500 ml of Superbroth, containing 100p,g/ml 
Ampicillin in a 1 litre glass conical flask (to allow good aeration), then returned to 
the shaking incubator for 48 hours. Superbroth is composed of two solution, A 
and B. Solution A consists of 12 g of bactotrypton, 24 g of yeast extract, and 5 ml 
of glycerol made up to final volume of 900 ml with distilled water. Solution B 
consists of 12.5 g of di-potasium hydrogen orthophosphate (K2HPO4) and 3.8 g of 
potassium dihydrogen orthophosphate (KH2PO4) made up to a final volume of 
100 ml. Both solution were autoclaved separately and combined just prior to use.
Bacterial cells were pelleted by centrifugation in a Sorvall RC-5B 
centrifuge (Sorvall GS-3 rotor) at 5,000 rpm for 10 min at 4°C and the supernatant 
was removed. The pellets were resuspended in 18 ml of TEG (50 mM glucose, 
lOmM Tris-HCl (pH8.0), 10 mM EDTA). Resuspended pellets were pooled into 
one centrifuge bottle and 2 ml of lysozyme (10 mg/ml) were added. The 
suspension was mixed gently and allowed to stand on ice for 10 min. 40 ml of 
freshly prepared alkaline SDS (Q.2 M NaOH, 1% SDS) were added and the 
suspension mixed by gentle inversion and placed on ice for 5 min. 30 ml of ice 
cold 5M potassium acetate (490.7 g KAc and 115 ml glacial acetic acid made up 
to 1 litre in water) were added, the whole solution inverted sharply five times and 
then returned on ice for 20 min. The flocculate was centrifuged at 8,000 rpm for 5 
min at 4°C in a Sorvall GS-3 rotor and the supernatant filtered through gauze into 
a 250ml measuring cylinder. 0.6 volumes of room temperature propan-2-ol was 
added, then the whole solution transferred to 250ml centrifuge bottle and mixed 
by inversion several times and left at room temperature for lOmin. The nucleic 
acid in this cleared lysate was precipitated and pelleted by centrifugation at 8,000 
rpm for 5 min at 4°C. The supernatant was removed and the nucleic acid pellet 
washed with 50ml room temperature 70% ethanol to remove any salt. The solution 
was centrifuged for a further 5 min at 8,000 rpm at 4°C. After discarding the 
supernatant, the pellet was allowed to dry at room temperature for 10 min before 
being resuspended in 9ml of TE.
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Ultracentrifugation through a caesium chloride (CsCl) density gradient was 
then carried out to further purify the plasmid DNA. 10 g of caesium chloride was 
added to the solution and allowed to dissolve at room temperature. 500pl of a 
lOmg/ml ethidium bromide solution was added to visualise the DNA band after 
centrifugation. The refractive index of this solution adjusted to 1.395. The 
solution was transferred to a sealable centrifuge tube (11.5ml Dupont disposable 
tube) with a protective metal cap over the top of each tube. Samples were spun in 
a balanced Beckman ultracentrifuge at 55,000 rpm for 16 to 24hr at 18°C in a 
T1270 rotor. The tube was carefully removed from the centrifuge rotor and placed 
securely in a clamp on a rotor stand. After centrifugation, any contaminating RNA 
was found to have pelleted at the bottom of the tube. Two distinct bands were 
observed; the upper band contains sheared linear plasmid DNA and residual 
bacterial chromosomal DNA while the lower band contains closed circular 
plasmid DNA. An 18 gauge needle was first inserted into the top of the tube to act 
as an air inlet and the lower band was gently withdrawn by similarly piercing the 
side of the tube ~ 1cm below the lower band with an 18 gauge needle connected to 
a syringe. The plasmid DNA band was then transferred to a clean ultracentrifuge 
tube. The tube was filled with CsCl/TE (RI=1.395) as before and underwent 
further centrifugation prior to plasmid extraction.
The band removed as described above was transferred to a 5 ml Bijoux 
tube. Ethidium bromide was removed from the solution by extracting with an 
equal volume of water saturated butan-2-ol. The solution was mixed and ethedium 
bromide separated with the upper organic phase which was carefully aspirated off 
and discarded into appropriate bottles. This extraction process was repeated until 
the lower aqueous phase was clear and colourless. The CsCl was removed by 
dialysing the plasmid DNA into a dialysis tube (Collodion Bag) and placed in a 
large beaker containing 2 litres of TE. Plasmid DNA was dialysed against TE on a 
magnetic stirrer for 4 hours at room temperature. The TE buffer was changed and 
dialysis continued for a further 4 hours at room temperature or overnight at 4°C. 
DNA was then ethanol precipitated and the DNA pellet was finally resuspended in 
0.5-1 ml TE (pH 8.0), depending on the size of the pellet. The DNA concentration
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was determined as described in section 2.2.1.4. The plasmid DNA was aliquoted 
and stored at -20°C.
2.2.2 Cell Culture and Transfection
2.2.2.1 Cell Culture
All cell culture work was performed following strict aseptic techniques 
inside a laminar flow hoods (Class II Microbiological safety Cabins; Medical Air 
Technology Ltd., Manchester, England). Cells were incubated in dry 37°C 
incubators containing 5% (v/v) CO2 (Heraeus, Essex, England) and were routinely 
screened for mycoplasma infection using a fluorescent dye technique (M. 
Freshney, Beatson Institute, Glasgow).
2.2.2.2 Isolation of Primary Bovine Fibroblasts
The fibroblasts from foetal bovine palate were isolated as described 
previously by Jaggar et al., (1990). A small section of soft palate tissue was taken 
from bovine foetuses of less than 5 months gestation obtained from the veterinary 
post-mortem room at the Glasgow University Veterinary School. The palate tissue 
was sterilized by a 30 second wash in 70% ethanol and then dissected into small 
pieces approximately 2mm2 in size using crossed scalpels and placed into a 90mm 
dish being well spaced apart. The tissue was allowed to adhere to plastic by 
placing the dishes in a dry 37°C incubator containing 5% (v/v) C02for 5 minutes. 
Culture medium was then added slowly to each dish so as not to disturb the 
adherent samples. The samples were fed twice weekly over a period of two weeks 
in which time fibroblasts and keratinocytes grew out of tissue mass. The medium 
used for both isolation and subsequent routine growth of PalF cells was DMEM 
supplemented with 10% foetal calf serum, 2mM glutamine, ImM pyruvate, 
0.375% sodium bicarbonate (DMEM-10). This medium selectively favoured the 
outgrowth of fibroblasts and, as expected, keratinocytes died. After four passages 
in culture the newly extracted fibroblasts were trypsinised and reseeded into large 
(T175 cm2) flasks. Cells were expanded and stocks of PalF cells were frozen 
down in liquid nitrogen for further experiments.
59
Chapter Two M aterials & M ethods
2.2.2.3 Maintenance of Primary Bovine Fibroblasts in Culture
Cells were fed twice weekly, old medium was aspirated from sub­
confluent flasks and fresh medium added. PalF cells were grown until just sub­
confluent whereupon they were passaged approximately 1 in 4. Replating was 
performed as follows: for T80 cm2 tissue culture flask medium was aspirated off 
and the cells washed twice with 5 ml phosphate-buffered saline (PBS). The PBS 
was removed and 1 ml of trypsin solution (0.25% trypsin in lx  PE buffer; PBS 
with the addition of EDTA to 1 mM), which had been pre-warmed to 37°C, was 
added to cells. Flasks were transferred to the 37°C hot room until the cells had 
detached from the flasks. Complete medium was added and the cell suspension 
transferred to a sterile universal tube. The cells were pelleted by centrifugation at 
lOOOrpm for 5 mins at room temperature. The pellet was then resuspended in fresh 
growth medium and the cells reseeded at an appropriate density.
2.2.2.4 Long Term Cell Storage
To freeze cells stocks for storage, confluent cultures were trypsinised, and 
pelleted as described above (section 2.2.3.3). The pellet was then resuspended at a 
concentration of approximately 106 cells/ml in growth medium containing 10% 
(v/v) DMSO. The DMSO in the medium acts as a cryoprotectant but all solution 
must be chilled as DMSO is toxic to cells at room temperature. Suspensions were 
divided into 1 ml aliquots in 1-2 ml Nunc cryotubes and placed in a polystyrene 
box and frozen, well insulated, at -70°C overnight to ensure a slow rate of cooling. 
The ampoules were then transferred to a liquid nitrogen bank containing labelled 
storage rack until required. Frozen stocks were recovered by removing the 
ampoules from liquid nitrogen and placed into a small, covered bucket of water at 
37°C. Once thawed, the cells were added to 10ml of the appropriate pre-warmed 
growth medium, centrifuged, resuspended in fresh growth medium and transferred 
to 80 cm2 flasks.
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2.2.2.5 Mycoplasma Screening
A 60mm dish of NRK (Newborn Rat Kidney) cells was provided by 
Marion Lacey (Beatson Institute, Glasgow). 2ml of growth medium, taken from 
cells being tested for the presence of mycoplasma, was added to the dish of NRK 
cells containing 2ml fresh medium (SLM supplemented with 10% (v/v) FCS and 
2mM glutamine) and incubated for 3-4 days in a humidified incubator at 37°C in 
an atmosphere of 5% C 02. The growth medium from cells being screened must 
have been in contact with the cells for a minimum of 2 days. At the end of the 
incubation period all medium was removed and cells washed twice with PBS. 
2.5ml of PBS followed by 2.5ml of fixative (75% (v/v) methanol, 25% (v/v) 
glacial acetic acid) was added to the dish. This was removed and 5ml fixative 
only added. Fixative was aspirated off and a second 5ml volume of fixative added 
and then incuated at room temperature for 10 minutes. Fixative was poured off 
and the dish placed at 37°C for 15 minutes to dry completely. 5ml of Heochst 
33458 stain (0.05pg/ml in PBS) was added and the cells allowed to stain for 5 
minutes at room temperature. When the staining solution was removed the plate 
was rinsed twice with distilled water and left to air dry. A drop of distilled water 
was added to the centre of the dish and covered with a clean glass cover slip. 
Cells were finally examined using a water immersion lens on a fluorescence 
microscope (Leitz Wetzlar) with a Mercury vapour lamp light source. 
Mycoplasma, if present, can be identified as extranuclear fluorescent specs against 
the dark background.
2.2.2.6 Transient Transfection of Primary Bovine Fibroblasts (PalFs)
PalF cells were transfected with a range of plasmid DNAs (section 2.1.11) 
using the cationic lipid N-[l-(2, 3-Dioleoyloxy) propyl]-N, N, N- 
trimethylammoniummethylsulfate (DOTAP; Boehringer Mannheim BCL) 
following the manufacturer s recommendations. Briefly, cells (2xl05) were plated 
in each 60mm plate, in duplicate, containing 3ml of appropriate growth medium 
(DMEM-10) the day before transfection. For each plate of cells to be transfected 
the following transfection mixture was set up.
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DNA, DOTAP and serum free medium were mixed at a ratio of 1:4:25 
respectively at room temperature and incubated for 15 minutes at room 
temperature.
This mixture was then added directly into the medium above the cells. 
The plates were moved slowly to disperse the transfection solution throughout the 
culture medium, and were then incubated at 37°C for 16-18 hours. After 
withdrawal of the medium, cells were washed twice with 2ml of pre-warmed PBS 
and incubated in DMEM-10 medium, until quercetin or other treatments were 
initiated. Typically cells were left for 12 hours after transfection before quercetin 
treatment began, 32 hours before UV treatment and 48 hours before bleomycin 
sulphate exposure.
2.22.1 Luciferase Assays
2xl05 cells were seeded in DMEM-10 for each 60mm plate, with 3ml of 
medium per plate, the day before transfection. Transfection was performed using 
the standard DOTAP method (section 2.2.3.6). After 16-18hr., the cells were 
washed twice with 2ml PBS and incubated in DMEM-10 for a further 8 hrs, after 
which time 20-100pM quercetin or an equivalent volume of its diluent, ethanol, 
was added to the growth medium of the PalF cells. Incubation typically continued 
for a further 36 hours, with application of fresh quercetin/solvent medium every 
12 hours. If required transfectant plates were exposed to either UV irradiation (50 
or 120J/m2 ) 16 hours before harvesting, or bleomycin sulphate exposure (15pU) 
for 6 hours before harvesting.
To harvest cells were then washed twice with PBS, the PBS was 
completely removed by aspiration and 300pi of 1 x reporter lysis buffer (Promega) 
added to each well. Following 15 minutes incubation at room temperature, cells 
were scraped off the culture well and each lysate transferred to a 1.5ml eppendorf. 
Cell debris was pelleted by spinning lysates at 4°C in a microcentrifuge at 14000 
for 5 minutes. The supernatant was transferred to a second eppendorf tube taking 
care not to disrupt the cell pellet. The lysate were either assayed for reporter 
enzyme activity immediately or stored at -20°C.
Luciferase activity was determined using a luminometer with automatic 
injection (BioOrbit, model 1251). For each sample, 80pl of lysate and 120pl of
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Luciferase assay buffer (Promega) were used. Luciferase activity was normalised 
for protein content determined using the BCA assay (Pierce), and p-galactosidase 
activity as a measure of transfection efficiency.
2.2.2.8 Stable DNA Transfection of Primary Bovine Fibroblasts
PalF cells were transfected with a range of plasmid DNAs (section 2.1.11) 
using the cationic lipid N-[l-(2, 3-Dioleoyloxy) propyl]-N, N, N- 
trimethylammoniummethylsulfate (DOTAP; Boehringer Mannheim BCL) 
following the manufacturer s recommendations. Each reaction contained 5 pg of 
each relevant plasmid DNA plus 2 pg of a plasmid construct containing the 
selectable marker gene for neomycin resistance (pZipneo; Chapter 2.1.11).
Transfection classes are described in Chapter three in the Results section. 
Reactions were made up to 20 pg with sonicated salmon sperm DNA (Sigma). 
PalF cells were plated at a density of 5 xlO5 into an 80 cm2 flask 24 hr prior to 
transfection. The cells were fed with 13.5mls of growth medium on the day of 
transfection, the transfection mix was as follows: 80 pi of DOTAP was diluted up 
to 250pl with serum free DMEM medium in a separate reaction vial. DNA 
(20pg) was also diluted up to 250pl with serum free DMEM medium in a separate 
reaction vial. Both solution were mixed together and incubated for 15 min at room 
temperature. This mixture was then slowly added to the flask of cells and 
incubated at 37°C overnight. After withdrawal of the medium, cells were washed 
twice in PBS and then fresh complete medium was added to the flask. If 
appropriate, transfected cells were treated with 20 pM quercetin one day after 
transfection for 48 hours. The next day cells were split at a dilution of 1:2 and 
allow to settle for 24 hr prior to selection.
2.2.2.9 Selection of Transfected Cells
Cell were selected in medium containing 500 pg/ml G418 for 21-28 days, 
being fed twice weekly. After this time, G418-resistant colonies were scored. 
Where appropriate, several colonies were picked from each transfection class in 
order to expand them clonally.
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2.2.2.10 Isolation of Clonal Populations
Single neomycin resistant colonies were identified and their position 
marked using a microscope ring marker attachment. The cells were then washed 
twice in sterile PBS. A sterile 6 mm stainless steel cloning rings coated with 
sterile silicon grease (Merck, England) at the base was then placed over the 
identified colony thus providing a waterproof seal round each isolated colony. A 
total volume of 100 pi trypsin solution, which had been pre-warmed to 37°C, was 
pipetted within each cloning ring. After 1-2 min an equal volume of complete 
medium was added and the cell suspension transferred to a 24-well plate (Costar) 
along with 2ml medium and returned to the 37°C incubator for expansion into cell 
lines.
2.2.2.11 Transformation Assays
2.2.2.11.1 Anchorage Independent Growth
The ability of a cell line to form colonies in semi-solid media is taken as a 
phenotypic measure of its degree of transformation. The extend of transformation 
of cell populations was assayed by plating cells in Methocel based medium.
Efficiency of methocel colony formation was determined by adding 
3.75xl05 cells to 15 ml of 1% methocel including 30% Foetal Calf Serum (FCS).
The mix was plated in bacterial petri dishes. Bacteriological petri dishes 
were used to discourage cells from adhering to the bottom of the dishes. Cells, 
tested in duplicate, were left at 37°C for 12 days before being scored and 
photographed with PanF 50 technical film. Methocel medium was made up as 
follows:
3g of Methocel MC 4000 (Fluka) was added to 200 mis of distilled water 
and autoclaved. The Methocel was left to dissolve with stirring for 2-3 days at 
4°C. Following dissolution, 22 mis of 10 x FI0-HAM medium (Gibco), 4 mis of 
50 x minimum essential amino acids (Gibco), 4 mis of 0.1M sodium pyruvate, 5 
mis of 7.5% sodium bicarbonate, 100 mis of foetal calf serum (FCS) and 2% 
penicillin and streptomycin were added.
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2.2.2.11.2 Tumorigenicity Assay in Nude Mice
The ability to form tumours is an indicator of full cellular transformation. 
The transformed cells were assayed in nude mice. Cells were removed from 
selection and expanded at identical cell density. The cells were suspended in 
sterile PBS at a concentration of 108 cells/ml. 0.1 ml of this suspension (107 cells) 
were injected subcutaneously into a four-week old female athymic nude mice, 
strain MF1 nu/nu (Harlan-Olac, Bicester, England) at a single injection site. 
Typically five mice were injected per cell line tested and examined for tumour 
growth weekly up to 15-20 weeks post injection. If no tumour had developed by 
then the cells were considered to be non-tumorigenic.
2.2.2.12 B-Galactosidase Assay
The plasmid pCHHO was used in all transient transfections as an internal 
control against which the efficiency of transfection could be normalised, 
p-galactosidase can catalytically convert colourless o-nitrophenyl-p-D- 
galactopyranoside (ONPG) to yellow o-nitrophenol. The level of activity of this 
enzyme can be assayed by measuring changes in light absorbance at 420nm.
Cells were lysed as detailed in section 223.1 . To 80pl of each cell lysate, 
lml of solution I (60mM Na2HP04, 40mM NaH2P 0 4, lOmM KC1, ImM MgCl2, 
50mM P-mercaptoethanol) and 0.2ml of solution II (60mM Na2HP04, 40mM 
NaH2P 0 4, 2mg/ml) was added. After mixing, all samples were incubated at 37°C 
for 30-60 minutes or until a yellow colour change could be seen. Samples were 
transferred to plastic disposable cuvettes and the reactions stopped by the addition 
of 0.5ml 1M sodium carbonate. The absorbance was read at 420nm using a 
Beckman DU 650 spectrophotometer.
2.2.2.13 Fluorescence Activated Cell Sorting (FACS) Analysis
Fluorescence Activated Cell Sorting was used to analyse the cell cycling 
status of the cell lines in a particular population. Cells were grown in the presence 
or absence of 0-100pM quercetin according to the experimental conditions for up 
to 48 hours in DMEM-10 medium with medium changes every 12 hours.
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Cells were harvested by trypsinisation and pelleted at 4°C in growth 
medium. Each cell pellet was washed twice with ice cold PBS spinning cells, as 
before, between each wash. The second volume of PBS was aspirated off and the 
pellet was resuspended in a small residual volume of PBS (~ 500pl) before cells 
were fixed by the slow, drop by drop addition of 4.5ml ice cold 70% ethanol. 
Samples were left on ice for 1 hour. Cells were either stored at -20°C under 70% 
ethanol for no longer than 1 week or stained immediately.
To stain cells for analysis, each cell suspension in 70% ethanol was 
pelleted at 4°C for 5 minutes at 2000rpm. Ethanol was aspirated off and each cell 
pellet was washed once with ice cold PBS cells to remove any residual ethanol. 
Cells were then again pelleted at 4°C for 5 minutes at 2000rpm then resuspended 
in 500pl of staining solution (PBS containing 250ng/ml RNAse A, 20pg/ml 
propidium iodide). Samples were left covered, at room temperature for at least 30 
minutes, or for longer staining times cells were then placed at 4°C, before 
analysis.
Stained cell samples were filtered through 70pm nylon gauze into Falcon 
2054 polystyrene round bottom tubes. Samples were assayed using a Becton 
Dickinson FACScan machine and analysed using the ‘Modfit v2.0’ software 
package.
2.2.2.14 CD20 Tagging of Transient BPV-4 E7 Transfected PalF Cells
lxlO6 cells were seeded into 140m Nunc culture plates in 25 mis of 
DMEM-10 medium, and left to adhere to the substratum. The following day cells 
were transfected with 5pg of pZipneo E7 and 25pg of pCMVCD20 plasmid using 
the Superfect™ lipofection reagent as per manufacturers guidelines. Briefly 
plasmid DNA was diluted with serum free DMEM and mixed before addition of 
the Superfect™ reagent at 4pi per pg of plasmid DNA used. The mixture was 
incubated at room temperature for 15 to 20 minutes., before addition of full 
DMEM-10 to a final volume of 10 mis.
Cells were washed with pre-warmed PBS during the incubation period, 
then the transfection medium was added to the cells, ensuring full coverage of the
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plate. The transfection plate was then incubated at 37°C, 5%C02 for 5 hours 
before a single wash with pre-warmed PBS and refeeding of the plate with 25 ml 
of DMEM-10.
Transfected cells were then treated with either 0 or 50pM quercetin over 
36 hours with fresh medium being applied every 12 hours. These cultures were 
then harvested by trypsinisation.
Cells were then resuspended in 5ml of DMEM-10 and spun at lOOOg for 5 
minutes at room temperature. The pellet was then taken up in lOOpl of medium 
containing 20pi of FITC-conjugated anti CD20 antibody (DAKO) and incubated 
on ice for 30 minutes. Following the incubation cells were spun down at lOOOg for 
5 minutes and washed twice with PBS containing 1% calf serum.
The cells were then fixed overnight at 4°C in 70% ethanol. Before analysis 
the cells were then washed once in PBS and stained in 20pg per ml propidium 
iodide and 200pg per ml RNAase A in PBS for 30 minutes at room temperature.
Samples were then assayed the using a Becton Dickinson FACScan 
machine and analysed using the ‘CellQuest’ software package. CD20 positive 
cells were classed as those exhibiting FITC fluorescence 20 time that of 
background PalF cells.
2.2.3 DNA & RNA analysis
2.2.3.1 Total RNA Extraction from Cell Lines
Cells were grown in a 175cm (T175) flask to approximately 80% 
confluency. Total RNA was then extracted by either the RNAzol B method of 
extraction (Biogenesis Ltd, England) or by use of the RNeasy Kit (Qiagen). For 
the RNeasy kit method of purification cells were washed once with pre warmed
f \  7sterile PBS and trypsinised and counted. 3x10 tumorigenic or 1x10 cells of all 
other cell lines were subjected to the RNA extraction method as per manufacturers 
details.
For the RNAzolB method cells were washed twice with ice cold PBS and 
lOmls of RNAzol B was added directly to the flask. The lysate was transferred to 
a Falcon 2059 polypropylene centrifuge tube and 1 ml of chloroform was added 
with vigorous pipeting. The top of the tube was then covered with Parafilm
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(American National Can, USA) and the tube was left on ice for 15 minutes to 
allow phase separation to take place. The tube was then centrifuged in a sorval 
RC-5B (HB6 rotor) at 10,000rpm for 15 minutes at 4°C. The upper, aqueous 
phase was transferred to a fresh tube and an equal volume of isopropanol added. 
The samples were mixed and stored overnight at -20°C to allow precipitation of 
RNA and the RNA pelleted by centrifugation as before. The pellet was 
resuspended in 5 mis of 75% ice cold ethanol (made with diethylpyrocarbonate 
(DEPC) -treated RNase-free water), and transferred to an eppendorf tube. The 
RNA was pelleted in a microfuge at full speed at 4°C for 30min, dried on a 
speedivac and then resuspended in DEPC-treated RNase free water. If required 
RNA extracted by the RNAzolB protocol was given a DNA-ase treatment. This 
was carried out using a S.N.A.P Total RNA Isolation Kit (Invitrogen) as per 
manufacturers guidelines.
For all RNA extractions the concentration of RNA was measured 
spectrophotometrically as described in section 2.2.1.4. RNA samples were 
aliquoted and stored at -70°C.
2.2.3.2 Polymerase Chain Reaction (PCR)
2.2.3.2.1 Amplification of DNA
All reagents were provided in the HotStarTaq PCR Kit with the exception 
of dNTP’s which were obtained from the Perkin-Elmer Core DNA PCR kit. 
Primer sequences are described in table 2.1.
Table 2.1 Oligonucleotide PCR primers
Primer Name Primer Nucleotide Sequence
Forward E7 gctgaccttccagtcttaat
Reverse E7 tgaagaggagattgaaactg
The reaction mixture comprised 200pM of each dATP, dGTP, dCTP and 
dTTP, 1 x PCR kit buffer, 0.2[iM of each primer, 2.5 units HotStarTaq 
polymerase (a modified thermolabile DNA polymerase from Thermus aquaticus)
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and lp,g of DNA sample (controls included distilled water, pZipneo E7 plasmids, 
and l|ig  of DNA from parental PalF cells). It was aliquoted into 0.5ml GeneAmp 
PCR reaction microfuge tubes in a final volume of lOOpl. The tubes were placed 
into the PCR machine (Perkin-Elmer Cetus type 9600) and heated to 95°C for 15 
minutes to inactivate DNase and ensure all DNA duplexes were melted, in 
addition to activating the HotStarTaq. The DNA was then amplified (using 
Perkin-Elmer Cetus type 9600 thermocycler) for 35 cycles at 94°C for 60 seconds, 
59°C for 60 seconds, to allow the primers to anneal to the template DNA, 
followed by 72°C for 60 seconds, for E7, to allow extension of the amplimer 
sequences. After completion of the cycles, the reaction was incubated at 72°C for 
a further 7 minutes to ensure full extension and then cooled to 4°C. 5 pi of each 
sample was analysed by agarose gel electrophoresis (as described in section 
2.2.1.6) to check the correct product was amplified.
2.2.3.2.2 Amplification from RNA Reverse Transcriptase-PCR (RT-PCR)
RNA was prepared (see section 2.2.4.2) and used as the template for 
reverse transcription and PCR amplification of cDNA. Firstly cDNA was 
synthesised from RNA by reverse transcription using the Omniscript RT kit 
(Qiagen). The reaction was carried out according to the manufacturers 
instructions, to the following final concentrations: lx  RT buffer, 5mM of each of 
dATP, dGTP, dTTP, dCTP, 10 unit RNase inhibitor,lp,g RNA, 4 units Omniscript 
reverse transcriptase, lpM  of Oligo-dT primer, and DEPC-treated water to a final 
volume of 20 pi. Control reactions using no Omnicript reverse transcriptase were 
carried out, in addition to assaying suitable negative cell lines for each experiment.
All samples were placed in the thermocycler and further incubated at 37°C 
for 60 minutes, and then incubated at 4°C for 5 minutes. The above reaction was 
then stored at -20°C until use. Typically 2pi of the RT reaction was carried 
forward to the amplification step. PCR reactions were carried out as per 
manufacturers guidelines (Qiagen) for HotStarTaq amplification. Briefly final 
reaction volumes were 100pi consisting of 2pi of RT reaction mixture combined 
with a final concentration of lx  PCR Buffer, 200p,M of each dNTP, 0.2p,M of the 
forward and reverse primers, 2.5 Units of the HotStarTaq made up to 98pl with
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distilled water. To activate the HotStarTaq an initial incubation of 95°C was 
carried out for 15 minutes. Amplification proceeded for 35 cycles of 94°C for 60 
seconds, 59°C for 60 seconds, plus a 60 second extension at 72 °C for E7, or 3 
minute extension of p53. PCR was carried out in a Perkin-Elmer Cetus 9600 
thermocycler. The samples were then analysed by agarose gel electrophoresis as 
described in section 2.2.1.6 to ensure correct amplification.
2 ,2 3 3  DNA Sequencing
The sequence of all new plasmids was checked using Taq terminator 
sequencing on an Applied Biosystems 373A automated DNA sequencer which 
was performed by Beatson Institute technical services staff.
The region to be sequenced first underwent PCR amplification. 0.5pg of 
template DNA was added to 12pl RQ grade H20 plus 3.2pmoles the appropriate 
primer. 8pl of dye terminator cycle sequencing ready reaction premix (Perkin 
Elmer) was then added to each reaction volume contained in 250pl thin walled 
eppendorf tubes. The samples were placed in a PTC-100 programmable thermal 
controller (Genetic Research Instrumentation Ltd) and exposed to 25 cycles of 95° 
C for 30secs, 50°C for 15secs and 60°C for 4min. The PCR products were ethanol 
precipitated as detailed in section 2.3.2.4, washed with 70% ethanol and finally 
dried under vacuum before being given to a member of technical services for 
loading onto the sequencing gel. Details of the primers, and their sequences, used 
for the p53 cDNA sequencing reaction are listed in table 2.2:
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Table 2.2
Primer Name Position Primer Nucleotide Sequence
Bp53FF 1-18 5 ’ - tcgaaagcttatggaagaatcacaggca -3’
Bp53RRR 1140-1161 5 ’ - tcgatctagatcagtctgagtcaggccc -3’
Bp53F2 303-318 5 ’ - ttccgtctagggttcctg -3’
Bp53F3 637-654 5 ’ - tatgagtcccccgagatc -3’
Bp53F4 880-898 5 ’ - cctaggagcactaagcga -3’
Bp53R2 303-318 5 ’ -caggaaccctagacggaa -3’
Bp53R3 637-654 5 ’ -gatctcgggggactcata -3’
Bp53R4 880-898 5 ’ -tcgcttagtgctcctagg -3’
2.2.3.4 End Labelling Double Stranded Oligonucleotide
Single stranded oligonucleotides were synthesised using Cruachem 
chemicals and an Applied Biosystems 392 DNA/RNA automated oligonucleotide 
synthesising machine by Beatson Institute technical services. Oligonucleotides 
were deprotected by incubating at 55°C overnight, ethanol precipitated and 
resuspended in TE buffer. The concentration of oligonucleotide solutions was 
measured spectophotometrically at described in section 2.3.2.3. However, an 
optical density reading of 1 at 260nm (Abs260nm) f ° r a single stranded
oligonucleotide is roughly equivalent to a solution of 33pg/ml compared to 50p 
g/ml for double stranded DNA.
Complementary single stranded oligonucleotides were mixed together in 
equimolar amounts, heated to 95°C for 5 minutes and then allowed to cool slowly 
to room temperature which enabled the two strands to anneal together into double 
stranded molecules. The concentration of the double stranded oligonucleotide 
solution was measured spectrophotometrically and diluted with TE buffer to give 
a final concentration of 0.1 mg/ml. Oligonucleotide solutions were stored at -20°C.
Double stranded oligonucleotides with sticky ends were end labelled as 
follows. Using a random primed labelling kit (Boehringer Mannheim), lp l 
(0.5nmol) dCTP, lp l (0.5nmol) dATP and lp l (0.5nmol) dGTP solutions were
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added to 200ng of double stranded oligonucleotide. The reaction volume was 
made up to 12pl with distilled water. 2pl of lOx Klenow buffer (0.5M Tris-Cl 
(pH7.2), 0.1M MgSC>4 , ImM DTT, 0.5mg/ml bovine serum albumin (BSA -
fraction V)) was added followed by 5pi [a-32P]dATP and lp l (2 units) Klenow 
enzyme (also taken from the random primed labelling kit). The contents of the 
reaction were mixed and incubated at 37°C for 30 to 60 minutes. The 
radiolabelled oligonucleotide was separated from unincorporated nucleotides by 
polyacrylamide gel electrophoresis as described in section 2.3.2.15.
2.2.3.5 Purifying Radioactive Probe Using Polyacrylamide Gel
Electrophoresis
A 6% non-denaturing polyacrylamide gel was made by adding 15% (v/v) 
40% (w/v) acrylamide:2.1% (w/v) bisacrylamide solution to 0.5x TBE buffer 
(89mM Tris base, 89mM orthoboric acid, 2mM EDTA (pH8.0)). Polymerization 
of the gel was catalysed by the addition of 0.07% APS and 0.08% TEMED. After 
mixing thoroughly, the solution was poured between two glass plates which had 
been siliconized with repelcote, washed with detergent and cleaned with 70% 
ethanol prior to use. A comb forming sample wells was placed in the top of the gel 
immediately after pouring. The gel, 2mm thick, was left to polymerize in a vertical 
position for 1 hour before use.
The gel spacer was removed and the gel, formed between the two glass 
sheets, was placed vertically into the electrophoresis tank (ATTO) containing 0.5x 
TBE and secured in place. 0.5x TBE buffer was added to the top reservoir of the 
tank to cover the top of the gel. The comb was removed carefully from the gel and 
each well rinsed out with 0.5x TBE buffer using a 20ml syringe. The gel was run 
for 15 minutes at 150 volts to equilibrate the gel before any samples were loaded.
The radioactively labelled sample(s) was loaded into a single gel well. No 
loading dye was added to the sample, however lOpl of bromophenol blue loading 
buffer was added to the extreme wells to monitor the gels progress. The sample(s) 
was electrophoresed at 150 volts at room temperature until the blue dye front was 
approximately 5cm from the end of the gel. The position of each radiolabelled 
oligonucleotide was determined by exposing the gel, covered with cling film, to a
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sheet of Fuji RX medical X-ray film for 1-2 minutes. Using the X-ray film as a 
guide, the band containing the labelled probe was excised from the gel using a 
clean scalpel blade. The gel slice was transferred to a clean eppendorf tube and TE 
buffer was added to the tube sufficient to cover the gel slice. The tube was placed 
in a lead pot, sealed and left at room temperature overnight during which time the 
oligonucleotide eluted from the gel slice into the TE buffer. The polyacrylamide 
gel slice was removed from the solution and the radioactive oligonucleotide 
solution stored at -20°C.
2.2.3.6 Electrophoretic Mobility Shift Assay (EMSA)
Cells were harvested for their nuclear extract as described in section 
2.2.4.2. Samples of nuclear extract were removed from storage at -70°C and 
thawed on wet ice. To 5pl (10-15pg) of nuclear protein extract, still on ice, lOpl 
5x binding buffer (25mM Tris-HCl (pH7.3),5% Glycerol, 50mMMgCl2, 175mM 
NaCl, 50pg/ml BSA, 28pg/ml polydAdT and 50mM DTT) was added followed by 
lp l (~lng) of radioactively labelled double stranded oligonucleotide DNA 
(section 2.3.2.14). lOOng of various unlabelled (cold) double stranded 
oligonucleotide was added to selected samples for competition analysis. The 
volume of each reaction mix was made up to 50pl with distilled water, mixed and 
incubated on ice for 30 minutes.
Each sample was loaded into a separate well on a 5% non-denaturing 
polyacrylamide gel prepared as described in section 2.3.2.17. 5pl loading dye 
mixed with 45pi lx  binding buffer was added to the end wells on the gel to allow 
migration of the samples down the gel to be monitored. Samples were 
electrophoresed at 150 volts at 4°C until the blue dye front in the tracking wells 
was ~3cm from the end of the gel. The gel was transferred onto Whatman 3MM 
filter paper and dried down on a Biorad 583 gel drier at 80°C for 2 hours using a 
slow rise in temperature cycle. The dried gel was placed in a lead, light tight 
casette with intensifying screens, covered with a sheet of Fuji RX medical X-ray 
film and placed at -70°C overnight.
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2.2.3.7 Non-Denaturing Polyacrylamide Gel Electrophoresis
A pair of 2mm ATTO glass plates were siliconized with repelcote, washed 
with detergent and cleaned with 70% ethanol prior to use. A 5% polyacrylamide 
gel was made by adding 12.6% (v/v) of 40% (w/v) acrylamide:2.1% (w/v) 
bisacrylamide solution to 0.5x TBE buffer (89mM Tris base, 89mM orthoboric 
acid, 2mM EDTA (pH8.0)). Polymerization of the gel was catalysied by the 
addition of 0.07% APS and 0.08% TEMED. After mixing thoroughly, the solution 
was poured between two glass plates held securely together in the gel forming 
apparatus (ATTO). A comb to make the samples wells was placed in the top of the 
gel immediately after pouring. The gel was left to polymerize in a vertical position 
for 1 hour before use.
The gel spacer was removed and the gel, formed between the two glass 
sheets, was placed vertically into the electrophoresis tank (ATTO) containing 0.5x 
TBE and secured in place. The upper reservoir was filled with 0.5x TBE buffer, 
the comb was removed carefully from the gel and each well rinsed out with 0.5x 
TBE buffer using a 20ml syringe. The gel was run for 15 minutes at 150 volts 
prior to use to equilibrate the gel.
2.2.4 Protein Analysis
2.2.4.1 Protein Preparations from Cells for Western Blot Analysis
Cells were lysed by aspirating the culture medium off, washing the cell 
monolayer twice with ice-cold PBS, the PBS was completely removed by 
aspiration. 1.5ml of ice-cold PBS was added, cells were scraped off the dish and 
transferred to a 1.5 ml microcentrifuge tube. Cells were pelleted by spinning at 
4°C in a microcentrifuge at 5,000rpm for 5 minutes, the supernatant was removed 
and 300pl of boiled lysis buffer was added to the pellet. Cells were lysed 
following a 5 minutes boiling, and then sonicating the resulting cell suspension 
using an MSE Soniprep 150 sonicator. Cell debris was pelleted at 14000 rpm and 
the supernatant transferred to a new microcentrifuge tube.
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2.2.4.2 Protein Preparations from Cells for EMSA Analysis
Approximately lxlO7 cells were used in each preparation. Cells were 
trypsinised, pelleted and washed twice with ice cold PBS, with the second PBS 
wash including transfer to 1.5ml eppendorf tube. Pelleted cells were then gently 
resuspended in 400pl of Buffer A (Hypotonic Buffer) by flicking the tube. The 
mixture was then left on ice for 10 minutes before a 10 second vortex. Cells were 
then pelleted by a 10 second spin in a microfuge. The supernatant was then 
discarded and the pellet was resuspended in 20-100pl of Buffer B (High Salt 
Buffer). This was incubated on ice for 20 minutes then the cellular debris was 
pelleted by centrifugation in a microfuge for 2 minutes at 4°C. Supernatant was 
then removed, aliquoted and stored at -70°C. Protein concentration was 
determined as described in section 2.2.5.2.
2.2.4.3 Protein Concentration Assays
The BCA/CuS04 Protein assay was used to spectrometrically determine 
the protein concentration of dilute solutions following the manufacturer’s 
instructions. Protein reduce alkaline Cu(II) to Cu(I) in a concentration-dependent 
manner. Bicinchoninic acid is a highly specific chromogenic reagent for Cu(I), 
forming a purple complex with an absorbance maximum at 562nm. lOpl of 
protein solution was placed in separate wells in 96 well plate. 200pl of developing 
solution (5ml BCA(Biocinchoninic acid) solution, lOOpl of 4% (w/v) CuS04 
(copper II sulphate pentahydrate solution) was added to the protein samples and 
incubated at 37°C for 30 minutes.
The absorbance of each sample was read at 590nm using a Dynatech 
MR7000 automatic plate reader. The absorbance reading was converted to 
concentration in pg/ml for each sample using a standard curve generated from a 
series of control BSA solutions of known concentration. The actual concentration 
of each protein sample was calculated after multipling by the relevant dilution 
factor.
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2.2.4.4 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Protein samples were resolved according to the molecular weight using 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 15cm 
gels were used, containing gels of varying polyacrylamide content, depending on 
the molecular weight of the proteins being resolved, but typically 10% 
polyacrylamide resolving gel was used. For a single 10% gel of 15cm the
following solutions were prepared:
30% acrylamide 16.67ml
Water 20.83ml
SDS-PAGE Resolution Gel Buffer 12.5ml
10% ammonium persulphate (freshly prepared) 0.2ml
TEMED 0.008m
This resolving gel was poured between two glass plates (cleaned with 70% 
ethanol) sealed on three sides with a gasket, then overlaid with isopropanol and 
left to polymerise at room temperature. Once the gel was set, the isopropanol was 
removed using Whatman 3MM filter paper and the stacking gel consisting of 5% 
polyacrylamide was poured on top of the resolving gel, a comb inserted and left to 
polymerise for at least 30 minutes before use. The stacking gel was prepared as
follows:
30% acrylamide 2.67ml
Water 12.33ml
SDS-PAGE Stacking gel buffer 5ml
10% ammonium persulphate (freshly prepared) 0.04ml
TEMED 0.004ml
Once the stacking gel had polymerised the whole gel was transferred to an 
electrophoresis tank. The tank reservoirs were then filled with Tris-glycine 
electrophoresis buffer. After the removal of the combs, the wells were flushed 
with electrophoresis buffer to remove any excess stacking buffer.
Prior to loading, equivalent amount of each protein samples (80pg) was 
mixed with an equal volume of 2x SDS gel loading buffer. The prepared protein 
samples were then loaded into consecutive wells and 10pl Rainbow™ protein 
molecular weight marker mix (molecular weight range 14.3KD-200KD) added to
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the first and/ or last well on the gel. The gel was run by electrophoresis at a 
constant current ~ 35mA/gel for 2-3 hours. Once the dye front was approximately 
5-10cm from the bottom of the gel, the gel was removed and used for western blot 
analysis.
2.2.4.5 Western Blotting
Separated protein samples were transferred to a nitro-cellulose membrane 
by semi-dry blotting. For this purpose the gel was removed from the 
electrophoresis tank, then excess gel was cut away. The dimensions of the 
remaining gel was measured and 2 pieces of Whatman 3MM filter paper were cut 
to an equal size, as was one piece of nitro-cellulose (ECL-hybond). The transfer of 
the protein from the gel to the nitro-cellulose was performed as follows:
1. Two sheets of Whatman paper were soaked in transfer buffer (122mM 
Glycine, 25 mM Tris, 20% Methanol) and placed neatly on the centre of the 
blotting apparatus, avoiding any air bubbles.
2. Onto these was laid the nitro-cellulose membrane, the gel, then a further 
6 sheets of Whatman paper, all soaked in transfer buffer.
3. The stack of sheets was rolled with a glass pipette to eliminate any air 
bubbles
4. 200mA was applied across the blot for approximately 60 mins, the time 
taken for the pre-stained marker proteins to be completely transferred
Once the transfer was completed, the membrane was blocked by shaking 
for a minimum of 2 hours in 50 ml of block buffer (5% Marvel (dried milk) in 
PBS or 3% BSA in PBS) at room temperature. The nitro-cellulose filter was 
washed in wash buffer (PBS) for 4 x 10 minutes. The filter was then placed in 7ml 
blocking buffer containing suitable primary antibody and incubated at room 
temperature for 1 hour with gentle shaking. The primary antibody solution was 
removed and the filter rinsed in blocking buffer then washed 4 times, each for 10 
minutes, in 100ml volumes of fresh washing buffer. The filter was then incubated 
in 50 ml blocking buffer containing a 1/5000 dilution of the applicable HRP 
linked secondary antibody for 1 hour at room temperature with gentle shaking. 
The filter was washed 3 x 10 minutes with washing buffer. Excess surface liquid
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was removed from the filter by briefly blotting with a piece of Whatman 3 MM 
paper. The detection consisted of incubating the filter in an equal volume of an 
Amersham Enhanced chemilluminescence (ECL) detection reagents I and 2 for 1 
minute at room temperature. The excess detection solution was drained off the 
nitro-cellulose filter and this was then wrapped in Saran wrap and exposed to Fuji- 
XR film for 30 second and up to 30 minutes (depending on the strength of the 
signal).
2.2.4.6 Stripping Western Blot Membranes
If a western blot membrane was required for multiple analyses with 
different probe antibodies then the initial primary and secondary antibodies were 
removed from the membrane by stripping.
The membrane post exposure to the Fuji-XR film was washed for 10 
minutes three times in PBS before being incubated for 1 hour at room temperature 
in Stripping Buffer (0.2M Glycine pH 2.5, 0.2% SDS). The membrane was then 
washed with copious amounts of PBS until all traces of the SDS were safely 
removed. The membrane was then blocked as per protocol for the next probing 
primary antibody.
2.2.4.7 Immunofluorescence
8000 cells were seeded into single well glass chamber slides and left 
overnight at 37°C with DMEM-10 media, under humid conditions to minimise 
evaporation. Quercetin exposure was initiated on the following day as described in 
section 2.2.2.13. Post quercetin exposure tissue culture media was aspirated off 
and the cells were washed once with PBS and fixed in ice cold methanol/ acetone 
(2:1 v/v) for 30 mins.
The acetone was removed and each chamber was washed three times with 
PBS before a 10% FCS (in PBS) blocking solution applied to the cells for 1 hour 
at 4°C. After removing the blocking solution the primary antibody was applied at 
the appropriate concentration in the blocking solution and left in a moist chamber 
at 4°C for 16 hours.
The cells were then washed 3 times with the blocking solution and 
incubated with the secondary FITC-conjugated antibody for 1 hour at 4°C . The
78
Chapter Two M aterials & M ethods
cells received a final wash in blocking solution and were then mounted under 
Vectashield™ solution. Cells were analysed under UV illumination using a Leitz 
vario orthomate microscope (Confocal microscope). Counter staining with 
propidium iodide was also undertaken to visualise the cell nuclei. After washing 
off any residual secondary antibody if applicable cells were incubated with the 
staining solution (PBS containing 250pg/ml RNAse A, propidium iodide (20p, 
g/ml) for at least 30 minutes at room temperature before mounting.
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CHAPTER THREE 
_____________________________ RESULTS______________________________
3.1 Introduction
Cancer is a multi-stage process in which the cell accumulates a 
series of genetic alterations. These alterations will in turn allow the cell to 
overcome the normal checkpoints that regulate cellular proliferation. The resultant 
phenotype of these successive genetic lesions that will affect the regulation and 
function of oncogenes and tumour suppresser genes is invariably advanced 
malignancy of the tumour.
The study of the processes that contribute to the control of cell 
proliferation, and the factors that affect them is invaluable to achieve cures and/or 
preventions of this disease.
Many viruses can be critical factors in the abrogation of cell cycle control. 
Such viruses require their host’s cellular machinery for the replication of their own 
genome for their life cycle, and as such often express proteins that are capable of 
over-riding cell cycle control. This is to permit the host cell to enter DNA 
synthesis and consequently express the factors the virus requires for the 
replication of its genome. One example relevant to this study are the 
papillomaviruses.
Papillomaviruses belong to the family papovavirus and are oncogenic 
viruses (zur Hausen, 1991b) which infect cutaneous and mucosal epithelia, giving 
rise to benign hyperproliferative lesions, commonly called warts. In the great 
majority of cases, these lesions are under host immunological surveillance and 
regress spontaneously. However, if other factors intervene, the lesions can 
undergo malignant transformation and develop into squamous cell carcinomas. 
While the co-factors that promote neoplastic progression of warts are ill-defined in 
humans, they have been identified in animal systems (LARC, 1995). One of such 
system is the papilloma-carcinoma syndrome of cattle (Campo, 1997).
Cattle are infected in their upper GI tract by bovine papillomavirus type 4 
(BPV-4) which induces squamous epithelial papillomas (Campo and Jarrett, 
1986). In healthy cattle, the papillomas develop and persist for approximately one
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year and are then rejected by a cell mediated immune response (Knowles et al, 
1996). However, in cattle grazing on bracken fern the papillomas can progress to 
squamous cell cancer (Campo and Jarrett, 1986). Bracken fern contains 
immunosuppressants and mutagens. Bracken-eating cattle become chronically 
immunosuppressed and are incapable of mounting an appropriate immune 
response against the virus or virus infected cells (Campo, 1997). The bracken 
mutagens are probably responsible for the observed activation of ras (Campo et 
al, 1990), mutation of p53 (Scobie, 1996) and increase in epidermal growth factor 
receptors (Smith et al., 1987) observed in cancers as well as the increased level of 
chromosomal damage observed in cattle fed on bracken fern (Moura et al, 1988).
The progression of papillomas to carcinomas has been experimentally 
reproduced in bracken-fed cattle (Campo et al., 1994b) thus confirming the 
epidemiological studies conducted in the field.
The multistep nature of BPV-4 cell transformation has been studied in 
vitro by use of primary bovine fibroblast cells (PalFs) from the foetus palate. E7 
and E8, the transforming proteins of BPV-4, are not capable of fully transforming 
these cells (Pennie et al, 1993). However in co-operation with Ha-ras, E7 induces 
morphological transformation of PalF cells and E8 is required for their anchorage 
independent growth but, although the cells have an extended lifespan and are 
capable of growing independently of adhesion to the substrate, they are neither 
immortal nor tumorigenic (Pennie etal., 1993; O’Brien & Campo, 1998).
Although BPV-4, or E7, can transform PalFs only partially, exposure of 
the cells to a single dose of quercetin ( 3,3’,4’,5,7-pentahydroxyflavone, see figure 
2 for the structure), a flavonoid found in bracken, can achieve oncogenic 
transformation and the cells can induce tumours in nude mice (Pennie and Campo 
1992; Caimey and Campo, 1995). These in vitro observations reflect the 
involvement of bracken chemicals in BPV-4 associated carcinogenesis.
Quercetin is a well known mutagenic flavonoid present in bracken fern 
(Bjieldanes and Chang, 1977; Nakayasu et al, 1986); it binds DNA causing single 
strand DNA breaks (Fazal et al, 1990), DNA rearrangements (Suzuki et al, 1991) 
and chromosomal damage (Ishidate, 1988).
Quercetin has also been shown to inhibit a plethora of cellular enzymes 
(Nishino eta l, 1984; Glossman et al, 1981; Graziani et al, 1983; Graziani et al,
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1981; Gschwendt et al, 1984; Srirastava, 1985; Lang & Racker, 1974; Shoshan & 
MacLennan, 1981; Beretz et al, 1978; Ruckstuhl et al, 1979). Much of this 
inhibition may well be through quercetin’s ability to competitively inhibit ATP 
binding (Graziani et al, 1983).
One resulting effect of the properties of quercetin is cell cycle arrest. This 
has been experimentally shown in a variety of cell lines, where quercetin exposure 
has arrested the cell at different stages of the cell cycle (Yoshida et al,. 1990, 
Hosokawa et al, 1990, Gong et al, 1994, Scambia et al, 1990, Ranelletti et al, 
1992, Avila et al, 1994, Plaumann et al, 1996). Most studies on quercetin’s 
effect on the cell cycle have been carried out on tumorigenic cell lines, or 
immortalised cell lines. This causes some difficulty in the analysis due to the 
presence of unidentified genetic alterations that have occurred in these cells which 
might have affected the cell cycle checkpoints already. Hence, work to examine 
cell cycle control on primary cells where one can assume that there have been no 
alterations to the proteins controlling cellular proliferation is desirable in order to 
examine quercetin’s effect on the cell in the context of full checkpoint capability.
Previous work demonstrated that quercetin induces G1 arrest in normally 
cycling PalF cells (Connolly et al, 1998). Speculation that this abrogation of the 
G1 arrest may play a significant role in the progression to a fully transformed state 
of the PalF cells came from the amino acid similarity between BPV-4 E7 and the 
HPV-16 E7 protein, the latter being well characterised as an oncoprotein capable 
of over-riding G1 arrest induced by DNA damage (Hickman et al, 1994; Slebos et 
al, 1994; Demers et al, 1994). Additionally the BPV-4 E7 protein contains a 
putative pRbl05 binding site, and has two cys-X-X-cys zinc binding domains. 
Mutations of these domains abolished the E7 ability to cause morphological 
transformation with Ha-ras (Campo et al, 1994a; Jackson et al, 1996). Hence it 
was hypothesised that the expression of the BPV-4 E7 and Ha-ras proteins would 
allow the cell to overcome a quercetin induced G1 arrest. This would allow the 
cells to pass through at least one round of DNA replication in the presence of 
quercetin. This would then lead to generation of inheritable damage, and 
progression to full transformation.
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3.2 Generation of Cell Lines
To study the effects of quercetin in the in vitro model of transformation, 
cell lines had to be derived. This would allow an analysis of changes that had 
occurred within the cell to permit full transformation. Limitation on this form of 
analysis though would rest on the fact that only tumourigenic derived clones 
would be likely to be suitable for continued passage in tissue culture, and thus for 
comparison to the parental PalF cells.
To overcome this problem pooled populations, rather than single clonal 
populations, were used for certain transfection classes to permit passage in tissue 
culture for a duration suitable for study.
3.2.1 Experimental Method
Stable transfection of the parental PalF cells was carried out as described 
in section 2.2.2.8. See table 3.1 for a description of the transfection classes carried 
out:
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Table 3.1
Transfection
Class
Plasmids Transfected Quercetin 
Treatment (*)
Resultant Cell Lines
1 Salmon Sperm DNA alone N/A None
2 pZipneo & Salmon Sperm DNA 0p,M (24 hrs) None
3 pZipneo & Salmon Sperm DNA 20pM (24 hrs) None
4 pZipneo & Salmon Sperm DNA 20pM (240 hrs) None
5 pZipneo, pZipneo E7 & Salmon 
Sperm DNA
OpM (24 hrs) None
6 pZipneo, pZipneo E7 & Salmon 
Sperm DNA
20|_iM (24 hrs) None
7 pZipneo, pZipneo E7 & Salmon 
Sperm DNA
20|iM (240 hrs) None
8 pZipneo, pT24 & Salmon Sperm 
DNA
OpM (24 hrs) None
9 pZipneo, pT24 & Salmon Sperm 
DNA
20pM (24 hrs) None
10 pZipneo, pT24 & Salmon Sperm 
DNA
20p,M (240 hrs) None
11 pZipneo, pZipneo E7, pT24 & 
Salmon Sperm DNA
0(iM (24 hrs) 11 A, 11 Aa, 1 IT, 1IX, 
11AP
12 pZipneo, pZipneo E7, pT24 & 
Salmon Sperm DNA
20p,M (24 hrs) E7Q,E7Qb,E7QPap, 
E7QPPp,E7QPyp 12F#
13 pZipneo, pZipneo E7, pT24 & 
Salmon Sperm DNA
20p.M (240 hrs) 13B,13I,13J,13N
14 pZipneo, pZipneo E7 & Salmon 
Sperm DNA
n.d. E7RP
Key:
* = Quercetin treatment indicates the concentration used for 24 hours exposure. Number in 
parenthesis indicates the time after transfection the quercetin exposure initiated.
p = Indicates the cell line was derived from a pooled population.
The last column indicates cell lines that were successfully expanded to allow injection into nude 
mice for tumorigenicity assay.
# = Cell line generated, but lost due to contamination.
Cells were quercetin treated after transfection as indicated and selected in 
G418 medium for 2-3 weeks. The resultant clones were either pooled or if deemed 
large enough were isolated by ring cloning. Clones and pooled cells were
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expanded to a minimum of 4xl07 cells for assay in nude mice and for generation \ 
of long term frozen stocks: 3 mice per cell line at lxlO7 cells per mouse and 10 
vials of lxlO6 cells per vial for storage in liquid nitrogen as a master stock. An , 
aliquot of the master stock was then thawed and expanded to generate a further 10 
vials of lxlO6 cells per vial for storage as a working stock. Subsequent analysis 
was conducted on frozen stocks thawed and grown in tissue culture as described 
for parental PalF cells, namely passaged twice per week being split 1 in 4, but 
maintained under G418 selection.
Cells were expanded up to the required numbers for subsequent analysis. 
Different lines grew at different rates (see below) so the time intervals between 
passages varied. PalF cells were not maintained in culture for more than 3 weeks 
and the transformed cells for more than eight weeks, after which new stocks were 
thawed.
3.2.2 Experimental Results & Discussion
As can be seen from table 3.1 no clones isolated from transfection classes 
2-10 were successfully expanded in tissue culture to permit analysis of their 
tumorigenic state in nude mouse, or other studies. This in itself would strongly 
suggest that the cells were poorly transformed with a limited lifespan. No clones 
of salmon sperm DNA transfectants developed due to the lack of a selective 
resistance plasmid being inserted into the cells, thus ensuring that the selective 
process was successful. Transfection classes 11-13 were the conditions that 
generated stable cell lines for further study. Clones were picked from all 3 classes, 
however only a few were capable of the required expansion for the nude mouse 
assay. Listed below in table 3.2 are the figures for the number of clones picked per 
class and the number of successfully expanded single clones.
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Table 3.2 Clone Isolation and Expansion Numbers
Transfection
Class
Total Number of 
Cells Used in 
Transfections
Number of Clones 
>1mm diameter
Number of 
Expanded 
Clones
Number of 
Tumorigenic 
Cell Lines
11 1.6xl06 30 5 0
12 2.4 xlO6 17 3* (2) 1 (E7Q)
13 1.6xl06 18 4 0
* = Three clones were capable of the required expansion level although one clone (12F) was lost 
through contamination before injection.
As can be seen in table 3.2 the number of clones was decreased 
considerably in quercetin treated cells, suggesting that exposure to the chemical 
could be a significant cellular stress to the cell. Thus quercetin exposure in 
combination with transfection could induce a high stress level for the cell, 
probably causing a greater number of cells to commit to apoptosis in response to 
this combination of insults.
The number of clones successfully expanded to at least 4xl07 cells was 
also significantly lower than the number originally isolated as well, suggesting 
that the transfection of E7 & Ha-ras alone was generally insufficient to confer an 
extended lifespan upon the transfected cell. In addition all clones isolated by this 
method with one exception (tumorigenic cell line from transfection class 12) 
proved very slow to passage, and exhibited cellular morphology indicative of 
senescence on continued passage in tissue culture. Hence these cell lines were 
deemed unsuitable for further studies after limited preliminary analysis.
One complicating factor for the generation of the clonal cell lines was 
likely to be the initial low number of cells post transfection. This may well have 
had a deleterious effect on the proliferation capability, thus resulting in clones 
with limited expansion potential. To facilitate studies with suitable cell lines, 
pooled populations were used to allow easier expansion of the transfected cells. 
Transfected cells were selected as per standard protocol, then resultant clones 
were trypsinised and pooled into tissue culture containers to ensure at least an 
initial 50% confluency.
This approach was undertaken for transfection class 12 and resulted in 
E7QPa, E7QPP and E7QPy (from two different transfections), which proved to be
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able to survive continued passage in tissue culture and suitable for 
experimentation. Additionally E7R cells were also derived in this manner due to 
the failure of any suitable clones derived from transfection classes 5-10, 
suggesting ring cloning would be ineffective as a source of material for this class.
Due to the low number of cell lines obtained, previously generated cell 
lines ( QOD and Q2D see section 2.1.4, and table 3.3) were also studied in order to 
widen the breadth of analysis. These contained the whole BPV-4 genome rather 
than just pZipneoE7, thus allowing analysis of E7 expression under the control of 
the BPV-4 LCR.
Cell lines under analysis did not all grow at the same rate. Although no \
quantitative analysis of cell proliferation was conducted, the frequency at which \
cells needed passaging gave an indication of their growth rate. Thus parental PalF, 
E7QPP and E7QPy grew at approximately equivalent rates and were passaged I
twice per week being split 1 in 4. E7R, E7Qb and QOD grew more slowly and 
were passaged only once per week on average. On the contrary E7Q, E7QPa, 
E7QT2 Q2D and 88529B grew more rapidly and were passaged roughly 3 times 
per week. Growth curves could have been established by measurement of the 
number of viable cells at each passage in culture, and would have given a more 
detailed knowledge of the proliferation rates of the cell lines. Nevertheless it is 
interesting to note that the faster growing cells proved to be tumourigenic in the 
nude mouse assay (see below).
3.3 Phenotypic Analysis
To allow proper evaluation of the stable cell lines generated presently or 
previously a characterisation of the lines was carried out. The phenotype of the 
transformed lines was analysed by assessing their ability to grow independently of 
substrate and to induce tumours in nude mice (for summary see table 3.3), in 
addition to any morphological alterations.
3.3.1 Experimental Method
Cell lines were expanded in culture as described in section 2.2.2.3 and 
section 3.2.2 under continuous G418 selection (500p,g/ml) and allowed to 
proliferate to sufficient cell number to permit injection into nude mice.
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Prior to injection aliquots of cells were frozen in liquid nitrogen at an early 
passage in order to facilitate long term usage (see section 2.22.4), and screened 
for mycoplasma infection in order to ensure cell line purity (see section 2.22.5).
Typically at least 3 mice were used per clone for transfection classes 11 &
13. This initial number was decided due to the potentially large number of clones 
to be assayed. To ensure any observed developing tumours were not a result of the 
injection protocol a negative control of PalF cells were used. Additionally to 
ensure that any lack of observed tumour was not due to a vestigial immune 
response in the mice a positive control cell line was used. This was either Q2D, 
previously demonstrated to be tumorigenic in the nude mouse assay (Caimey & 
Campo, 1995), or another cell line ‘15.6’ which contains the BPV-4 genome, 
activated ras, HPV-16 E6 and a mutant p53. This latter cell line had also shown to 
be tumorigenic in the nude mouse assay (Scobie et al., 1997). Later injections 
using the cell lines E7Q, E7QPa,|3,y and E7R used a greater number of mice (5 to 
8 per clone, see table 3.3 for summary).
n
For each injection 1x10 cells were used per mouse in a volume of lOOpl 
of PBS. Cells were kept on ice until the point of injection. See section 2.2.2.11.2 
for full details.
In addition to analysis of the cell lines capability to form solid tumours in 
nude mice, they were also assayed for their ability to grow independent of 
substrate. In brief, 5mls of 1% Methocel medium containing 1.25xl05 cells (taken 
from a stock of 5xl06 cells grown out from frozen stocks) were plated into 60mm 
bacterial grade petri dishes and stored at 37°C, 5% CO2 in a humid atmosphere for 
10 days. After the incubation colonies, of 0.1mm or greater diameter, were scored ^  
in 3 random field of 16mm . The average efficiency colony formation was then 
calculated on the basis of number of cells seeded to number of colonies formed.
8 8
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3.3.2 Experimental Results & Discussion
3.3.2.1 Cell Morphology
In addition to the analysis of the cell lines ability to grow in methocel 
medium and to form tumours in nude mice a more basic level of transformation, 
that of morphological alteration, was observed in all the cell lines generated. 
Figures 3 to 5 show the non tumourigenic, transformed cell lines exhibit a spindle 
like cell morphology when compared to PalF cells. Additionally they also adopt a 
‘criss-cross’ growth pattern over each other. If left to grow to confluence these cell 
lines will form foci of cells piling on top of each other which can elongate to form 
long foci. Comparison between the E7R and QOD cell lines shows little difference 
in the cell morphologies indicating that E7 and Ha-ras expression alone is 
sufficient for the cellular morphology alteration and overcome contact inhibition. 
Other viral proteins are unlikely to play a part in gross alteration as evidenced by 
the similarity of QOD to E7R.
The quercetin exposure protocol used to induce full transformation does 
not always confer additional changes to the cell morphology or contact inhibition 
behaviour as can been seen in E7Qb and 12F. Both cell lines resemble those of 
transfection class 11, and both display the ability to form foci in confluent flasks, 
but show no obvious other morphological alterations.
The progression of the cells to full transformation however is associated 
with a morphology differing from both wild type and transformed cells. Q2D and 
E7Q were shorter and more rounded. This may be due to the faster proliferation 
rates of these cell lines, not allowing cells to increase in size as compared to the 
non tumorigenic cell lines. In addition to their altered appearance these cell lines 
and their derivatives showed a high level of cell debris during normal tissue 
culture passaging, as deduced by the excessive level of cell debris formed in the 
culture medium and that still attached to the growing monolayer. While some 
apoptosis was seen in the non tumorigenic transformed cell lines during passaging 
the level was much lower than that observed in E7Q and Q2D. In the main 
apoptosis in these non tumorigenic cell lines was associated with the lines entering 
senescence.
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3.3.2.2 Anchorage Independent Growth
Upon analysis of whether the cell lines could grow independent of 
substrate or not, only those cells that had also proven to be tumorigenic were 
capable of growth in methocel medium. All other cell lines tested were incapable 
of anchorage independent growth.
Figure 6 shows the results of the initial set of methocel assays. PalF cells 
were used as the negative control cell line. These cells were incapable of forming 
colonies in methocel, the small clumps of cells seen are most likely to be the result 
of a few rounds of cell division before loss of integrin signalling for example 
(Giancotti &Ruoslahti, 1990) would result in cell cycle arrest possibly via loss of 
cyclin A expression (Guadagno et al, 1993). As a positive control the cell line
15.6 (Scobie et al, 1997) was used as it had been previously proven to show 
anchorage independent growth.
In this assay E7Qb, 11A|3,11X, 13B and 131 were tested. The cell line 12F 
was not tested due to loss in tissue culture. The cell lines 13N, 13J, 11T, H A a 
and 11A were not tested due to their low growth rates at the time of 
experimentation. Their inability to proliferate on tissue culture plastic made them 
poor candidates for growth independent of substrate. A likely explanation is that 
these cell lines were entering senescence upon prolonged culturing. As figure 6 
demonstrates however those cell lines tested were also incapable of anchorage 
independent growth.
In the second round of assays (figure 7) again PalF cells were used for 
comparison as the negative control cell line, with Q2D used as the positive control 
cell line ( Pennie and Campo, 1992). All the cell lines in culture at this point were 
capable of normal rates of proliferation in comparison to PalF cells and all were 
assayed.
Colonies only formed in those cell lines proven to be tumorigenic 
(see section 3.3.2.3), namely E7Q and its derivative E7QT2, E7QPa and 88529B. 
The cell lines E7R, QOD and E7QPp and E7QPy all failed to form colonies of 
0.1mm or greater diameter in methocel. Hence this indicates that not only 
expression of BPV-4 E7 and Ha-ras does not confer anchorage independent 
growth, but the stable transfection of the
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full genome with Ha-ras into PalF cells (QOD) did not confer this capability either, 
in this system, although Pennie et al, in 1993 did show that the full genome and 
Ha-ras were capable of conferring anchorage independent growth to PalF cells. 
However the expression level of the other viral protein which is implicated in 
anchorage independent growth, BPV-4 E8, is not known. Lack of growth may be 
attributable to loss of expression of this protein.
The ability of the tumorigenic cell lines, E7Q, E7QPa and Q2D, to form 
anchorage independent colonies in contrast to the non-tumorigenic cell lines, 
E7Qb and QOD, shows that quercetin treatment can permit transformation of the 
cell to be independent of substrate. However this is not an obligatory result of 
quercetin treatment of the cells as E7QPp, E7QPy fail to form anchorage 
independent colonies. This is further reinforced by the results of 13B & 13J in 
which exposure of the transfected cells to quercetin, 10 days after transfection, 
does not establish this phenotype either.
3.3.2.3 Tumour Formation in Nude Mice
All cell lines capable of culturing to sufficient levels were assayed for 
tumour formation in nude mice, this representing full transformation of the cell. 
For a full summary see table 3.3.
PalF cells were used as a negative control with either Q2D or 15.6 used as 
a positive control as previously these cells were shown to be tumorigenic (Pennie 
and Campo 1992; Scobie et al, 1997). The cell line QOD was previously shown to 
be non tumorigenic (Pennie and Campo 1992) whereas 88529B was capable of 
forming tumours (Campo et al, 1985).
Injection of the cell lines derived from transfection protocol 11 or 13 
resulted in no tumour formation or observed differences from injection with PalF 
cells. The same was true for injection with E7R or the quercetin treated cell line 
E7Qb.
Injection with Q2D,E7Q or E7QPa resulted in rapid tumour formation. 
The mice had to be sacrificed due to tumour load within 3 weeks of injection of 
the cells. However there was one exception, where Q2D cells were injected in a 
different mouse strain (ICRF1). In this case Q2D injected mice survived the
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course of the assay (2 months) with only 4 out of the 5 mice developing tumours. 
At this point the cells were used as a positive control for the cell lines E7QP|3 and 
E7QPy. These latter two cell lines formed lumps at the point of injection which 
regressed and failed to induce tumours beyond reasonable doubt. With concern 
over whether these observations over E7QPP and E7QPy had been adversely 
affected by a vestigal immune response in these mice, a repeat injection was 
carried out using the original strain of mice. In this experiment again all the cohort 
of Q2D mice had to be sacrificed after 17 days due to tumour load. E7QPp and 
E7QPy derived lumps which began regressing after 23 days, but not tumours. 
These ‘lumps’ were likely to be cysts generated from the injection of the cells 
(personal communication, T.Hamilton, Beatson Institute). However the PalF or 
E7R cohorts carried out in the same experiment showed no such lumps.
Tumours derived from injections with Q2D, E7QPa or E7Q were 
explanted and cultured in vitro. Of the tumours derived there were two successful 
explantations from each of the cell lines E7QPa and E7Q. These resulted in the 
cell lines E7QPT1 and E7QPT2 from E7QPa tumours, and E7QT1 together with 
E7QT2 from E7Q tumours. There were three successful explantations of Q2D 
tumours resulting in the cell lines Q2DT1, Q2DT2 and Q2DT3. The Q2D cell 
lines derived from explantations were not used for further experimentation and 
will not be discussed further.
In summary, where expression of the BPV-4 E7 protein in conjunction 
with activated Ras morphologically transformed the cell, only cells treated with 
quercetin 24 hours post transfection were capable of growth in semi-solid media 
(Table 3.3 & Figure 7), in agreement with previous results (Pennie and Campo 
1992; Caimey and Campo, 1995). However of these five quercetin-treated lines, 
only two induced tumours in nude mice (Table 3.3), indicating that quercetin 
treatment does not inevitably leads to a fully transformed phenotype.
It is interesting to note that the ability to proliferate independent of 
substrate also correlates with whether the cell is fully tumorigenic. This anchorage 
independent growth ability may well be a critical late event in the progression to 
full transformation.
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In order to address this situation a more detailed analysis, possibly down to 
single cell seeding in methocel to ensure no aggregation, then analysis of the 
resultant substrate independent clones could allow determine expression levels of 
key proteins e.g. by quantitative RT-PCR.
3.4 Determination of Transfected Gene Expression
3.4.1 Expression of BPV-4 E7 in Cell Lines
3.4.1.1 Experimental Method
To relate the observations of the cell lines capabilities in nude mice and 
methocel, to the E7 expression of the cells, analysis of the viral gene expression 
was undertaken. This would ensure any anomalous results were not due to loss of 
E7 expression in the cell lines or indeed gross over expression.
Due to the lack of a suitable antibody for the detection of E7, RT-PCR 
approach was taken to check not only for stable retention of the plasmid but also 
its expression, to ensure that there had been no silencing on integration into the 
host genome for example. The limit to this approach was of course that there 
would be no definitive answer to expression levels, only a rough guide by the PCR 
product level. However due to time constraints making antibody generation 
unfeasible, RT-PCR was considered a more suitable option.
Primers to an internal portion of the BPV-4 E7 message were kindly 
donated by G.Sibbet (Beatson Institute), which generated a 170bp product upon 
PCR amplification (5’-gctgaccttccagtcttaat (642-661) and 3’-tgaagaggagattgaaactg 
(793-812)). As a positive control, pZipneoE7 was used with the same primers; 
negative controls were reactions without RT or without template (dH20).
Initially total RNA was isolated using the RNAzolB method with a DNA­
ase treatment step to ensure removal of DNA contamination. However this proved 
to be unreliable in generating RNA of high enough quality for RT-PCR, hence the 
extraction and purification protocol was switched to using the RNeasy Kit 
(Qiagen). Total RNA was extracted from the cell lines and purified according to 
the manufacturers guidelines, quantified for RNA concentration, and stored at 
-70°C until use ( see sections 2.2.3.1 and 2.2.1.4).
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For full details see section 2.23.2 on methodology of the RT-PCR 
protocol. In brief lpil of total RNA was used for the reverse transcriptase reaction 
with an Oligo dT primer. The enzyme and buffers were from the Omniscript RT 
kit (Qiagen). Reactions were made up according to the manufacturers 
recommendations and incubated at 37°C for 60 minutes to allow extension from 
the primer along the template.
For the tumorigenic cell lines 10% of the RT reaction was carried forward 
to the PCR step, whilst with the transformed, non-tumorigenic cell lines 50% of 
the RT reaction was carried over to the PCR stage.
PCR was carried out using the HotStarTaq Kit (Qiagen) as per 
manufacturer guidelines. At this point the BPV-4 internal primers were used for 
amplification. 35 rounds of PCR were carried out for each reaction. Note other 
DNA Polymerases were tried, but failed to give consistent results and often lacked 
specificity. Thus conversion to a hot start protocol proved to increase specificity 
and reliability, in conjunction with an improved RNA isolation and RT stage.
3.4.1.2 Experimental Results & Discussion
As can be seen in figure 8 (a) and (b) E7 mRNA was detected in all cell 
lines except the negative control line PalF and the transforming papilloma cell line 
88529B. This latter result is in agreement with the absence of BPV-4 DNA in this 
cell line (Campo et al., 1985).
It is interesting that although the RT-PCR was not performed under 
quantitative conditions, increased E7 RNA amplification was obtained from the 
quercetin-treated cell lines and particularly from the tumorigenic lines E7Q, 
E7QT2 and also possibly Q2D, since only 10% of the RT reaction was used for 
the PCR step for E7Q, E7QT2 and Q2D, whereas 50% of the RT reaction was 
needed for the PCR step for the other cell lines (Figure 8 (a) and (b)).
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3.4.2 Expression of Ras in cell lines
3.4.2.1 Experimental Method
Western blot analysis was undertaken to analyse expression of Ras, using 
an antibody raised against human Ha-Ras. See section 2.2.4 for full experimental 
methodology on protein analysis. In brief, cycling cells in normal tissue culture 
conditions were harvested and lysed. E7QPa, E7QPp and E7QPy cell lines were 
treated with a variety of conditions prior to harvesting. 80pg of each cell lines 
lysate was then loaded onto an SDS-PAGE gel (4% Stacking gel, 10% Resolution 
gel) to facilitate separation. The gel was then blotted to nitrocellulose, and non 
specific protein interaction were blocked using 5% Marvel milk in PBS for at least 
1 hour at room temperature. Post blocking, the membrane was probed with the 
anti-Ha-ras antibody then visualised using an HRP conjugated secondary antibody. 
As a control for expression levels both normal PalF cells and HeLa protein 
extracts were used. The latter ensures that any band detected in the bovine samples 
can be matched for mobility with a human ras protein. PalF cells allowed 
determination of whether the antibody would detect bovine Ras, and to allow 
estimation of the wild type expression level, in comparison to the other cell lines.
3.4.2.2 Experimental Results and Discussion
Ras was elevated in the transformed cell lines and markedly so in the 
tumorigenic cell lines (Figure 9 (a) to (d)). Whether the Ras protein detected in the 
transformed cells is human Ha-ras, endogenous bovine Ras or both is not known 
as the antibody also detected Ras in PalF and 88529B cells (Figure 9 (a)), 
indicating that the antibody could react with both bovine and human Ha-ras 
protein.
Figure 9 (b) &(c) also shows the ras expression in response to different 
stimuli in the E7QPa, E7QPP and E7QPy cell lines. There is no evident alteration 
of Ras expression in the three cell lines when exposed to quercetin, UV or 
bleomycin sulphate in comparison to untreated cells. However E7QPP and E7QPy 
both show an elevated expression of the Ras protein in comparison to parental 
PalF cells (figure 9 (d)).
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CHAPTER FOUR 
RESULTS
4.1 Cell Cycle Analysis
Following from the earlier results showing the G1 and G2/M arrest in PalF 
cells in response to quercetin, it was hypothesised that the abrogation of the arrest 
may play a part in the transformation of the cell. Under normal conditions 
quercetin exposure would induce cell cycle arrest by causing cellular stresses and 
DNA damage (see section 1.4.3.4). The cell would pause and either decide to 
repair the damage or if this is excessive commit to apoptosis. Under conditions of 
expression of the E7 protein and activated Ha-ras cell cycle arrest would be 
abrogated due to the activation of the MAPK pathway by Ha-ras providing a 
proliferative growth signal to the cell, and inhibition of the cell cycle inhibitor 
pl05Rb by E7. This latter effect would aid the proliferative signal generated by 
the release of the transcription factor E2F, driving gene expression required for 
DNA synthesis. This drive to enter DNA synthesis would then overcome the G1 
arrest occuring in normal PalF cells.
Upon entry into S phase, cells would accumulate DNA damage, caused by 
quercetin exposure, which would result in additional genetic lesions contributory 
to full transformation of the cell. These genetic lesions may be due to direct 
mutation of key oncogene or tumour suppressor genes, or indeed may result in a 
temporary ‘mutator’ phenotype. A result of this temporal state of instability again 
would further permanent genetic lesions allowing full transformation.
Focus is retained on the G1 transition due to several factors. The major 
reason is due to the timing of quercetin exposure. Quercetin exposure in the 
generation of the tumourigenic cells is only a single dose for 24 hours, whereas 
the quercetin exposure required for cells to significantly start accumulating in 
G2/M is 36 to 48 hours. Although when treated with quercetin in the 
transformation schedule some cells will have already traversed G1 and will 
therefore stop in G2/M, the majority of the cells would be upstream of the G1 
checkpoint. In addition to this factor, the E7 oncoprotein of papillomaviruses has
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been well documented to be able to overcome G1 arrest (Hickman et al, 1994; 
Slebos et al, 1994; Demers et al, 1994) and thus the abrogation of the G1 arrest 
by BPV 4 E7 is likely. There are also reports of E7 induced endoreduplication of 
the DNA under mitotic arrest (Di Leonardo et al, 1997; Thomas &Laimins, 
1998). However this fails to indicate a true ability to override G2/M control and 
subsequent normal entry into Gl, more of an ability to trigger the cellular 
mechanisms for DNA synthesis under unsuitable conditions.
4.1.1 Experimental Method
See section 2.2.2.13 for full methodology of the cell cycle analysis by 
FACS. In brief cells were plated in 90mm culture dishes and treated with either 0, 
20, 50 or lOOpM quercetin over 48 hours with fresh medium being applied every 
12 hours. Some cell lines were assayed with only 0 or 50pM over 48 hours as 
50pM caused a significant cell cycle arrest. Cells were then harvest and fixed 
using EtOH. Fixed cells were then stained using propidium iodide and RNAase A 
(the latter to remove any staining of RNA which would cause errors in the 
resultant FACS analysis) to stain the DNA. The stained samples were then 
analysed on the FACS scan to determine the percentage of the cells in each of the 
phases of the cell cycle. Sample data were then modelled on ‘Modfit v2.0’ 
software for detailed cell cycle population distribution.
4.1.2 Experimental Results and Discussion
The initial observation from the cell cycle data is that all transformed lines 
except one, are capable of overriding the Gl cell cycle arrest. In addition to this it 
is also plain that none of the cell lines are capable of overriding the G2/M cell 
cycle arrest.
Confirming earlier observations, the quercetin treatment of the PalF cells 
resulted in a large decrease in the S phase population concomitant with an increase 
in the G2/M population, indicating the cells moving out of S phase into, and 
arresting in, G2/M. The decrease in the S phase population paralleled by a stable 
G l population, provides evidence of the G l arrest. There is normally a slight 
decrease over 48 hours in the Gl population which would likely be due to cells
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bypassing the Gl checkpoint before a sufficient signal from the quercetin 
exposure would have triggered the cell cycle arrest response.
Examination of the E7Q cell line showed a dramatic alteration in response 
to quercetin. Over 48 hours of 20pM to 100[xM quercetin, there only remained a 
very small percentage of the cells left in Gl (see figure 10 and table 4.1), and also 
resulted in a significant reduction in the S phase population. There was also a 
large accumulation of cells in the G2/M phase. This was a clear example of the 
loss of G l checkpoint but retention of the G2/M checkpoint.
The cell line Q2D showed a similar, if less dramatic, response. Again there 
was a drop in Gl population together with an increase in G2/M population 
indicating G l arrest abrogation. There was also a decrease in S phase, as in E7Q. 
However as under propidium iodide staining this is only a ‘snapshot’ of the cell 
cycle, it is unknown whether the observed decrease is due to cells progressing into 
and through the S phase slower then normal or due to increased rates of entry into 
G2. The former argument could be postulated to be caused by quercetin’s effect 
on the kinases and phosphotases within the cell (see section 1.4.3.4). The 
signalling pathways required for entry, and progression through DNA synthesis 
may therefore fail to induce correct phosphorylation cascades or alter gene 
expression, for example, sufficiently for commitment to S phase. Another aspect 
could be DNA adducts inducing stalls in the replication machinery, whilst repair 
was carried out. Alternatively accelerated exit from S phase could come from the 
same mechanisms, kinases and phospohatases may be affected in order to shift 
bias towards a faster progression rather than inhibition in the signalling pathways 
e.g. Abrogation of cell cycle inhibitor proteins or inhibition of DNA repair 
complexes hence no signalling for the DNA Polymerase to pause during synthesis.
The fact that E7Q and Q2D show abrogation of the G l arrest could be due 
to one of two main mechanisms. Firstly one possible explanation is that 
expression of E7 and activated Ha-ras could lead as described earlier to a 
significant growth proliferation signal and inhibition of cell cycle inhibitor 
proteins such as pl05Rb. This would then permit passage through the Gl 
checkpoint. The second could be due to inheritance of an alteration in the cell due 
to previous exposure to quercetin. This resistance to quercetin G l arrest may work 
upon the cell cycle regulation directly such as loss of function of the cell cycle
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inhibitor proteins or be due to a selection of some more classical method of 
resistance e.g. enzymatic detoxification of quercetin, increased export, enhanced 
DNA repair complex activity.
Studies of the cell lines E7R and QOD were carried out to resolve this 
question. Both of these cell lines expressed E7 and activated Ha-ras, without 
having been previously exposed to quercetin. Test results for QOD showed a loss 
of G l arrest. The overall change in cell cycle population was equivalent to Q2D. 
There was a drop in G l and S phase with a concomitant increase in G2/M. Hence 
this experiment suggested that it was the expression of the viral proteins in 
conjunction with activated Ha-ras that was inducing the bypass of the Gl 
checkpoint. In support of this conclusion the cell line expressing only BPV-4 E7 
and activated Ha-ras, E7R, also failed to arrest in G l. Figure 12 shows that there 
was a drop in G l phase and increase in G2/M phase after 48 hours of quercetin 
exposure. In addition there was also an increase in S phase. This is likely to be due 
to cells moving through the S phase, slower than the PalF cells, to arrest in G2/M. 
Evidence supporting this hypothesis is the fact that the E7R cells proliferate at a 
slower rate in tissue culture (data not shown), and by the lower basal percentage of 
cells in S phase of an E7R population than a PalF population (figures 11 and 12 ).
The abrogation of G l arrest in E7R cells appeared be dependent on the 
number of passages in tissue culture. Early passage E7R cells were capable of 
abrogating the G l arrest but not the G2/M arrest (figure 12). However at later 
passages they reverted to a response more closely resembling wild type PalF cells 
arresting in G l and G2/M (see table 4.3 and figure 12 labelled E7R(HP)). In 
addition the alteration in cell cycle response to quercetin correlates to an alteration 
in the morphology of the cell line. High passage E7R cells lose their spindle like 
morphology and closely resemble PalF cells (data not shown).
The mechanism for this shift is unknown and requires further study. 
Possible reasons for the change in behaviour could be a selection against high 
levels of BPV-4 E7 expression and/or Ha-ras in stable cultures. Thus at low 
passage there would be sufficient levels of E7 to bind and inhibit pl05Rb and cdk 
inhibitors p27Kipl and p2 lWafl/Cipl and/or Ha-ras to drive MAPK pathway to
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Table 4.1
Summary of Cell Cycle Response to Quercetin
in PalF & E 7 0  cells
Exposure Quercetin [  ]  G1 Phase S Phase G2/M Phase
Time (hours) ^  I Average Average Average
0 0 58.40 +/- 5.6 28.96 +/- 7.4 12.63 +/- 2.4
12 0 55.25 +/- 5.9 32.60 +/- 7.1 12.15 +/- 3.4
24 0 54.01 +/- 7.2 33.99 +/- 9.3 1Z07 +/- 3.7
36 0 55.43 +/- 5.5 30.59 +/- 6.4 13.98 +/- 1.9
48 0 54.60 +/- 5.5 31.33 +/- 6.0 14.07 +/- 1.1
0 20 59.60 +/- 1.4 26.65 +/- 3.1 13.76 +/- 3.6
12 20 64.08 +/- 6.3 19.99 +/- 3.1 15.89 +/- 2.5
24 20 57.62 +/- 2.8 19.52 +/- 3.3 2Z86 +/- 0.4
36 20 59.59 +/- 2.0 13.09 +/- 0.7 27.33 +/- 2.2
48 20 58.34 +/- 6.9 10.19 +/- 1.4 31.47 +/- 4.5
0 50 61.26 +/- 4.0 24.95 +/- 5.1 13.79 +/- 3.3
12 50 61.12 +/- 7.1 15.11 +/- 1.9 23.76 +/- 5.2
24 50 59.29 +/- 3.6 16.10 +/- 1.5 24.61 +/- 2.6
36 50 58.65 +/- 5.8 10.08 +/- 3.7 31.27 +/- 7.0
48 50 56.84 +/- 4.7 8.94 +/- 4.1 34.22 +/- 6.4
0 100 57.30 +/- 2.9 29.95 +/- 1.4 1Z76 +/- 1.2
12 100 67.98 +/- 1.9 7.93 +/- 1.7 24.10 +/- 2.9
24 100 67.40 +/- 3.8 9.18 +/-1.2 23.43 +/- 4.1
36 100 61.27 47- 5.4 5.76 +/- 2.6 3Z98 +/- 6.6
48 100 5Z03 +/- 6.1 4.14 +/-1.6 43.84 +/- 6.3
Exposure Quercetin [ ]  G1 Phase S Phase G2/M Phase
Time (hours) u M Average Average Average
0 0 49.10 +/- 0.56 2455 47- 0.43 2635 47-0.99
12 0 46.00 47- 1.20 29.57 47- 0.74 2444 4-/- 0.45
24 0 48.82 47- 1.80 26.62 47- 1.22 24.57 47- 0.59
36 0 50.58 47- 1.52 28.29 47- 2.19 21.13 4-/- 3.71
48 0 50.48 47- 1.97 28.78 47- 1.19 20.75 47- 0.78
0 20 47.77 +/- 1.42 2617 47- 0.61 2606 4-/- 0.81
12 20 39.75 47- 8.31 3463 4 /-  4.69 2663 47- 3.62
24 20 15.51 4/- 5.13 2695 47-1.54 5654 4-/- 3.59
36 20 9.43 47-2.67 2640 47- 0.66 6617 4-/- 3.33
48 20 7.25 47-0.75 19.73 47-2.54 73.03 4-/- 1.78
0 50 45.99 WA 2628 WA 2673 l\7A
12 50 43.22 WA 31.54 WA 25.24 WA
24 50 10.64 N/A 2418 WA 6618 N/A
36 50 10.13 m 27.24 WA 6Z63 N/A
48 50 5.01 N/A 1656 N/A 79.43 N/A
0 100 50.10 N/A 2477 N/A 25.13 N/A
12 100 39.55 N/A 33.68 N/A 2677 N/A
24 100 11.72 N/A 2Z46 N/A 6682 N/A
36 100 10.32 N/A 2681 N/A 6Z87 N/A
48 100 6.37 N/A 19.04 N/A 7459 N/A
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Table 4.2
Summary of Cell Cvcle Response to Quercetin 
in E7QPg. (3 and y cells
E7Q Pa Exposure Quercetin [ ] G1 Phase S Phase G24W PhaseTime ( hours ) \i M Average Average Average
0 0 59.92 +/- 2.04 24.91 +/- 1.25 15.18 +/- 0.79
12 0 57.17 +/- 0.44 25.60 +/- 0.07 17.24 +/- 0.50
24 0 60.08 +/- 1.83 24.64 +/- 1.46 15.28 +/- 0.37
36 0 58.42 +/- 0.50 29.28 +/- 0.36 12.32 +/- 0.15
48 0 61.75 +/- 1.65 25.69 +/- 1.60 12.56 +/- 0.06
0 20 59.45 +/- 1.72 24.17 +/- 1.44 16.39 +/- 0.28
12 20 56.78 +/- 1.61 24.78 +/- 2.73 18.45 +/- 1.11
24 20 32.97 +/- 6.25 31.27 +/- 0.83 35.76 +/- 5.43
36 20 27.29 +/- 1.16 27.11 +/- 1.94 45.61 +/- 3.10
48 20 27.19 +/- 3.95 23.78 +/- 0.49 49.04 +/- 3.47
0 50 59.26 N/A 22.84 N/A 17.90 N/A
12 50 53.81 N/A 28.20 N/A 17.99 N/A
24 50 32.75 N/A 33.89 N/A 33.36 N/A
36 50 20.88 N/A 31.96 N/A 47.17 N/A
48 50 22.79 N/A 23.86 N/A 53.35 N/A
0 100 58.39 N/A 26.20 N/A 15.42 N/A
12 100 47.38 N/A 30.26 N/A 22.35 N/A
24 100 31.84 N/A 28.94 N/A 39.22 N/A
36 100 21.30 N/A 33.25 N/A 45.45 N/A
48 100 20.42 N/A 25.17 N/A 54.41 N/A
E7QP(3 Exposure Quercetin [ ]  G1 Phase S  P h a se G2JM PhaseTime ( hours ) H M  1 Average A verage Average
0 0 53.4 +/- 1.3 14.4 +/- 0.7 32.3 +/- 2.0
12 0 52.7 +/- 2 .6 14.6 +/- 1.0 32.7 +/- 1.6
24 0 51 .8 +/- 1.5 14.2 +/- 3.3 34.1 +/- 2.0
36 0 50.4 +/- 2 .6 14.6 +/- 1.9 35.1 +/- 1.0
48 0 48.5 +/- 1.4 16.2 +/- 2.5 35.4 +/- 1.5
0 50 52.6 +/- 1.2 14.1 +/- 0 .3 33.3 +/- 1.0
12 50 49.3 +/- 3.7 16.9 +/- 3.4 33.8 +/- 0.8
24 50 42.3 +/- 3.6 20.5 +/- 3 .4 37.2 +/- 2.0
36 50 3 4 .0 +/- 4.0 19.5 +/- 3.0 46.5 +/- 4.0
48 50 34.1 +/- 6.0 17.1 +/- 1.8 48.8 +/- 4.3
E7QPy Exposure Quercetin [ ]  G1 Phase S  Phase G 2/M  PhaseTime ( hours ) w m  M Average Average Average
0 0 36.1 +/- 0.3 8 .4 +/- 0.3 5 5 .6 +/- 0.0
12 0 34.4 +/- 0 .3 8.4 +/- 0 .8 57.1 +/- 0 .5
24 0 35 .5 +/- 0.9 7 .6 +/- 0.6 5 7 .0 +/- 0.3
36 0 37.4 + /- 0 .5 8.2 +/- 0 .0 54.4 +/- 0 .5
48 0 39 .3 +/- 1.3 7 .7 +/- 0.4 5 2 .9 +/- 0.9
0 50 35.4 +/- 0 .8 8.2 +/- 0.1 56.4 +/- 0 .9
12 50 3 5 .7 +/- 0.7 4 .6 +/- 1.4 5 9 .8 +/- 0.8
24 50 33.5 +/- 0 .5 7.6 + /- 0 .6 58.9 +/- 0 .1
36 50 29 .0 +/- 1.4 10.0 +/- 0.3 6 1 .0 +/- 1.1
48 50 33.2 + /- 0 .3 10.4 + /- 0 .4 56.4 + /- 0 .2
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Table 4.3
Summary of Cell Cycle Response to Quercetin
in E7R and 88529B Cells
Exposure Quercetin [ ]  G1 Phase SPhase G^M Phase
Tim e(hoirs) Average Average Average
0 0 62.6 +7- 3.9 13.0 +7- 1.8 24.4 +7-2.1
12 0 69.7 +7-0.0 9.8 +7-1.2 20.4 +7- 1.2
24 0 69.4 +7-2.4 ao +7-2.6 226 +7- 5.0
36 0 70.2 +7- 2.3 5.9 +7-1.2 23.9 +7- 1.2
48 0 70.3 +7- 1.0 11.8 +7-4.1 18.0 +7-3.1
0 50 65.1 +7-3.2 15.0 +7- 0.4 19.9 +/- 2.8
12 50 72.7 +7- 2.9 7.0 +7-2.2 20.4 V- 5.1
24 50 68.8 +7-4.2 16.3 +7-5.6 14.9 +/- 9.8
36 50 67.4 +7-4.3 14.0 +7-9.7 18.7 +7-5.4
48 50 36.6 +7-9.8 21.0 +7-13.1 424 +7-3.2
Exposure Quercetin [ ] G7 Phase S  Phase G2/M Phase
Time ( hours) p  M Average Average Average
0 0 74.9 +/- 5.3 8.9 +/- 2.0 16.2 +7- 3.9
12 0 65.0 +7- 8.7 19.2 +/- 7.4 15.9 +/- 3.0
24 0 66.9 +/- 4.3 15.1 +/- 4.0 17.9 +7- 2.5
36 0 67.4 +-/- 3.6 16.2 +-/- 6.8 16.4 +/- 3.7
48 0 67.9 +7- 4.0 18.9 +7- 10.3 13.2 +7- 7.2
0 50 74.2 +/- 4.8 9.9 +/- 3.7 15.9 +/- 2.0
12 50 68.6 +7- 6.8 11.7 +7- 6.3 19.7 +7- 9.7
24 50 65.2 +7- 6.8 15.6 +7- 5.9 19.2 +/- 6.5
36 50 727 +7- 3.9 5.9 +7- 3.8 21.4 +7- 1.7
48 50 66.7 +-/- 4.0 6.3 +-/- 4.1 27.0 +-/- 2.5
Exposure Quercetin [ ]  G1 Phase S  Phase G2/M Phase
Time ( hours) fi M Average Average Average
0 0 43.8 +7- 6.5 43.5 +/- 6.2 127 +7- 0.3
12 0 429 +7- 2.2 44.6 +7-1.7 125 +/- 0.5
24 0 423 +7- 2.3 46.1 +/- 5.1 11.5 +7- 2.8
36 0 38.8 +/- 3.0 50.5 +/- 5.2 10.7 +7- 2.1
48 0 423 +7- 1.7 46.9 +7- 2.7 10.9 +7- 1.0
0 50 47.3 +/- 4.6 36.7 +7- 2.9 16.0 +/- 1.7
12 50 227 +/- 3.6 71.8 +/- 9.0 5.4 +7- 5.4
24 50 427 +/- 4.5 50.1 +7- 6.5 7.2 +-/- 2.0
36 50 35.6 +/- 1.0 30.2 +7- 0.9 34.2 +/- 1.9
48 50 28.4 +/- 1.5 40.6 +-/- 0.6 31.4 +7- 1.8
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Table 4.5
Summary of Cell Cvcle Response to Quercetin
in E7QT1 and E7QT2 Cells
E 7Q T1
Exposure Quercetin [ ]  Gl Phase S Phase G2/M Phase
Time (hours) p  M Average Average Average
0 0 41.2 47-0.8 26.3 47- 1.8 325 47- 1.0
12 0 440 47-1.8 28.0 47-0.1 27.9 47- 1.9
24 0 43.0 47-3.0 28.4 V- 0.2 267 47-2.8
36 0 445 47-1.5 29.2 47-0.6 264 47-0.9
48 0 46.5 47-4.5 28.9 V- 1.1 246 47- 3.3
0 20 41.5 47-0.9 25.7 47-0.7 327 +/- 1.6
12 20 43.8 47- 6.7 248 V- 4.4 31.4 47- 2.3
24 20 31.3 47-4.3 2ao 47- 0.2 427 47- 4.0
36 20 26.3 47-8.7 29.2 47-0.5 445 4/-8.2
48 20 240 47-5.9 29.4 47-4.4 467 +/- 1.5
0 50 46.3 N/A 267 I'M 27.1 N/A
12 50 51.7 N/A 21.4 I'M 27.0 N/A
24 50 31.7 N/A 260 I'M 423 N/A
36 50 38.6 N/A 29.3 I'M 321 N/A
48 50 25.7 N/A 23.3 N/A 51.0 N/A
0 100 45.9 N/A 244 N/A 29.7 I'M
12 100 50.2 N/A 19.3 N/A 30.5 N/A
24 100 35.3 N/A 264 N/A 39.4 N/A
36 100 37.5 N/A 30.1 N/A 324 N/A
48 100 349 N/A 21.8 N/A 464 N/A
E7QT2
Exposure Quercetin []  G1 Phase S  Phase G2/M Phase
Time ( hours ) p  M Average Average Average
0 0 40.6 4-/- 4.6 269 +/- 1.0 35.5 +/- 3.7
12 0 39.3 4-/- 3.1 25.6 +/- 0.8 35.1 +/- 2.3
24 0 39.3 47- 2.2 27.5 4-/- 1.6 33.2 47- 3.8
36 0 45.2 +/- 2.8 28.5 +/- 1.5 26.3 47- 1.3
48 0 41.9 4-/- 1.8 27.6 +/- 3.0 30.6 +/- 1.2
0 20 41.1 +/- 2.5 24.3 +/- 0.1 34.6 +/- 2.5
12 20 48.6 4-/- 4.0 19.9 +/- 1.4 31.5 47- 2.7
24 20 321 +/- 6.9 30.7 4-/- 6.1 37.2 +/- 0.9
36 20 15.7 4-/- 5.8 325 47- 2.1 51.8 47- 3.7
48 20 9.3 +/- 5.2 25.4 4-/- 5.8 65.3 +/- 11.0
0 50 43.1 N/A 24.0 I'M 329 I'M
12 50 47.6 I'M 17.8 N/A 34.7 N/A
24 50 24.2 N/A 39.1 N/A 36.7 N/A
36 50 10.2 N/A 38.6 N/A 51.2 N/A
48 50 13.1 N/A 27.0 N/A 59.9 N/A
0 100 45.8 N/A 19.3 N/A 349 N/A
12 10 0 43.3 N/A 19.0 N/A 37.7 N/A
24 100 24.6 N/A 327 N/A 427 N/A
36 10 0 10.3 N/A 43.1 N/A 46.6 N/A
48 100 4 7 N/A 222 N/A 73.1 N/A
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Table 4.6
Summary of Cell Cycle Response to Quercetin
in E7QPT1 and E7QPT2 Cells
E7Q
PT1
E7Q
PT2
Exposure Quercetin [  ]  Gl Phase S Phase G2/M Phase
Time (hours) p  M Average Average Average
0 0 49.0 ■»7-0.0 25.5 47-2.8 25.4 47- 2.8
12 0 525 47-1.7 25.9 47-0.8 21.6 47- 2.5
24 0 57.4 47-1.5 240 47- 1.0 ia 6 47-2.6
36 0 522 47-0.6 27.3 4-/- 0.6 20.5 47-0.1
48 0 55.7 47-1.0 25.1 47- 0.3 19.2 47-0.7
0 20 46.3 47-0.0 27.1 47-2.6 26.6 47- 2.6
12 20 46.6 47-12.1 26.3 47-3.0 27.1 47-9.2
24 20 29.9 47-6.8 240 47-0.5 46.2 4-/- 6.3
36 20 221 47-3.2 240 47-0.5 520 47-2.7
48 20 15.3 47-2.3 20.9 47-0.6 628 47- 1.7
0 50 47.6 N/A 26.3 N/A 26.1 N/A
12 50 31.7 N/A 25.9 N/A 424 N'A
24 50 19.6 N/A 20.5 N/A 59.9 N/A
36 50 16.5 N/A 19.6 N/A 640 N/A
48 50 10.6 N/A 220 N/A 66.4 N'A
0 100 446 N/A 21.9 N/A 325 N/A
12 100 34.2 N/A 25.7 N/A 40.1 N/A
24 100 21.8 N/A 227 N/A 55.5 N/A
36 100 147 N/A 21.6 N/A 628 N/A
48 100 15,6 N/A 21.8 N'A 626 N'A
Exposure Quercetin [ ]  Gl Phase S Phase G^M Phase
Time (hours) IL M Average Average Average
0 0 48.6 47- 3.1 29.7 47- 3.4 21.7 47-0.3
12 0 53.2 47- 2.5 28.7 47-0.4 18.1 47-2.9
24 0 49.1 47- 1.2 30.9 47-0.7 20.0 47-0.4
36 0 49.3 47- 1.0 328 47-0.9 18.0 +/- 0.1
48 0 51.0 47- 0.1 30.4 47- 0.3 18.7 47-0.2
0 20 527 47- 1.2 28.0 47-2.6 19.4 47- 1.3
12 20 46.2 47- 6.1 30.9 47-6.8 23.0 47-0.8
24 20 29.4 47- 1.3 33.0 47-2.2 37.6 +/- 1.0
36 20 18.0 47- 1.4 26.8 47- 2.0 55.2 47-0.6
48 20 16.4 47- 1.4 25.6 47-0.1 58.1 47-1.4
0 50 47.7 N/A 31.1 N/A 21.2 N/A
12 50 426 N/A 33.4 N/A 24.0 N/A
24 50 21.9 N'A 34.6 N/A 43.5 N/A
36 50 16.5 N/A 28.4 N'A 55.1 N/A
48 50 14.7 N/A 26.7 N/A 58.5 N/A
0 100 45.9 N/A 31.1 N/A 21.6 N/A
12 100 55.7 N/A 33.4 N/A 26.4 N/A
24 100 429 N/A 34.6 N'A 34.7 N/A
36 100 38.4 N/A 28.4 N/A 29.5 N/A
48 100 39.4 N/A 26.7 N/A 37.8 N/A
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stimulate passage into S phase. Higher passage cultures could have selected 
against expression of the proteins and thus have insufficient levels to create a 
strong enough proliferative drive into DNA synthesis. This selection may be 
through activation of the bovine homologue of p l9ARF (see chapter six for more 
details) Alternatively counteracting cellular proteins, such as the cdk inhibitors for 
example, may be elevated in response to E7 and Ha-ras. This would then balance 
the action of the oncoproteins. Possible requirements of other viral proteins to 
eliminate this selection/counter-action would explain why this process does not 
occur in the cell line QOD.
Analysis of the cell lines E7QP|3 and E7QPy was also undertaken. E7QPP 
displayed loss of G l arrest with a drop in Gl and increase in G2/M populations 
(see figure 11 and table 4.2). Note though this cell line did not display a 
significant drop in S phase. Again this maybe due to the balance of the oncogene 
expression in the cell lines, with those that displayed high levels of Ha-ras protein 
and the strongest E7 RT-PCR product levels being able to maintain a significant 
population undergoing DNA synthesis.
E7QPy displayed two unusual features. Firstly under normal passage 
conditions it maintained a large G2/M population in relation to wild type PalF 
cells, indeed any of the other cell lines (see figure 11 and table 4.2). Additionally 
under quercetin exposure, no significant shift in cell cycle population distribution 
was observed. Likely explanations for this lack of shift in cell cycle profile could 
be that there is no cell cycle arrest in these cells. This is unlikely as none of the 
other cell lines expressing E7 and Ha-ras were capable of overcoming the G2/M 
block. Inheritance of a genetic alteration allowing inhibition of the G2/M block is 
not unfeasible and cannot be ruled out as a possible explanation. Another 
hypothesis would stem from the observation that the base cell cycle profile 
resembles the other cell lines once arrested i.e. low G l and S phase and high 
G2/M. This would indicate that during the period of experimentation these cells 
were undergoing a cellular crisis and were already in an arrested state. Hence 
quercetin treatment would have no effect. One argument against this point was the 
fact that the cells were tested over a period of three weeks in which time they were 
able to be passaged normally indicating no state of arrest. The final explanation is 
that this is the normal distribution of cycling E7QPy cells. The low Gl and S
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phase may well reflect the cells rapid passage through these stages due to the 
oncogene expression. Again further analysis with techniques suitable to a dynamic 
view of the cell cycle would help elucidate these issues.
In addition to E7QT2, other cell lines derived from explanted tumors were 
also examined for loss of G l arrest. When exposed to quercetin E7QT1, E7QPT1 
and E7QPT2 all demonstrated the loss of G l arrest, and the maintenance of the 
G2/M arrest (see tables 4.5 & 4.6).
The study of the transforming papilloma cell line, 88529B, continued the 
demonstration of cells transformed by BPV-4 to bypass G l arrest. As figure 11 
shows there is a characteristic drop in the percentage of cells in G l and an 
increase in the number of cells in G2/M, with only a small alteration in the S 
phase population. As an additional note, examination of table 4.3 also 
demonstrates this cell line exhibits a prominent elevation in S phase, 12 hours 
after initiation of quercetin exposure. This would significantly increase the 
number of cells exposed to quercetin undergoing DNA synthesis. It would be 
interesting to examine whether this would also be a feature of primary 
keratinocytes.
Overall in summary it can be seen that the loss of the G l arrest in response 
to quercetin exposure does not automatically indicate tumorigenic status of the 
cell. Although the abrogation of the Gl arrest may be necessary for the full 
transformation of the cell, indicated by the fact that all the tumorigenic cell lines 
tested in the study have lost the Gl arrest in response to quercetin, it is not 
sufficient to confer tumorigenic status. This latter point is proven by the ability of 
the transformed non-tumorigenic cell lines to bypass the Gl arrest. Also the ability 
to bypass the G2/M arrest is not required for tumorigenic status as none of the 
tumorigenic cell lines were able to bypass this arrest.
The ability to overcome the G l arrest requires the expression of BPV 4 E7 
and activated Ha-ras as far as can be determined by this series of studies. Whether 
E7 or Ha-ras alone could overcome the arrest is unknown. Although the fact that 
no clones expressing only E7, or an activated Ha-ras, were able to be isolated and 
outgrown, let alone be tumorigenic in combination with quercetin treatment, 
suggests that these oncogenes are insufficient to abrogate the arrest in isolation.
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Examination of a pooled population of cells expressing either gene in isolation 
would help determine this question, if such a population could be established.
4.2 Reversibility of the Quercetin Induced Cell Cycle Arrest
Based on the hypothesis that the abrogation of the quercetin induced arrest 
of the cell is pivotal to the progression of the cell to full transformation 
investigation into the nature of the cell cycle arrest was required.
To address this question PalF cells or E7QT2 cells were treated with 
quercetin for 48 hours and then maintained in normal DMEM-10 medium. At 24 
hours intervals cells were harvested, fixed in ethanol and stained with propidium 
iodide. Cell cycle distributions were then examined on the FACS machine as per 
cell cycle analysis as described in section 2.2.2.13.
4.2.1 Experimental Method
PalF or E7QT2 cells were exposed to OpM or 50pM quercetin for 48 hours 
as per cell cycle analysis protocols (section 2.2.2.13). Cells were then maintained 
in normal DMEM-10 medium for up to a further 96 hours post arrest with fresh 
medium being applied every 12 hours. In addition quercetin treated cell samples 
were also maintained in OpM or 50pM quercetin for up to a further 96 hours to 
determine cell cycle profiles under prolonged exposure to quercetin.
Cells were harvested every 24 hours post arrest, by trypsinization, and 
fixed in 70% EtOH at 4°C for at least 1 hour. Samples were then stained with 
propidium iodide and cell cycle distribution determined by analysis on the FACS 
machine.
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Chapter Four Results
4.2.2 Experimental Results and Discussion
Upon removal of quercetin both cell lines rapidly re-entered the cell cycle. 
Figure 13 demonstrates that in PalF cells, that had undergone Gl and G2/M arrest, 
within 24 hours of quercetin withdrawal there was a large decrease in the 
percentage of cells in the G l phase of the cell cycle. There is of course a 
concomitant increase in the percentage of cells in S and G2/M phase. This 
indicates a rapid release from the G l arrest in these cells and the movement of the 
released cells through to G2/M. The evidence of the reversibility of the quercetin 
induced G2/M arrest comes from the fact that from the time points 24 hours to 72 
hours the G2/M population decreases, indicating cells moving out of the G2/M 
phase back into cell cycle. Thus for the PalF cells arrest induced by quercetin is 
rapidly reversible.
Examination of the cell line E7QT2 indicates also the reversible nature of 
the G2/M arrest. Figure 13 shows that after 24 hours of quercetin withdrawal this 
cell line actually continues to arrest, with a further decrease in Gl and S phase as 
the cells empty into the G2/M phase of the cell cycle. However 48 hours post 
withdrawal re-entry into the cell cycle initiates as the percentage of cells in G2/M 
decrease and cells re-enter G l. This indicates that also in this cell line the arrest is 
reversible.
4.3 Analysis of the NIH3T3 cell line as a Possible Alternative Cell Line
4.3.1 Cell Cycle Analysis
Due to the shortage of suitable antibodies available against bovine antigens 
, and the possibility of analysis of E7 only expressing cell lines, an investigation 
was carried out to determine whether another cell line could be used for analysis.
As an initial choice, due to immediate availability of both parental and 
stable cell lines expressing BPV-4 oncogenes, NIH3T3 cells were examined.
Following from previous work displaying the ability of quercetin to induce 
a G l and G2/M cell cycle arrest in PalF cells, it was decided, as an initial 
parameter, to examine whether the NIH3T3 cell line would behave in a similar 
manner. This feature would be important to ensure that the mechanisms through
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which quercetin would be acting in the primary bovine fibroblasts would also 
likely elicit the same responses in the murine cell line.
4.3.2 Experimental Method
The essential details of the FACS analysis are in section 2.2.2.13. Briefly 
either PalF or NIH3T3 Zipneo (NIH3T3 cells stably transfected with pZipneo) 
cells were plated in 90mm culture dishes and treated with either 0, 20, 50 or 
lOOpM Quercetin over 48 hours with fresh medium being applied every 12 hours. 
Cells were then harvest and fixed using EtOH. Fixed cells were then stained using 
propidium iodide and RNAase A (the latter to remove any staining of RNA which 
would cause errors in the resultant FACS analysis) to stain the DNA. The stained 
samples were then analysed on the FACS scan to determine the percentage of the 
cells in each of the phases of the cell cycle.
4.3.3 Experimental Results and Discussion
Upon treatment with quercetin PalF cells arrest in Gl and G2/M phases of 
the cell cycle. This can be observed in Figure 14, by the stable G l percentage 
upon quercetin exposure occurring with a concomitant decrease in S phase 
population and an increase in the G2/M population. Exposure to increasing levels 
of quercetin resulted in a more prominent shift in the populations in each phases 
of the cell cycle e.g. 20pM quercetin for 48 hours results in a decrease of the cells 
in S phase from 23.55% to 11.58%, however 100p,M quercetin for 48 hours causes 
a decrease from 31.37% to 2.52%, displaying a dose dependent effect on the cell 
cycle distribution of the PalF cells.
Examination of the cell cycle profiles of the NIH3T3 Zipneo cells, under 
quercetin exposure, showed a different response. Quercetin exposure caused an 
arrest in G2/M evidenced by the increasing percentage of G2/M, but failed to 
cause a Gl arrest. Figure 14 shows that even after 48 hours of quercetin treatment 
at 50 or 100|iM NIH3T3 Zipneo cells showed little decrease in the S phase 
percentage. Additionally to this they also showed evidence of a decrease in the Gl 
population rather than the stable population seen in PalF cells, suggesting that 
cells were moving out of Gl and S phase and accumulating only in G2/M.
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Figure 14 (facing page). Cell cycle profiles o f  normal and transformed PalF cells 
PalF or NIH3T3 cells grown in 20-100p.M quercetin or equivalent volume of EtOH 
for 48 hours were analysed by FACS.
The lines represent percentage of cells in the G l, S or G2/M phases of the cell cycle.
Key:
OpM Quercetin 
20pM Quercetin 
50pM Quercetin 
lOOpM Quercetin
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This lack of G l arrest in response to quercetin exposure in the NIH3T3 
cells meant this cell line was not a suitable alternative for study.
4.4 Analysis of Transient BPV-4 E7 Transfectants
To attempt to determine wheter BPV 4 E7 expression alone could cause 
abrogation of the quercetin induced arrest, transient transfections of BPV-4 E7 
were examined.
Ideally a study of a transfected population in which all cells expressed the 
protein of interest would be desirable. This would commonly be attained through 
use of retroviral vectors which are capable of very high transfection rates, or by 
the generation of stable transfected cell lines.
Unfortunately both of these techniques at the time of study were unsuitable 
for use. The retroviral system of transfection had been established but required 
extensive initial set up time, and as detailed earlier cell lines expressing only E7 
were unable to be cultured in vitro.
Hence in order to tackle the problem of examining E7-only transfectants a 
system of tagging was used.
4.4.1 Experimental Method
See section 2.2.2.14. In brief, lxlO6 PalF cells were transfected with a 
combination of 5pg of pZipneo E7 with 20^ig of the transfectant tag plasmid 
pCMVCD20, or as a control 4p,g of pZipneo with the pCMVCD20 plasmid. This 
plasmid expresses a cell surface marker, the CD20 antigen, which is used to 
identify the transfected population from the background untransfected cells.
In these cases DOTAP transfection was substituted with the lipofection 
reagent Superfect™ (Qiagen) but otherwise was carried out essentially as in 
section 2.2.2.6. Transfected cells were then treated with either OpM or 50pM 
quercetin over 36 hours with fresh medium every 12 hours, 24 hours post 
transfection.
Cell were then harvested by trypsination and probed with the primary 
FITC tagged antibody that recognises the CD20 epitope. Once unbound antibody 
was washed away cells were then stained with propidium iodide.
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Samples were analysed in the FACS machine and cells expressing FITC 
florescence were gated, and propidium iodide staining of DNA content measured 
in this population to determine cell cycle distribution.
4.4.2 Experimental Results and Discussion
Transient transfection levels were obtained using the Superfect™ reagent 
by examination of cells transfected with a green fluorescent protein (GFP) 
expression plasmid, pEGFPNl, under the florescent microscope. This allowed 
quick and easy determination of the approximate number of transfected cells in 
the population Florescence was assayed 48 hours after transfection to allow 
expression of the GFP as this would be close to the time of harvesting of cells in 
the actual experiments. Roughly 10% of the population was transfected at this 
point, indicating a good efficiency of transfection.
Positive control experiments were carried out to ensure the ability of the 
system to work, by using a cell line which constitutively expresses the CD20 
antigen (Raji cells). The antibody bound to the cells and induced a shift in the 
FITC florescence profile of the cell population in comparison to control treated 
populations (data not shown).
Despite greater than the requisite 5000 E7-only transfected cells being 
collected and assayed, background noise made meaningful determination of the 
cell cycle profile of these cells difficult. Overall this meant an inability to clarify 
any change in cell cycle behaviour in the transfected population in comparison to 
the parental PalF cells with this technique at present.
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CHAPTER FIVE 
RESULTS
5.1 Analysis of p53 Protein in Cell Lines
Understanding the nature of the cell cycle arrest in the PalF cells would be 
invaluable in the study of the transformation process by BPV-4 E7 and Ha-ras.
As quercetin induced a G l and G2/M arrest in the PalF cells, yet only a 
G2/M arrest in the transformed cell lines, the determination of the mechanism of 
the Gl arrest was paramount. It has been shown by a wealth of literature that p53, 
the so called ‘guardian of the genome’, is involved in mediating cell cycle arrest in 
G l (for reviews see Ko & Prives, 1996; Agarwal et al., 1998; Giacca & Kastan, 
1998), in response to many stimuli, and indeed the involvement of p53 in the 
G2/M arrest is also likely (Di Leonardo et al, 1997) and is the subject of much 
study.
A good initial candidate for the cell cycle regulator of the quercetin 
induced cell cycle arrest was the p53 protein. At the time of the investigation there 
was not an antibody that was known to react against the bovine p53. However as 
bovine p53 cDNA had been sequenced, the amino acid sequence was derived and 
comparison of the bovine protein to the human protein was undertaken. This 
analysis showed several regions of complete homology between the human and 
bovine amino acid sequences, mainly in the conserved regions of the DNA 
binding domains, in addition to a region in the N terminus. This region also 
corresponded to the epitope of a commercially available antibody, Bp53.12, which 
recognises residues 18-30 in human p53 (see figure 15) and the antibody was 
suitable for western blotting.
Most other commercially available antibodies were unsuitable due to poor 
sequence homology between bovine and human p53 protein sequences in the 
corresponding epitope regions. However two other antibodies were also tested 
against bovine p53 due to promising sequence homology in the recognised 
epitopes. These were clone PAB240 (residues 213-217) and clone DO-1 (residues
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21-25). However both of these antibodies failed to cross react with bovine p53 on 
western blot membranes.
The Bp53.12 antibody was successful in detecting bovine p53 in western 
blots even though it overlapped the region recognised by clone DO-1. The DO-1 
antibody failed presumably due to the single amino acid alteration between bovine 
and human p53 in the epitope. Bp53.12 may well have succeeded in binding to the 
region as it binds a larger epitope in which homology between human and bovine 
p53 is maintained. This fact would then permit strong enough binding despite the 
single amino acid difference between the two species.
5.1.1 Experimental Method
Cell lines were treated with various concentrations of quercetin for 36 
hours with fresh medium being used every 12 hours as per the treatment protocol 
for cell cycle assays (section 4.1.1). This was in order to allow comparison 
between the cell cycle studies and the protein levels investigated. In addition to 
quercetin treatments, control treatments of UV exposure (120J/m2 24 hours before 
harvesting) or in some instances bleomycin sulphate (15pU for 6 hours before 
harvesting) were used to induce p53 in the cell lines. Additional samples from 
untreated cells were also taken.
Protein samples were then derived from these treated cell lines, and protein 
concentration estimated. 80pg of total cell lysate was used per well, ran out on an 
SDS-PAGE gel and blotted on to nitrocellulose membrane. The membrane was 
then probed using Bp53.12 and a HRP-linked secondary antibody. In order to 
double check loading, a control probing for actin levels was carried out, by 
stripping the blot and re probing with the anti actin antibody (see section 2.2.4 for 
full details).
5.1.2 Experimental Results and Discussion
As figure 16 indicates the exposure of PalF cells to quercetin induces an 
increase in the p53 level. Additionally exposure to UV irradiation also causes an 
increase in p53 protein levels. This figure also displays that in E7Q cells p53 
protein levels increase upon exposure to quercetin or UV. The descendent of E7Q, 
E7QT2, shows an elevation of p53 in response to UV but not to quercetin This
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Chapter Five Results
may be due to the high levels of p53 in the absence of quercetin. Importantly 
however it is evident that the E7Q cell line not only retains expression of p53 but 
also retains responsiveness to DNA damaging agents.
One way to examine whether the p53 protein was functioning normally in 
the tumorigenic cells was to assay the expression of p21Wafl/Cipl, a known target of 
p53 transcriptional activation (El-Deiry et al., 1993).
Reprobing the blot with a p2lWafl/c,pl reactive antibody shows differences 
between the cell lines. As can been seen in figure 16, p2 lWafl/Cipl is elevated in 
PalF cells in response to quercetin or UV as one would expect from an elevation 
of p53 in these cells, thus reinforcing the hypothesis that quercetin induces the cell 
cycle arrest via p53 and p21Wafl/Cipl. Figure 16 also shows no p2 iWafl/Cipl staining 
in the E7Q and E7QT2 sample lanes. This indicates that there may be dysfunction 
in the p53 up-regulation of p21Wafl/Cipl.
In E7R, E7QP|3, E7QPy and QOD p53 is elevated in response to quercetin 
and thus is p21(figures 17 and 18). E7QPcx and Q2D show variation from the wild 
type response. E7QPa shows a response to UV and bleomycin sulphate in p53 
protein levels indicating functional response pathways/mechanisms and 
expression of the protein. However no visible difference is observed with 
quercetin treatments in comparison to ethanol treated cells. This may due to the 
high background of the blot rather than a dysfunctional response due to the protein 
level elevation to the other DNA damaging agents. As in E7Q no p21 protein is 
present in these cells as detected by western blot analysis, thus although present 
the p53 protein seems incapable of inducing expression of the p21 protein.
Q2D provided further evidence of dysregulation in the p53 response 
pathway. As seen in figure 18, Q2D displays a constitutive overexpression of p53, 
and no response to DNA damaging agents such as quercetin, UV or bleomycin 
sulphate. However despite high levels of the p53 protein in these cells there was 
no evidence of p2 lWafl/Cipl expression.
The cell line 88529B although assayed for p53 protein levels in response 
to UV exposure or quercetin exposure, failed to generate a signal with the 
Bp53.12 antibody. Note though due to low protein concentrations of the cell 
lysates derived for the western blot analysis only 60pg rather than 80pg of total 
cell lysate was loaded per well. This may be in part an explanation however some
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detection of p53 protein levels should have been visible at this loading level. Thus 
at this point no information is known about p53 response to quercetin or UV 
exposure in this cell line, apart from a presumed low level of expression.
In summary the non tumorigenic transformed cell lines display a normal 
p53 protein level elevation in response to quercetin. However the tumorigenic cell 
lines although showing expression of the p53 protein show no expression of the 
p2 1 Wafi/cipi protein, the inhibitor of the cdk2 protein kinase activity.
5.2 Analysis of p53 Transcriptional Activity in PalF
Following on from the observations obtained from the western blot 
analysis, investigations into determining the status of p53 function in the cell lines 
was started. Reporter assay systems were used to elucidate whether the loss of p21 
expression in the tumorigenic cell lines was likely due to loss of p53 
transcriptional function, indicating that although p53 may be present it was 
inhibited as a transcriptional activator.
The main reporter consttruct used in the analysis of the p53 protein was 
pRGCfosLuc. This contains two p53 consensus binding sites derived from the 
ribosomal gene cluster promoter upstream of a minimal murine c-fos promoter. 
This was linked to a firefly luciferase reporter gene. A control reporter, pfosLuc 
was the same as pRGCfosLuc with the exception that it lacked the two p53 
binding sites. Any activity difference between the two plasmids in a reporter assay 
could be attributed to the binding of p53 to the DNA binding site and induced 
transcription of the reporter gene.
In addition to this system two other reporters were used on a more limited 
scale. These were WWP-Luc and pGL2NA(mdm2). The former links the human 
p2 1 Wafi/cipi gene promoter to the firefly luciferase gene, and the latter uses the 
human Mdm2 gene promoter, another known target of p53 (Barak et al., 1993) 
linked to the firefly luciferase gene. These two additional reporter systems allowed 
examination of a more ‘natural’ target of p53 binding and transcriptional 
activation.
As with the FACS and western blot analysis cells containing the reporters 
were treated with quercetin and/or UV in order to ascertain the response of the 
p53 protein to these agents.
133
An
aly
sis
 o
f 
p5
3 
and
 
p2
1 
Pr
ote
in 
Le
ve
ls 
by 
W
es
ter
n 
Bl
ot
tin
g
in 
Pa
lF
, 
E7Q
 
and
 
E7
Q
T2
m z  A n o n
<N
H
a
r -
W
I
O '
W
H9£ DOS |
H9£ 0 0  |
H t Z  AflOZl I
H9£ DOS 1 • 
H9£ DO « f j l
uu
CL,
H f Z  AflOZl
H9£ DOS
H9£ DO
m  .5tp  <>) +->P . Oh O
<
a
S*c05
&0a
i
1  
•8
?
Q
2  
"a
0 < 5©
VJ
"a 
* *—*
205
.05
5
»oCv,
sD
0)u3W)
134
Ce
lls
 
we
re 
tre
ate
d 
wi
th 
qu
er
ce
tin
 
at 
50(
liM
 
or 
lO
Op
M 
or 
eq
ui
va
le
nt
 v
ol
um
e 
of 
Et
OH
 
for
 
36 
ho
ur
s. 
W
he
re
 
in
di
ca
te
d 
ce
lls
 
we
re
 
tre
at
ed
 
wi
th 
12
0J
/m
2 o
f 
UV
 
an
d 
ha
rv
es
te
d 
24 
ho
ur
s 
la
te
r, 
or 
bl
eo
m
yc
in
 
su
lp
ha
te
 
at 
15
pU
 
fo
r 
6 
ho
ur
s 
an
d 
ha
rv
es
te
d 
im
m
ed
ia
te
ly
 
af
te
r. 
M
em
br
an
es
 
we
re 
pr
ob
ed
 
for
 
p5
3 
(to
p 
ro
w
), 
p2
1 
(m
id
dl
e 
ro
w
) 
an
d 
ac
tin
 
as 
a 
lo
ad
in
g 
co
nt
ro
l 
(b
ott
om
 
ro
w
).
An
aly
sis
 o
f 
p5
3 
Pr
ote
in 
Le
ve
ls 
by 
W
es
ter
n 
Bl
ot
tin
g
in 
E7
Q
Pa
9'SI
3 jB i |d |n s  o 3 | a
H P Z  AH031
H9£ D00I
H9£ DOS 
H9£ DO 
JU 3U I^3JX  °M
O
~o<u
■(—I
3
’"6c
0)u1)
x
T3
Bm
ro
>
c3
X
T3
I
i I
U
M
«  I*
i I
4 £
I  !
. £
^  <
as
S•«05
be
s:
i
5
• I
I
3O
X
X
m ,
£
Xo
w
V-o
roa
_3
O > «—• 
cD
3 O'0) 
t->O
2  
z t
g  
© —
3^
05©
8 -
05
3^
0 5
•»»
s
0 5
0 5
5
sd
X>u.
3t>0
z tO•o
w3
_C
"5Ou.0>
3CT“
-o1J
3D
0)o
a
CL
Cxr-
X
3O
JZ
sO
S-H
X
I t
■<— > 
3
0)
3
xjz.
3
C /5
CJ>»
£ojj
X)
u-o
t-T
B
3
3OX
3"CN
~o
BinD
>
c3
X
"0
>
X
o<N
-a<uw
31)
135
im
m
ed
ia
te
ly
 
af
te
r. 
M
em
br
an
es
 
we
re 
pr
ob
ed
 
for
 
p5
3 
(to
p 
ro
w
) 
an
d 
ac
tin
 
as 
a 
lo
ad
in
g 
co
nt
ro
l 
(b
ott
om
 
ro
w
). 
15
.6 
us
ed
 
as 
a 
po
sit
iv
e 
co
nt
ro
l 
(e
xp
re
ss
es
 
m
ut
an
t 
hu
m
an
 
p5
3)
 (
p2
1 
da
ta 
no
t 
sh
ow
n 
fo
r 
E7
Q
Pa
 
as 
pr
ot
ei
n 
wa
s 
un
de
te
ct
ed
 
in 
bl
ot
)
An
aly
sis
 o
f 
p5
3 
and
 
p2
1 
Pr
ote
in 
Le
ve
ls 
by 
W
es
ter
n 
Bl
ot
tin
g
in
E7
QP
(3
, E
7Q
Py
an
d 
E7
R
r-W
Anon4 l I
Dooi11 l
Dos i i
Do 1 |!
Ohar-w
Anon I 
Oooi I 
Doe 
5o
CO.
Ouar-W
Anon | 
O o o i |  
O o e  
Do J
I
I
III
I!
I
I I I
m  r— c
*0 (N \Sa  a.
©©
T3©
3_©*6c
i©x
"O©w
C / 5©
>
a3x
X5
•—3Ox
X)
C/3 O3 ^o D 
=L
SO ^  C3 ~
£  s  
4—>3xQ.
•«>3
6/J
Xo-4—»UJ
©-o
©
EJ3
O>
1
a"<3©so0
1
s©
©
3^©
. 5 0
3
.'Os
sg
©  S—<3top
C©
3
>
' 3
cr©
=L
oIX3
_c
'■4—> © © 
S-H 
©  
3cr
x
T3
©  — -
©
©o
£o
i—
Eow4—*o
X
Co©top_c•63
3
c /33
©3
£
O
. 3  ©©
> 4£oj©
Xj
I—O
s-T 
© 
4—>
3
3Ox
3"(N
T3£
C / 3
©
>3x
T3
>
OCN
33
©  
4—>3©£3
E©£
TD-a
CN
a .
io
S-H
a .o
cniOa .
33
©-OEo ,
©
S-H©£
C/3©
X
E©
©
X!3
© 
4—>
3
'-a©E
E
136
An
aly
sis
 o
f 
p5
3 
and
 
p2
1 
Pr
ote
in 
Le
ve
ls 
by 
W
es
ter
n 
Bl
ot
tin
g
in 
Q2
D 
and
 
QO
D
Qo
DOOI |  f f
D o s  |  j
D o  |
\ I
—1 .3m <N 
Cl.  ( X  ^
Q
( Na
3)Bi|d{ns 09[g  
A d O Z l
O o o i
Dos
D o
ju s iu iE a ix  ojsj i
I !
r^ ,
G . O<
" f t
• f t1
!>3
fts
•8&ftft
" f tftft
a X£ O•N Wts u
"3
0) <—» 
3  
_o
C
3I—
3
-C
3
Ojc
sD
m
6 /)
|
5-§
§Q
"aft6*Sft
I"
ftft
§O)
"aft
5^'"5 e>*, *—
- f t8
>5
.s<a
ft
ft•♦«*ftft
f t ,r*"3
* o
f t ,
00
3I—3OP
T3
3*—>
3
3
3
U
"3
T3
3
O
-C
sD
D
3.iO
■t—>
3
0) -«—> 
3  
-C  
O ,
3JO*3>'3
cr
3
- 3  o
^ ° s  -=
3.8 <n 
"3” a0 £
1  Io ^
1 0  "3*-1 53  3
1 )
3t—
3
3cr
>
D
o
(N
- a
3 <—> 
3 
3
coCO
opc■3
3
3
C /3
3
3
3
”3
C
3
5oa
c
£o
.3 3
" 3-a
3
£o
3  —
jc2
c
(Na.
5ou-
D ,
O
co
10
a.
-0
3
_Dos-
O .
00u,
3£
C /3
3c
3
u
X)
£
3
3
<S
3 ■«—> 
3
■3
3E
£
■3
3 *—>
o
3■<—>
3
”3c
3£
a'3—ou>
O .
C /3
3Q
<Na
e-
C£o
-C
C /3
—
O
c
3  +—>
3
”3
cna .
?o1—
£oi—> <—»oXj
137
Chapter Five Results
5.2.1 Experimental Method
PalF cells were transfected with 4pg of the pRGCfosLuc reporter, or 
pFosLuc control, as described in section 2.2.2.6. The transfected cells were then 
treated with quercetin (0 , 20,50 or lOOpM) initiating 8 hours post transfection and 
lasting for 16 hours before harvesting. Control treatment of UV exposure was also 
carried out 16 hours pre-harvesting with an exposure of 50J/m2.
Cells were then harvested in the luciferase lysis buffer (Promega) and 
asssayed for luciferase activity as described in section 2.22.1, and normalised to 
protein concentration as described in section 2.2.4.3
5.2.2 Experimental Results and Discussion
As can be seen in figure 19 the exposure of the transfected cells to 
quercetin or UV induced a 3-4 fold elevation of the p53 transcriptional activity, in 
comparison to control treatment of ethanol alone in the medium. The DNA 
damaging agent UV also induced a 3 fold transcriptional activity.
This increase in transcriptional activity is attributable to the p53 protein 
rather than through the c-fos minimal promoter as the luciferase activity of the 
control reporter does not significantly alter with the quercetin treatments. This is 
visualised in the figure by the control plasmid bar. The standard deviation bars 
indicate total variation seen in the range of quercetin treatments.
5.3 Analysis of p53 Transcriptional Activity in all Cell lines
The result of p53 transcriptional activity elevation, in response to quercetin 
exposure, re-enforced the hypothesis that p53 was at least in part responsible for 
the cell cycle arrest observed in the PalF cells. Following from this the 
determination of the p53 status of the transformed and tumourigenic cell lines was 
undertaken, the hypothesis being that whilst p53 protein may be present in these 
cells, it may be dysfunctional and unable to induce transcription.
5.3.1 Experimental Method
Cells of the various cell lines were transfected with 4pg of the reporter 
with 4pg of pCHllO as a transfection control as described in section 2.22.6. The
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transfected cells were then treated with quercetin (OpM or 50|xM), initiating 8 
hours after transfection, over 36 hours with fresh medium being applied every 12 
hours. Control treatments of UV exposure were also carried out at 50J/m2 and/or 
120J/m2, 16 hours before harvesting.
Cells were then harvested in the luciferase lysis buffer (Promega) and 
asssayed for luciferase activity as described in section 2.22.1. Luciferase activity 
was then normalised to specific P-galactosidase activity (ascertained by measuring 
the P-galactosidase activity as described in section 2.2.2.12, and protein 
concentration as described in section 2.2.4.3)
5.3.2 Experimental Results
From examination of the parental PalF cells, it can be seen that the 
exposure of 50pM quercetin over 36 hours elevates the p53 transcriptional activity 
of the cells 2-3 fold over ethanol alone in the medium (figure 20). The initial 
observation with the short quercetin exposure normalised to protein concentration 
alone, is reproducible in this system of longer quercetin exposure controlled for 
transfection efficiency.
This activity increase of the pRGCfosLuc reporter can be ascribed to the 
p53 protein as the pFosLuc control reporter did not respond to quercetin exposure. 
Also in support of this fact, figure 20 shows that the activity of the pRGCfosLuc 
reporter was at least 20 to 120 fold higher than the pFosLuc control reporter 
construct. This shows that PalF cells even 36 hours after transfection, with ethanol 
only added to the medium, display a significant level of background p53 
transcriptional activity.
Treatment of E7Q, or the descendent cell line E7QT2, with quercetin over 
36 hours showed a very different response. As can been seen in figures 21 and 22, 
not only do the cell lines display a very low level of p53 transcriptional activity in 
comparison to the PalF cells, indeed there was no significant difference between 
the activity of pRGCfosLuc and of pFosLuc. Also a lack of a functional response 
to quercetin exposure was observed, with no significant difference between the 
quercetin treated cells and the ethanol treated cells.
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Chapter Five Results
An essentially equivalent picture emerged from analysis of the E7QPa 
cell line (see figures 23 and 24). In this assay UV exposure was also tested as to 
whether it would induce a p53 response. Again there proved to be no response and 
no luciferase activity attributable to the p53 protein i.e. no difference between 
pRGCfosLuc and pFosLuc.
This pattern of no p53 transcriptional activity response was repeated in the 
other tumorigenic cell line Q2D. Again this showed no response to quercetin 
exposure (see figures 25 and 26). There may be a slight elevation of p53 
transcriptional activity upon UV exposure of the cells, however this may be due to 
experimental variation due to low activities seen with this reporter in this cell line. 
It is however, also arguable whether any alteration of p53 transcriptional activity 
would be relevant in vivo due to the very low levels of p53 transcriptional activity 
in comparison to the PalF cells. This includes luciferase activity of PalF cells 
treated with ethanol alone, or by the lack of difference between reporter and 
control plasmids transfected into the tumorigenic cells.
One hypothesis to explain the loss of function by the p53 protein could be 
the expression of the BPV-4 E7 protein in these cell lines inhibiting p53 
transcriptional activity via TBP, as has been reported with HPV E7 (Massimi et 
al, 1996; Massimi & Banks, 1997). To address this question analysis of the other 
non tumorigenic cell lines was undertaken.
Initially the transformed E7R cell line was tested with quercetin exposure 
and UV exposure. As can been seen in comparison to PalF cells, the E7R cell line 
exhibits an equivalent level of p53 transcriptional activity (figure 27). Indeed 
when examined in comparison to E7R cells treated with ethanol alone the 
quercetin treated cells exhibited a normal p53 response, elevating the luciferase 
activity 2-3 fold (figure 28). It is interesting to note the lack of a functional 
response to UV. Whether the cell line exhibits a lack of response to UV, a 
resistance, or indeed a sensitivity is not known. Further testing of the E7R cells 
with a greater variation of UV exposures would answer this point. However in the 
context of the study the results of a normal p53 response, in the reporter assay, to 
quercetin exposure indicates that the loss of p53 transcriptional activity is not a 
requirement for the cells to bypass the G1 arrest. In addition it may well be likely
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that the loss of this function of the p53 protein is an important step in the 
progression to full transformation of the cell.
The QOD, E7QP|3 and E7QPy cell lines showed a level of p53 
transcriptional activity comparable to, or slightly higher than, that of the PalF cells 
(see figures 29 to 31). Quercetin treatment of these cell lines induced a functional 
p53 transcriptional response of 2-3 fold, equivalent to that of PalF cells. UV 
exposure of these cells displayed a slightly different result. E7QP(3 and E7QPy 
displayed a doubling of p53 transcriptional activity in response to a UV exposure 
of 50J/m2. However increased dosages resulted in a decrease of the response. 
Excessive exposure of UV to these cells may result in enough DNA damage not to 
permit normal functioning of the DNA damage response pathway.
QOD cells showed no response to UV exposure, which may be due to a 
resistance to UV induced damage. Such a resistance could be from mutation of 
p53 resulting in the inability to phosphorylate the protein at specific serine 
residue(s) associated with UV but not some other DNA damaging agents e.g. 
serine 392 in human p53 (Giaccia & Kastan, 1998 and references therein). 
Another possible mechanism is a sensitivity to UV induced damage, by loss of a 
DNA repair protein function for example. The cells would be unable to mount a 
full response due to the high level of DNA damage affecting transcription, 
resulting in no visible p53 transcriptional activity elevation even though the gene 
and protein may still be functional.
Analysis of the transforming papilloma cell line 88529B displayed an 
unusual response to the stimuli. These cells exhibited a level of p53 transcriptional 
activity roughly comparable to the PalF cells (figure 31) when taking the 
luciferase activity of the PalF cells treated with ethanol alone as a base figure. 
Comparison of the 88529B cells treated with 50pM quercetin showed that the 
reporter activity did not significantly vary from the control cells. However UV 
exposure at 50 or 120J/m2 resulted in an elevation. Again this may be due to 
varying tolerances of the different cell lines to the different agents. As the 88529B 
cell line is derived from keratinocytes this may suggest a cell lineage feature 
where the keratinocytes display a normal UV DNA damage response, yet require a 
greater exposure to quercetin than the fibroblasts to elicit a response. Analysis of 
primary keratinocytes would shed light on this question. Failure of the 88529B
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Chapter Five Results
cells to generate a reliable p53 transcriptional activity response to quercetin may 
be a factor in the cell line’s progression to full transformation.
In summary we find a correlation between the tumorigenic status of the 
cell and p53 transcriptional activity status, with the tumorigenic cells showing no 
response to quercetin. This suggests that loss of transcriptional activity of p53 may 
be a critical event in the progression to tumorigenic status. However it is also 
obvious that the abrogation of p53 transcriptional activity does not correlate with 
the ability to bypass G1 arrest in the cell lines as indicated by E7R, QOD, E7QP(3 
and E7QPy. This shows that the abrogation of the p53 transcriptional activity is 
not a requisite for the cell to bypass the quercetin induced G1 arrest.
5.3.3 Experimental Results and Discusion Part 2
In addition to the reporter studies carried out with the pRGCfosLuc 
reporter, limited further study was also carried out with two other reporters WWP- 
Luc and pGL2NA(mdm2). The latter was also used in conjunction with exogenus 
p53 as detailed later.
Transfection of the PalF, E7Q and E7QT2 cell lines with the WWP-Luc 
reporter provided further evidence of the loss of p53 transcriptional activity in 
those cell lines. Taking the PalF cells with the WWP-Luc reporter transfected with 
no treatment as a base level of luciferase activity, figure 33 demonstrates that 
quercetin treatment doubles the p53 transcriptional activity also in this system as 
well. UV exposure elicited a more modest elevation in p53 transcriptional activity.
Importantly with the use of this reporter it is also evident that the E7Q and 
E7QT2 cell lines again display a very low level of p53 transcriptional activity in 
comparison to the PalF cells. However close inspection of the luciferase activities 
shows that the E7Q (but not E7QT2) cell line does display a doubling of p53 
transcriptional activity in response to quercetin treatment. This may be due to 
experimental error due to the low activities observed with the tumorigenic cell line 
or due to possible quercetin responsive sites in the human p21 promoter other than 
the p53 responsive site. However it is unlikely that any elevation seen in the E7Q 
cell line would be relevant in vivo due to the low level of p53 transcriptional 
activity, in relation to PalF cells, even after any putative elevation.
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5.4 Analysis of Exogenus p53 Transcriptional Activity in E7Q and E7QT2
In a preliminary study the transcriptional activity of exogenus p53 was 
assayed in these cell lines. This would help determine whether the loss of p53 
transcriptional activity in the tumorigenic cell lines was due to mutation or post 
translational modifications to the protein.
5.4.1 Experimental Method
The various cell lines were transfected with 4pg of the reporter 
(pRGCfosLuc, pGL2NA(mdm2) or WWP-Luc) and 20pg of the relevant 
expression plasmid (pCB6wtp53 or pCB6mtp53) or vector control (pcDNA or 
pZipneo). 4\ig of pCHHO was also co-transfected as a transfection control as 
described in section 2.2.2.6 in the experiment with WWP-Luc or the pRGCfosLuc 
experiment in figure 36.
Cells were harvested 36 hours after transfection in the luciferase lysis 
buffer (Promega) and assayed for luciferase activity as described in section 
2.22.1. Luciferase activity was then normalised to specific P-Galactosidase 
activity (ascertained by measuring the p-Galactosidase activity as described in 
section 2.2.2.12, and protein concentration as described in section 2.2.4.3) in the 
experiment using the WWP-Luc reporter construct or the experiment with 
pRGCfosLuc shown in figure 36. The other experiments with either pRGCfosLuc 
or pGL2NA(mdm2) were normalised to protein concentration alone.
5.4.2 Experimental Results and Discussion
Figure 34 shows the results of the first experiment using the pRGCfosLuc 
reporter. The luciferase activity in the PalF cells is 3 fold greater than that of the 
E7QT2 cells. This initial observation suggested a decrease in the exogenus human 
p53 transcriptional activity when expressed in the tumorigenic cell line.
This initial observation was also supported by use of the mdm2 promoter 
reporter construct, pGL2NA(mdm2). As figure 35 shows, the transfection of this 
reporter into the PalF cells elicited a base level of luciferase activity in itself. The 
addition of pcDNA to the transfection elevated the luciferase activity 5 fold over
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the transfection of reporter alone indicating that the addition of the extra DNA to 
the transfection combination induced an elevation of p53 transcriptional activity in 
the cells. It is also evident that as with the pRGCfosLuc and WWP-Luc reporters 
the E7Q and E7QT2 cell lines exhibited a much lower level of luciferase activity 
demonstrating again the loss of the endogenous p53 function in the cells. 
Additionally it is also evident that when pcDNA or pCB6wtp53 is added to the 
transfection, whilst luciferase (i.e. p53 transcriptional activity) activity is increased 
in PalF cells, it fails to be elevated in the E7Q and E7QT2 cells.
Thus this second experiment also supports the initial observation that the 
transcriptional activity of exogenously added p53 is inhibited in these cells The 
results with the exogenous wild type p53 leave the possibility of either 
transcriptional repression in the tumorigenic cells, post translational modification 
or increased protein degradation as possible mechanisms for this inhibition of p53 
activity.
However one fault of the initial two experiments was that the luciferase 
activities were not controlled for transfection efficiency, a factor likely to have an 
impact when expressing a potent promoter of apoptosis and cell cycle arrest in the 
transfected cells for 36 hours and comparing to the control vector alone. Hence a 
third experiment was carried out using the pRGCfosLuc reporter. As can be seen 
in figure 36, co-transfection of the pCB6wtp53 plasmid rather than either pZipneo 
or pCDNA results in a large increase in reporter. Additionally although there is 
still a significant level of p53 transcriptional activity in the E7Q and E7QT2 cells 
upon co-transfection with pCB6wtp53 it is roughly one fifth that seen in PalF 
cells. This confirms that the exogenous wild type p53 is inhibited in the cell lines 
E7Q and E7QT2.
Finally a series of assays was carried out using the WWP-Luc reporter, in 
the presence of pCB6wtp53, in the PalF, E7Q and E7QT2 cells again with 
pCHllO used as a transfection efficiency control. Figure 37 illustrates the activity 
of the reporter as fold induction over the reporter transfected alone. Reduction of 
the reporter activity was seen with transfection into the E7Q and E7QT2 cells as 
before due to low endogenous p53 transcriptional activity in response to the 
exogenus DNA. Additionally elevation of reporter activity was seen upon co­
transfection with either pcDNA or pCB6wtp53. However although transfection
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with pCB6wtp53 into the E7Q or E7QT2 cells induced an elevation of p53 
transcriptional activity, the activity was significantly lower than that of the PalF 
cells, again repeating earlier findings with the other reporter constructs.
It is evident that co-transfection of WWP-Luc and pGL2NA(mdm2) with 
either pcDNA or pCB6wtp53 results in comparable reporter activities. In the case 
of the experiment utilising the pGL2NA(mdm2) this may be ascribed to lack of 
controlling for transfection efficiency thus artificially lowering the activity of cells 
expressing p53 but this cannot explain the lack of difference observed with WWP- 
Luc. One possible explanation of this phenomenon is that the reporter was 
sensitive to the transfection of the greater amounts of exogenous DNA, such p53 
response to transfected DNA has been reported before (Siegal et al., 1995). 
Reporter activity may well have been close to maximum from the levels of 
endogenous p53 induced by the transfection of pcDNA. It was observed that the 
co-transfection of greater amounts of DNA with the two reporters utilising p53 
binding in a the context of a whole gene promoter resulted in high background 
reporter activities in comparison to other p53 stimuli such as quercetin or UV.
5.5 Detection of p53 Protein Localisation by Immunofluorescence
In order to attempt to determine whether the p53 transcriptional activity in 
the E7Q and E7QT2 cells was due to an aberrant cellular localisation of the p53 
protein in these cells immunofluoresence was carried out. Examination of both 
endogenous bovine and exogenous human p53 was performed.
5.5.1 Experimental Method
PalF, E7Q or Q2D cells were seeded into chamber slides and either treated 
with OpM or 50pM quercetin for 36 hours before fixation and antibody binding as 
described in section 2.2.4.7. Alternatively cells were transfected with 4pg of 
pCB6wtp53 or pcDNA as control vector essentially as described in section 2.2.2.6 
with the exception of 8000 cells being seeded into 16 well chamber slides and 
300pl of medium used at each refeeding step. Transfected cells were then left for 
24 hours to permit expression of the p53 protein before fixation and antibody 
probing.
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Chapter Five Results
5.5.2 Experimental Results and Discussion
There was successful propidium iodide staining showing cells present 
throughout the protocol. However despite prolonged incubations with antibody no 
visible signal was detected from either endogenous or exogenous p53. Use of 
other antibodies may prove more effective at detection of p53 under these 
experimental conditions. The range of commercially available antibodies raised 
against human p53 would make the study of the localisation of the exogenous wild 
type human p53 possible. Reduction of the timing of expression of the exogenous 
p53 may also favour localisation due to the probability that fewer cells would have 
committed to apoptosis under a shorter time frame.
5.6 Detection of p53 Protein Binding by EMSA
Electromobility shift assays were carried out on the cell extracts of PalF, 
E7Q and E7QT2 cell lines in order to determine whether the endogenous p53 
protein was capable of binding to a target DNA sequence. Inability to successfully 
bind to the DNA would be an explanation for the proteins failure to induce 
transcription.
5.6.1 Experimental Method
Cell extracts were harvested from the cell lines assayed as described in 
section 2.2.4.2, and protein concentration estimated as in section 2.2.4.3.
Probe was then radioactivily end labelled with 32P and purified on a non­
denaturing polyacrylamide gel as described in sections 2.2.3.4 and 2.2.3.5. The 
probe used was the RGC (Ribosomal Gene Cluster) sequence as the p53 reporter 
pRGCfosLuc. The exact sequence is as follows:
Probe Name Sequence•*
RGC
AP-1
5 ’- gatccgattgccttgcctggacttgcctcgccttgccttttg -3’ 
5 ’- agctgtgtcctcatgct - 3 ’
Cell extracts were then mixed with the probe and competed with 100 fold 
excess of cold unlabelled probe for self competition or a cold AP-1 probe for non­
specific competition (see above for sequence) then run out on a non-denaturing
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polyacrylamide gel, dried down and exposed to film as described in section 2.23.6 
and 2.23.1
5.6.2 Experimental Results and Discussion
Although not conclusive the work does suggest that the p53 protein of the 
E7Q and E7QT2 cell lines is still capable of binding DNA.
As figures 38 to 41 demonstrate several candidate bands were detected 
upon incubation of the RGC probe with the PalF cell lysate. However the band 
indicated with the arrow was determined to be the prime candidate for study, 
because it was competed by cold RGC probe and not by a non-specific probe, AP- 
1. This experiment also shows that this putative p53 band is also present in the 
cell lysates from E7Q and E7QT2.
The analysis continued with work on cell extracts derived from cells 
treated with bleomycin sulphate. This was in an attempt to elevate the cellular 
levels of the p53 protein and thus to generate a greater signal in the bandshift 
assays. Figure 39 again displays the candidate band, marked by an arrow, 
competed by self oligonucleotide but not by the AP-1 probe. Figure 41 displays 
the results of the E7R cell line, with the candidate band seen in the cells treated 
with OpM quercetin for 36 hours. The comparatively lower band signal generated 
in the 50pM quercetin cell extracts could be due to protein degradation in these 
samples rather than any true effect of quercetin on p53 binding.
The stronger lower band seen in figures 38 to 41 is also a candidate band, 
due to the strength of the signal generated. However this band is sometimes 
competed by a non-specific competitor indicating that this band maybe the result 
of non-specific interaction. One possibility is that this band is monomeric p53, as 
there are 3 higher bands (with the highest band of this quartet being the prime 
candidate band) with could correspond to dimers, trimers and tetramers 
respectively.
However this is by no means definite evidence due to the lack of a suitable 
candidate supershift band, by use of the Bp53.12 antibody. In addition a non­
specific competitor more closely resembling the RGC probe such as a mutant 
form of the RGC sequence would permit greater confidence in the assays.
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Chapter Five Results
5.7 p53 cDNA Sequencing
As a further investigation into the nature of the loss of p53 transcriptional 
activity in the tumourigenic cell lines, sequencing of the p53 cDNA of E7Q, 
E7QPa, E7QT2 and Q2D was undertaken. The loss of p53 transcriptional activity 
in these cell lines may then be attributable to mutations in the sequence resulting 
in alterations in the amino acid sequence of the protein.
5.7.1 Experimental Method
Total RNA was extracted from the tumourigenic cell lines and the parental 
PalF cells as described in section 2.2.3.1. lpg  of total RNA was then used to 
synthesize cDNA and subsequent amplification (section 2.2.3.2.2).
The resultant RT-PCR product was then cloned into pcDNA3+ by 
digestion with Hindlll and Xbal (restriction sites included in the 5’ and 3’ RT- 
PCR primers) of the PCR product and vector. Following dephosphorylation of the 
vector the product was ligated into the pcDNA3+ vector.
DH5a bacterial hosts were then transformed with the ligation products and 
selected by ampicillin resistance. Plasmid DNA was extracted by use of Qiagen 
miniprep kits (see section 2.2.1).
Plasmids were then sequenced as described in section 2.2.3.3. Two 
separate clones were sequenced of each cell type cDNA with a series of primers to 
sequence the entire cDNA.
5.7.2 Experimental Results and Discussion
The entire p53 cDNAs of the parental PalF, E7Q, E7QT2 and E7QPa were 
successfully sequenced. p53 cDNA from Q2D was not obtained despite repeated 
RT-PCR attempts.
Analysis of the sequences showed that the p53 gene in parental PalF cells 
had undergone no mutations when compared to the published p53 cDNA sequence 
(Dequiet et al., 1995); however in E7Q and E7QPa two adjacent point mutations, 
gga to gtt (Position 835 and 836) were detected. These mutations were detected in 
both DNA strands and in both clones of each cell type. Additionally overlapping 
sequences over the mutated region consistently confirmed the alteration. These
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changes result in an amino acid alteration from Glycine to Valine at codon 278 in 
bovine p53 (equivalent to codon 271 in human) in conserved domain V, part of 
the DNA binding domain of the protein (see figure 42).
This may explain, at least in these cell lines, the loss of transcriptional 
activity of the p53 protein. The mutation being within the conserved DNA binding 
domains could result in the p53 protein being unable to bind to the DNA, and as 
such be inhibited in the transcriptional activation of downstream effectors.
5.8 Chromosome Karyotype Analysis
Karyotype analysis was done to determine whether the tumorigenic cells' 
had undergone gross chromosomal abnormalities. This then would provide 
information on whether the cells had decreased genomic stability due to the \ 
inhibition of the p53 protein. In addition identification of chromosomal damage 
site may identify further possible gene mutations contributing to the transformed 
phenotype.
Live cell cultures of the E7Q cell line together with the parental PalF cells 
were sent to collaborators in the laboratory of Dr Stocco dos Santos (Butantan 
Institute, San Paulo, Brazil) for chromosome analysis as part of a continuing 
collaboration.
Figure 43 shows the preliminary results. The PalF cells have sustained 
minor changes possibly due to the isolation of the line, indicated by the marker 
chromosomes. E7Q however seems to have sustained significantly greater levels 
of chromosomal abnormalities shown on the spreads labelled E7Q1 to E7Q3.
This initial evidence suggests that the loss of p53 function in these cells 
may have resulted in a decrease in chromosomal stability. The elevated level of 
chromosomal damage in these cells could contribute to further alterations in gene 
expression and ultimately transformed phenotype. Continued passages in vitro 
would be expected to result in more alterations to the karyotype and altered cell 
phenotype. Further characterisation of the karyotypes of these cells however is 
required for more support of this hypothesis.
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Chapter Six Discussion
CHAPTER SIX 
DISCUSSION
6.1 Introduction
BPV 4 infects the mucosal epithelium of the upper gastrointestinal tract of 
cattle which results in the development of papillomas (Campo et al, 1981). In 
cases of immuno-competent animals these papillomas are generally benign and 
will regress after roughly one year (Knowles et al, 1997).
In the cases of bracken grazing cattle these papillomas persist and can 
progress to squamous carcinoma (Campo & Jarret, 1986). The persistence of the 
papilloma is ascribed to the immunosuppressants of the bracken fern (Campo, 
1997; Evans W. C. et al., 1982) which make the animals incapable of mounting an 
adequate immune response against the virally infected cells.
Progression of the persistent papillomas to squamous carcinomas is then 
likely due to the continued exposure to the mutagens contained in the bracken fern 
(Evans I. A. et al, 1982) which induce successive genetic lesions. Support for this 
hypothesis comes from the observation that activation of ras (Campo et al, 1990), 
mutation of p53 (Scobie, 1996) and elevation in EGF receptor levels (Smith et al, 
1987) have been observed in naturally occurring alimentary cancers in cattle. 
These data again support the hypothesis of the multi-stage nature of cancer.
This synergy between the virus and the bracken fern observed in field 
cases has also been experimentally reproduced (Campo et al, 1994) further 
supporting the association of the two elements in the carcinogenesis of alimentary 
canal cancer of cattle.
Of the mutagens found in bracken fern, quercetin has been demonstrated to 
synergise with the virus in transformation of primary bovine palate fibroblasts in 
vitro (Pennie & Campo et al, 1992; Caimey & Campo, 1995). A single 48 hour 
exposure of 20(iM quercetin 24 hours after transfection of the BPV 4 genome and 
Ha-ras (or BPV 4 E7 and Ha-ras) can induce full tumorigenic transformation of
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the cell. The alteration of the activity of the viral LCR and phosphotyrosine status 
of proteins in the cell have been postulated to be involved in the process of 
transformation of the cell. However it is the ability of quercetin to induce cell 
cycle arrest that has received the most attention in the studies detailed here.
6.2 Generation and Characterisation of Cell Lines
This work generated a panel of cell lines from normal primary fibroblasts 
to fully transformed tumorigenic cells. These lines were extensively characterised 
biologically and molecularly and these studies have yielded a valuable insight into 
the synergy between viral and chemical factors in cell transformation. However 
further analysis of the proliferation rates of the different lines would be required 
for a deeper understanding of their biology and for a more accurate interpretation 
of the cell cycle profiles. Different numbers of population doubling may have 
affected the observed results but given that cells were maintained in culture for 
short periods only, any variation due to culturing would be limited.
The inability to derive clones expressing BPV 4 E7 or activated Ha-ras 
alone is evidence that neither oncogene is sufficient to confer an extended 
lifespan. The expression of both oncogenes permitted selection of clones for 
further expansion. However these clones proliferated slowly and most failed to 
grow in vitro for more than a few population doublings. Those clones that 
underwent sufficient passages for further analysis proved to be morphologically 
transformed but not anchorage independent or tumorigenic (see below). The 
expression of both BPV 4 E7 and Ha-ras therefore permitted morphologically 
transformed cells to survive in culture for a short period of time.
Due to the lack of a suitable cell line (i.e. capable of continued tissue 
culture passage) expressing BPV4 E7 and Ha-ras alone without quercetin 
exposure the generation of a pooled cell populations was then undertaken. This 
cell line (E7R) in common with other E7 and Ha-ras only cell lines proved to be 
morphologically transformed but incapable of anchorage independent growth. The 
change of morphology and cell cycle phenotype (see chapters three and four) of
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the E7R cell line was hypothesised to be due to decreased expression of the 
oncogenes. Expression of E7 alone without other viral oncogenes, or other 
alterations, may result in the triggering of cellular mechanisms designed to detect 
abnormal regulation of the cell cycle machinery This hypothesis would suggest 
that persistence of E7, and Ha-ras, expression in PalF cells may require further 
changes to the cell. This is supported by the observation that the cell lines QOD, 
E7QPp and E7QPy did not change in morphological appearance over the course of 
in vitro culturing. QOD has E7 expression under the control of the viral LCR and 
may have a lower basal E7 expression than that derived from the pZipneo plasmid 
promoter (MoLV). This lower level may be permitted by the cell, or alternatively 
other viral proteins may compensate for the cellular responses to E7 expression. 
The fact that neither E7QP|3 or E7QPy changed phenotype may be a consequence 
of quercetin exposure immediately after transfection. Although not causing the 
genetic lesions required for the full transformation of the cell, other inheritable 
events such as gene mutation, or epigenetic mechanisms e.g. altered methylation 
patterns, perturbation of autoregulatory loops (Macleod, 1996 for review) may 
have occurred to cause the cell to be permissive to high E7 expression levels, 
indeed quercetin has been shown to cause hypermethylation (Ishikawa et al.,
1987). Such alterations, that are non-transforming, may also be in effect in the 
QOD cells to permit E7 expression.
Studies have shown that the locus encoding the tumour suppresser protein 
p l6 INK4a also encodes another protein termed p l9ARF (in mice, p l4ARF in humans) 
(Quelle et al., 1995). Oncogenic signals such as overexpression of Myc, E l A or 
E2F-1 induce expression of the p l9ARF protein and result in an increase in p53 
protein levels by binding and inactivation of Mdm2 (a protein which binds p53 
and targets it for degradation and is in turn regulated by p53 resulting in a 
feedback loop) (Sherr, 1998 for review). Elevation of p53 would then in turn 
result in cell cycle arrest and/or apoptosis. With the case of E7, high levels of E2F 
due to pl05Rb inhibition may also act to induce p i9 " ^  expression. Whilst p53 
mediated cell cycle arrest may be ineffective in cells expressing high levels of E7,
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apoptosis would probably be unaffected based on the evidence that p53 mediated 
apoptosis occurs in HPV E7 expressing cells normally (Wang et al, 1996; Iglesias 
et al, 1998; Stoppler et al, 1998; Jones et al, 1997). However in cells also 
expressing HPV 16 or 18 E6, p53 would be targeted for degradation and as such 
inhibited in its capacity to induce apoptosis (Puthenveettil et al, 1996; Thomas et 
al, 1996). In the case of E7R, this mechanism would explain the change of 
morphology and cell cycle phenotype, however analysis of not only the E7 
expression levels in the cell line over a period of time after transfection would 
have to be assayed, but also levels of the bovine homologue of p l9ARF, Mdm2 and 
p53 would provide information on whether this response was undertaken by the 
cell. As stated above the cell lines QOD, E7QPp and E7QPy may have 
compensatory features such as one of the other viral genes or an alterations 
induced by quercetin to inhibit this p l9ARF response to E7 and/or Ha-ras 
expression. In addition the expression of mutant p53 in the tumorigenic cell lines 
(see later) may protect these cells from p l9ARF mediated apoptosis.
However the activation of p i9ARF is not the only mechanism of selection 
against E7 expression by p53 elevation. Work by Seavey et al, 1999 demonstrated 
that HPV 16 E7 could stabilise p53 by inhibiting interaction of p53 and Mdm2, 
through a p l9ARF independent mechanism.
The tumorigenic cell lines generated by expression of BPV 4 E7 and Ha­
ras combined with quercetin exposure and studied, namely E7Q, E7QPa and 
E7QT2, are morphologically transformed, appear immortal, and grow independent 
of substrate whilst lacking expression of E8. BPV 4 E8 is associated with 
conferring anchorage independent growth as, along with E7 and ras, expression 
results in anchorage independent growth of primary bovine fibroblasts. (Pennie et 
al, 1993) and recent work has shown that E8 expression can also induce 
anchorage independent growth of NIH3T3 (O’Brien & Campo, 1998). O’Brien 
and Campo also showed that in the NIH3T3 cells E8 was able to transactivate the 
cyclin A promoter and to elevate cyclin A levels. Cyclin A is likely to be the 
major target of adhesion signalling (Guadagno et al, 1993) as expression was
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found to be dependent on cell adherence in NRK cells and hence loss of adherence 
resulted in G1 arrest. Additionally transfection of cyclin A expression vectors 
resulted in restoration of cyclin A protein levels and cyclin A/cdk2 activity 
together with entry into S phase and multiple rounds of cell division whilst in 
suspension.
As mentioned earlier, consistent with previous findings the expression of 
E7 and Ha-ras alone did not confer anchorage independence in the cell line E7R. 
The failure of E7QPP, E7QPy and E7Qb to successfully grow independent of 
adherence suggested the expression of E7, Ha-ras combined with quercetin 
treatment does not automatically confer anchorage independence. However the 
inhibition of the transcriptional activity of p53 (evident in the tumorigenic cell 
lines), as a result of quercetin exposure, may be pivotal to the development of the 
anchorage independent phenotype in the absence of E8 expression. Supportive 
evidence for this are the experiments carried out with a human mutant p53 in PalF 
cells demonstrating that the mutant p53 was capable of conferring anchorage 
independent growth (Scobie et al.,1991).
The tumorigenic cell line Q2D expresses E8 and has an inhibited p53. This 
cell line is morphologically transformed, immortal and grows independent of 
substrate. It is unknown whether one or both of these events result in the loss of 
anchorage independence. E8 may cause upregulation of cyclin A whilst loss of 
function by p53 may result in loss of activation of other genes required for cell 
cycle arrest due to anchorage loss. A possibility would be a role for p21Wafl/Clpl, 
which is elevated by p53, to inhibit the cyclin A/cdk2 complex under conditions 
of anchorage loss. Also the effect of p53 may be more indirect and contribute to 
the phenotype due to increased levels of genomic instability, resulting in further 
genetic lesions impacting upon the adhesion dependence signalling pathway.
The failure of the cell line QOD to grow independent of substrate 
contradicts previous findings of Pennie et al., 1993. This may be due to loss, or 
decrease, of E8 expression in this cell line upon continued passaging or other
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undetermined alterations. The cell line however maintains a transformed 
morphology due to expression of BPV 4 E7 and Ha-ras.
Interestingly the analysis of the ability to proliferate independent of 
substrate correlated well with tumorigenic status whilst morphological 
transformation did not. This may well represent the fact that anchorage 
independence is a feature of cells at a later stage of transformation. The causative 
agent in the tumorigenic cells that permits anchorage independent growth is not 
yet pinned down and there may be different factors in each of the cell lines.
The highest Ha-ras, and possibly E7, expression was obtained with the 
tumorigenic cell lines with the exception of 88529B. The lack of high level Ha­
ras expression in 88529B may be a cell type specific effect or due to other 
compensating alterations to the cell such as over expression of cyclin D or a 
constitutively active Raf. The fact that this cell line also has lost the BPV4 
genome, and consequently E7 expression, suggests that the cell may well have 
undergone a greater number of genetic lesions than the cells derived in vitro in 
order to remain transformed and tumorigenic without the effects of the two 
oncoproteins E7 and Ha-ras.
The high level Ha-ras expression, in fibroblasts, may be required for 
tumorigenicity in order to supply a significant proliferative drive to the cell 
combined with a high E7 expression to permit efficient inhibition of the pl05Rb 
tumour suppresser protein. Such a high level of Ha-ras may well have been 
selected for as it exceeds that of cells normally expressing Ha-ras from the pT24 
plasmid e.g. E7R and QOD (figure 9). Evidence for elevation of E7 expression 
comes from the RT-PCR product level (figure 8) related to the initial template 
level used in each reaction i.e. tumorigenic cells generated greater product level 
with less starting template. This evidence however is circumstantial and further 
investigation by more quantitative mechanisms is required to prove whether E7 
expression is elevated in tumorigenic cells.
The activated Ras oncoprotein induces DNA synthesis and cell 
proliferation (Downward, 1997) and in cells with a functional Rho GTPase
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suppresses p2iWafl/Cipl (Olson et al, 1998). Ras expression is highest in the 
tumorigenic cells and undoubtedly activated Ras contributes to PalF 
transformation, with BPV 4 E7, maybe through further inhibition of p2 iWafl/Cipl. 
Additionally Ras activates the MAPK pathway causing upregulation of cyclin D 
(Downward, 1997; Kerkhoff & Rapp, 1998) and there are reports that cyclin 
E/cdk2 complexes are activated by Ras/Raf signalling via c-myc (Kerkhoff & 
Rapp, 1998 and references therein). Supportive of this was the report that Cyclin 
E/cdk2 complexes are normally inactive in cells that have lost adhesion signalling. 
However in Ha-ras transformed NRK cells the cyclin E/cdk2 complexes remained 
active (Carstens et al, 1996). Therefore the activation of both the cyclin D and E 
complexes would also cause an increase in the inactivation of pl05Rb by 
phosphorylation. It is worth stressing that neither activated Ras alone nor E7 alone 
are capable of PalF cell transformation, even partial. Hence it is likely that both 
oncogenes need to alter the control of the pl05Rb protein in order to achieve 
sufficient inhibition to permit cell cycle passage. Cumulative inhibition of the 
p21Wafl/Cipl CDKI by both Ha-ras signalling and directly by E7 would also be 
hypothesised to be more efficient that by one of the oncogenes alone.
As can be seen in table 3.2 (chapter three) the number of clones isolated 
decreased significantly upon treatment of the transfectants with quercetin. This 
drop in clone frequency could be due to quercetin’s action(s) causing the elevation 
of p53 and consequently cell cycle arrest (see later also). This cell cycle arrest may 
then progress to become apoptosis if the cell ‘decides’, possibly via a mechanism 
dependent on p53 level, that the cumulative stress of the transfection of DNA, 
expression of the oncogenes and quercetin exposure makes the cell non-viable for 
continued controlled proliferation (Chen et al, 1996; Ko & Prives, 1996 for 
review). In those cells with sufficient BPV 4 E7 and Ha-ras expression at the time 
of quercetin exposure, cell cycle arrest would fail to occur in G1 due to the 
inhibition of pl05Rb and p2 iWafl/Cipl by E7 and Ha-ras signalling. Ha-ras 
signalling would also generate a proliferative drive by activation of the MAPK 
pathway (see later). Whether BPV 4 E7 and/or Ha-ras would impact upon the
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apoptotic functions of p53 (or p53 independent mechanism) is unknown. However 
due to the lower level of clone formation upon quercetin exposure of the cells this 
would argue against an inhibition of apoptosis by BPV 4 E7 and Ha-ras. For the 
transfected cells to avoid entering apoptosis the heritable damage that occurs 
under quercetin exposure could not exceed a certain threshold. Beyond this 
threshold the cellular insult would be too great and apoptosis would ensue. 
However below the threshold, although genetic lesions may occur due to the 
abrogation of the G1 cell cycle arrest, apoptosis would not be initiated and the 
alterations would be inherited.
The alterations generated from the quercetin exposure would be largely 
untransforming, however mutations to key cell regulators i.e. oncogenes and 
tumour suppresser genes would promote progression to full transformation. The 
balance of damage sustainable by the cell for continued proliferation and the target 
requirement of the genes to promote transformation would explain the low 
frequency of tumourigenic clones resulting from this in vitro system.
Note though that the inheritable alterations that occur in the tumorigenic 
cells need not to have happened in the time of quercetin exposure. Due to 
quercetins wide ranging effects on the cell (see section 1.4.3.4) it would be 
feasible for exposure to the chemical to generate a ‘mutator’ phenotype for a 
limited duration. This maybe due to a variety of epigenetic mechanisms (Macleod, 
1996 for review) and enzymatic inhibition sufficient to permit accumulation of 
genetic lesions.
6.3 Quercetin-Induced G1 Arrest is Abrogated in E7 Expressing Cells.
Quercetin arrests primary bovine palate fibroblasts in both the G1 and 
G2/M phases of the cells. Upon quercetin exposure there was a noticeable increase 
in the percentage of cells in S phase 12 hours after initiation of the chemical 
treatment. Whether this was due to an elevation of entry into DNA synthesis or a 
lag of cells exiting DNA synthesis is unknown. Due to the potential for quercetin 
to induce DNA damage (see section 1.4.3.4) this may well suggest a stall in DNA
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synthesis as the DNA adducts induced by quercetin have to be repaired. 
Additionally quercetin has been shown to be able to inhibit DNA polymerases 
(Ono & Nakane, 1990) by competition with the template.primer complex. 
Quercetin has also been shown to inhibit RNA polymerase II (Nose, 1984) which 
may well contribute to the putative stall in S phase by slowing expression of 
essential genes. The general lower level of DNA synthesis after 48 hours of 
quercetin exposure may favour this hypothesis. However also possible could be 
the accelerated entry of cells into S phase. This could be envisaged by quercetin 
altering the phosphorlyation states of key proteins such as transcription factors and 
signalling molecules also by altering enzyme activities as described in section
1.4.3.4 resulting in the expression of genes required for DNA synthesis.
The IC50 for other cells exposed to quercetin i.e. the concentration of 
quercetin required for 50% inhibition of growth, has been reported to be between 
InM to lp,M (Scambia et al, 1990b; Ranelletti et al, 1992; Larocca et al, 1995; 
Piantelli et al, 1995) although some cell lines have been reported to require a 
greater concentration of 20pM or more (Hosokawa et al, 1990; Avila et al, 
1994). For those cell lines which undergo cell cycle arrest at low concentrations of 
quercetin this may be linked to the presence of high levels of type II oestrogen 
binding receptors (Ranelletti et al, 1992) which are also elevated by quercetin 
exposure (Scambia et al, 1993). This link with type II oestrogen binding receptors 
is reinforced by studies showing that the affinity of a flavonoid for the type II 
oestrogen binding receptors correlates with the ability to induce cell cycle arrest 
(Ferrandina et al, 1998; Scambia et al, 1990; 1990b) Those cell lines which 
require high quercetin levels may therefore contain low levels of the type II 
oestrogen binding receptors and arrest due to quercetin’s other effects such as 
enzymatic inhibition (see section 1.4.3.4). With quercetin arresting PalF cells at a 
concentration of 20pM or more it is evidence that these cells contain low levels of 
type II oestrogen binding receptors. Quercetin exposure has also been documented 
to cause reversible cell cycle arrest (Scambia et al, 1990b; Ranelletti et al, 1992)
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which has been corroborated in these findings on both the PalF cells and the 
tumorigenic cell line E7QT2.
Contrary to normal PalF cells which arrest in G1 and G2/M in the presence 
of quercetin (Connolly et al, 1998), all the transformed cells failed to arrest in Gl. 
These cells however maintained the G2/M check point. This observation was also 
paralleled by the data demonstrating that the tumorigenic cells transformed by 
transfection of the BPV 4 genome and Ha-ras with quercetin exposure also failed 
to arrest in Gl upon re-exposure to quercetin yet maintained the ability to arrest in 
G2/M.
The cell line E7QP|3 also demonstrated an abrogated Gl arrest and a 
maintained G2/M arrest. The fact that the line was not tumorigenic yet failed to 
arrest in Gl demonstrated that alteration of the cell cycle regulation of the cell was 
in itself not sufficient for the tumorigenic state.
In the cells transformed by transfection with the BPV 4 genome and Ha­
ras, i.e. QOD, the G l arrest in response to exposure to quercetin also failed to 
occur. The importance of this data was that it displayed that the expression of the 
activated oncogene in addition to the viral oncogenes was sufficient for the 
abrogation of the G l arrest.
The prime candidate thought to be responsible for the abrogation of this 
arrest was the BPV 4 E7 oncoprotein, due to the protein’s shared features with the 
HPV 16 E7, namely the putative pl05Rb and the zinc binding fingers (Jaggar et 
al, 1990). These domains are known to be important to the transforming 
properties of the protein as determined by mutation analysis (Campo et al, 1994b; 
Jackson et al, 1996). Additionally to this, the evidence from the experimental data 
on HPV E7 proteins (see section 1.4.2.1 for details) would also support the 
hypothesis that the BPV 4 E7 protein could be capable of abrogating a G l arrest.
The data from the studies of the cell line E7R which expresses the BPV 4 
E7 oncoprotein in the context of an activated Ha-ras gene was an initial approach 
to the analysis of this question due to the lack of E7 or Ha-ras only expressing cell 
lines.
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Exposure to quercetin resulted in the cells accumulating in G2/M only, 
thus abrogating the G l arrest. However this phenotype was only present in low 
passage E7R cells. Higher passages resulted in the cells arresting in G l and G2/M 
like the parental PalF cells. While unsubstantiated, the reversion of the cells was 
hypothesised to be due to alteration in levels of the E7 oncoprotein (see later).
An attempt to test cells expressing only BPV 4 E7 was undertaken by use 
of tagging transiently transfected cells using the CD20 cell surface marker. 
However whilst significant numbers of cells were able to be detected as CD20 
positive, cell cycle profile distribution was unattainable. Further experimentation 
to increase transfection efficiency together with reduction of non specific antibody 
binding may result in successful analysis of E7-only transfected cells by this 
mechanism.
The G2/M check point is reached after 36-48 hours of quercetin-treatment, 
well beyond the quercetin-exposure period used for cell transformation (24 hours). 
Although when treated with quercetin in the transformation schedule some cells 
will have already traversed G l and will therefore stop in G2/M, the majority of the 
cells would be upstream of the G l check point. Therefore our study concentrated 
on what mechanisms allow the transformed cells to overcome the quercetin- 
induced Gl arrest and to traverse through Gl to complete the cell cycle.
In summary the data presented shows that the BPV 4 E7 oncogene in the 
context of an activated Ha-ras confers the ability to bypass quercetin induced Gl 
arrest. The retained ability to bypass the Gl arrest over continued passages may 
also rely on expression of other viral genes as evidenced by the cell line QOD 
which retained the ability to overcome quercetin induced G l arrest even after 
prolonged passaging in cell culture. Alternatively further genetic lesions may also 
aid retention of high E7 expression.
6.4 p53 Malfunction in Transformed Cells.
In normal PalF cells, quercetin-induced Gl arrest is accompanied by a 
stabilisation and an increase in transcriptional activity of p53, consonant with
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DNA damage induced by quercetin (Fazal et al, 1990; Suzuki et al., 1991) and 
subsequent activation of p53 (Levine, 1997). In transformed cells, the behaviour 
of p53 differs depending on whether or not the cells are tumorigenic. In both 
quercetin-untreated and quercetin-treated non tumorigenic cells, p53 is stabilised 
as well as transcriptionally activated upon re-exposure to quercetin, whereas in 
quercetin-treated tumorigenic cells p53 is transcriptionally dead, although still 
capable of being stabilised or, as in the case of Q2D, constitutively stable.
How can the abrogation of G l arrest in non tumorigenic cells be 
reconciled with an activated, transcriptionally functional p53? In other systems, 
E7 has been shown to bind and inhibit p21Wafl/Cipl, thus preventing DNA damage- 
induced cell cycle arrest (Funk et al., 1997) and additionally Ha-ras signalling has 
also been implicated in p2 lWafl/Cipl inhibition (Olson et al., 1998). p2 lWafl/Cipl is 
an inhibitor of G l cyclin-dependent kinases (Harper et al, 1993) and its 
expression is transcriptionally regulated by p53 (El-Deiry et al., 1993). Inhibition 
of pl05Rb by E7 (Vousden, 1994) and Ha-ras signalling causing upregulation of 
cyclin D (Downward, 1997; Kerkhoff & Rapp, 1998) and activation of cyclin 
E/cdk2 complexes (Kerkhoff & Rapp, 1998; Carstens et al, 1996) would also 
serve to promote progression through the G l checkpoint by elevation of the levels 
of free E2F allowing expression of the genes required for entry into DNA 
synthesis. Accordingly, in our non tumorigenic transformed cells, where p53 
transcriptional activity is unaltered, p2 lWafl/Clpl is elevated but fails to cause a Gl 
arrest and is likely to be inhibited by E7 and possibly Ha-ras signalling. The 
quercetin-induced increase in LCR transcription activity (Connolly et al, 1998) is 
likely to lead to increased expression of E7 and thus further inhibition of 
p2 1 wafi/cipi an(j pl05Rb.This would explain how p53, apparently wild-type in its 
behaviour, fails to arrest the cells in Gl.
In contrast, in tumorigenic cells p53 is transcriptionally non functional and 
accordingly there is no production of p21Wafl/Cipl. The lack of p53 transcriptional 
activity in E7Q, E7QPa and E7QT2 can be ascribed to the mutation detected in 
their p53 sequence. The glycine to valine substitution has taken place in conserved
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region V, in the DNA binding domain (Ko and Prives, 1996). Although not tested 
directly, the mutation is the most likely reason for the malfunction of p53 in the 
tumorigenic cells. The report of inhibition of p53 transcriptional activity by E7 
(Massimi et al., 1996; Massimi & Banks, 1997) indicates this function may also 
be responsible for the inhibition. The low transcriptional activity of the wild type 
human p53 in the tumorigenic cells as compared to that seen in PalF cells 
suggested that there may be inhibition of the p53 transcriptional activity. However 
the possibility of the mutant bovine p53 forming complexes with the human p53 
or competing for binding sites, and therefore inhibiting is a complication.
The fact that E7Q and E7QPa have exactly the same mutation raises the 
possibility that they are in fact two populations of the same cell line. However 
despite this similarity the two cell lines show different western blot profiles for 
p53 protein levels upon treatment with quercetin or other DNA damaging agents. 
The mutation found in the E7Q, E7QPa and E7QT2 cell lines may be 
characteristic of quercetin induced mutation. Sequencing of Q2D would help to 
ascertain whether this is the case.
p53 mutations have been detected in two naturally occurring cancers in 
bracken fed cattle (Scobie, 1997). In these cases the same mutation, CCC to ACC, 
was found at codon 243 in conserved region IV, leading to a proline to threonine 
substitution. Further analysis of p53 mutations in both naturally occurring cancers 
and in vitro transformed cells will be needed to determine whether the mutations 
detected so far are particular to bracken/quercetin-exposed cells.
It is interesting to note that transformation by BPV 4, a papillomavirus 
lacking the E6 ORF, requires the inhibition of p53 for PalF cells to become 
tumorigenic. In essence the resultant effects of quercetin exposure are replacing 
the requirement of some, but not necessarily all, of the E6 protein functions for 
full transformation.
Further evidence for the loss of p53 function in the tumorigenic cells 
comes from the karyotype analysis of the E7Q cell line. This cell line contains a 
series of chromosome alterations in comparison to parental PalF cells suggesting a
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decrease of genomic stability, a phenotype associated with loss of p53 
function (Hollstein et al., 1991)
6.5 Conclusions.
Considering all the above observations together, we propose the following 
series of events as being the most likely to account for the synergism between 
virus and quercetin resulting in full tumorigenic cell transformation (figure 44): 
quercetin induces DNA damage and in normal cells this causes Gl arrest through 
the activation of p53 and p21Wafl/Cipl.
In cells containing the viral genome, quercetin trans-activates the LCR 
with consequent elevated expression of the viral transforming protein E7. Gl 
arrest is abrogated as pl05Rb and p2 iWafl/Cipl are inhibited by E7, together with 
the putative inhibition by Ha-ras signalling, and the traversing of G l by damaged 
cells allows their expansion into transformed clones. During clonal expansion, 
subsequent p53 mutations render the cells fully tumorigenic. This critical step will 
further increase the genomic instability of the cell and thus lead to further damage. 
Indeed chromosomal analysis of quercetin-treated fully transformed cells has 
revealed numerous abnormalities (see figure 43) (Stocco dos Santos, Beniston and 
Campo, unpublished observations), in agreement with previous results (Ishidate,
1988) and with the observed chromosomal instability in cells with non functional 
p53 (Ko and Prives, 1996).
The requirement for activated Ras for BPV-4 in vitro cell transformation 
and for quercetin exposure and mutant p53 for cell progression to tumorigenicity 
parallels the activation of Ras and the mutations of p53 observed in naturally 
occurring cancers in bracken-feeding cattle (Campo et al, 1990; Scobie, 1996). 
This supports the view that the interplay between E7 and quercetin observed in 
vitro cell transformation may well play a vital role in carcinogenesis of the upper 
Gl tract. What is the relevance of the synergy between BPV-4 and bracken to 
human cancer? In humans too, exposure to bracken fern, whether in the diet or as 
spores, has been epidemiologically linked to oesophageal and gastric cancer in
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several parts of the world (Galpin et al., 1990; Marliere et al., 1995; Alonso- 
Amelot et a l, 1996; Hirayama, 1979; Villalobos-Salazar et al, 1995) and 
quercetin has been shown to be absorbed by humans into the blood stream 
(Paganga & Rice-Evans, 1997). All forms of culinary bracken have been shown to 
be carcinogenic in experimental animals (Santos et al, 1987, 1992) and DNA 
adducts have been found in the upper Gl tissue of mice fed bracken extracts or 
bracken spores (Povey et al, 1996). Human papillomavirus (HPV) type 16 has 
been found in approximately 50% of cancers and pre-cancers of the upper Gl tract 
(Chang et al, 1990; Togawa et al, 1994; Suzuk et al, 1996) and Campo and 
colleagues have detected HPV-16 DNA in biopsies of oesophageal cancer from 
Brazil (unpublished observations). These findings suggest that some cases of 
cancer of the upper Gl tract in humans may have the same aetiology as in cattle, 
i.e. papillomavirus and bracken.
The unpublished observation that, like the LCR of BPV-4, also the LCR of 
HPV-16 is trans-activated by quercetin, opens up the possibility that the molecular 
mechanisms we have started elucidating for cell transformation and cancer in 
cattle operate also in humans.
6.6 Future Work
A more indepth analysis of cell doubling and growth rates should have 
been made for each individual cell line. This would have controlled for any 
variation in behaviour due solely to cell age. The avoidance of continued culturing 
and the periodic use of fresh stocks, lend confidence that the conclusions 
presented here are justified.
To continue the work detailed here the initial experiments would focus on 
the p53 status of the tumorigenic cells and the expression of E7. Analysis of the 
p53 sequence in Q2D would demonstrate whether the inhibition of the protein is 
likely to be by mutation rather than through the action(s) of E7. Also the type and 
position of mutations detected, if any, would show whether quercetin caused 
characteristic mutations.
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Determination of the expression levels of BPV 4 E7 in the PalF cells with 
an activated Ha-ras by either accurate western blotting, post development of a 
suitable antibody, or quantitative RT-PCR would help ascribe loss of the 
phenotype in the E7R to the putative loss of E7 expression. Additionally the use of 
a retroviral transfection system would be invaluable to the study of E7 in the 
ability to bypass p53 induced Gl arrest. Transient transfection with a retroviral E7 
vector followed by quercetin exposure would allow cell cycle analysis of E7-only 
expressing cells. Alternatively an inducible system of E7 expression from a 
mammalian expression vector would allow an equivalent analysis.
Continuing the further analysis of BPV 4 E7 action in the cells could 
include the analysis of pl05Rb phosphorylation status and pl9ARF expression 
levels to prove experimentally whether the BPV 4 E7 is capable of inhibiting the 
pl05Rb protein and activating the pl9ARF response. This would also open the 
possibility to determine whether cells expressing high levels of E7 and/or Ha-ras 
selected for loss of p53 and/or pl9ARF in order to sustain high expression of the 
oncogene(s).
A greater number of tumorigenic clones to study, as well as an efficient 
form of transient assays for oncogene expression would permit a broader scope of 
analysis. This would determine with greater clarity whether p53 inhibition by 
mutation was a consistent event in progression to full transformation. In addition 
the study of expression and function of other candidate genes, such as pl9ARF or 
p21Wafl/Clpl, £or transformation could be studied with greater statistical backing.
The further analysis of quercetins action upon the cell is also desirable. 
The determination of whether quercetin is capable of causing DNA damage in the 
PalF cells at the concentrations used in these studies is required to prove that the 
chemical agent could be directly responsible for the p53 mutation. Also this would 
give a causative link between quercetin exposure and p53 protein stabilisation and 
subsequent cell cycle arrest. The use of the Comet and Tunel assays to detect 
single strand DNA breaks in vivo would be invaluable in this study. However 
additional safeguards would have to be carried out in order to ensure that the DNA
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damage observed was due to quercetin and not through induction of apoptosis. 
This could be undertaken by examination of poly(ADP-ribose) polymerase 
(PARP) cleavage levels and the apoptotic promoting protein, Bak, levels. PARP 
causes a burst of poly-ADP-ribosylation of nuclear proteins required for onset of 
apoptosis in some cell lines (Simbulan-Rosenthal et al, 1998). PARP is then 
cleaved, which is catalysed by caspase 3, and is proposed to prevent depletion of 
NAD and ATP (both are PARP substrates) which are thought to be required later 
on in apoptosis (Berger, 1985). Bak is one of the Bcl2 family of proteins which 
influence the activation of the family of caspase proteases. These caspases then 
cleave a number of cellular proteins to bring out cell death (Rao &White, 1997)
The generation of the bovine p53 expression plasmids in this study also 
permits further analysis. One experiment would be to re-introduce the bovine p53 
expression into the tumorigenic cell lines. This would help determine whether re- 
introduction of the protein was capable of reverting the cell to a non tumorigenic 
phenotype. However experiments with the human p53 expression plasmid 
suggested that although there may be inhibition of the transcriptional activity of 
the exogenous p53, apoptosis was still activated due to the low transfection 
efficiencies. Also the observations that the tumorigenic cell lines seem to undergo 
a significant amount of cell death whilst proliferating in cell culture and exposure 
to DNA damaging agents reduce transfection efficiencies (personal observations) 
suggests that the apoptotic pathways is still functional in these cells. Whether 
these pathways are p53 dependent or not is unknown.
In addition to re-introduction of the wild type p53 into the tumorigenic 
cells, a more interesting experiment would be to introduce the mutant p53 into 
cells expressing E7 and Ha-ras such as E7QP|3, E7QPy or E7R (low passage), or 
indeed carrying out transfections with pZipneo E7, pT24 and pBov53mut (mutant 
p53 cDNA from E7Q cloned into pcDNA3+). The transfection of PalF cells with 
the pBov53mut plasmid by itself would also have to be carried out to ensure that 
in isolation this was not able to cause full transformation. All of these would help
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determine whether these three alterations of the cell were capable of causing full 
transformation.
The study by Scobie et al, 1997 showed that a mutant human p53 by itself 
or in conjunction with the BPV 4 genome was unable to generate tumorigenic 
clones, and that this required the addition of HPV 16 E6. These experiments 
suggest that further changes to the cell would be required to induce 
tumorigenicity, however the use of a different mutant p53 may be a crucial 
difference in the system.
The comparison of E7QPP and E7QPy to E7R, upon the addition of the 
mutant bovine p53, would also shed light into whether quercetin exposure 
generates other inheritable changes required for transformation apart from p53 
mutation. Treatment of the pZipneo E7, pT24 and pBov53mut PalF transfectants 
with quercetin would eliminate possible errors induced by examination of already 
established cell lines.
As described earlier introduction of human p53 into the tumorigenic cell 
lines indicated that there may be inhibition of the protein by E7 in reporter assays. 
Further experimentation could be carried out with the bovine p53 to determine 
whether the E7 oncoprotein was capable of inhibiting it. However due to the 
likelihood of inhibition by the mutant p53 in the tumorigenic cell lines this would 
have to be carried out in other cells with do not contain mutant p53 but have high 
E7 expression levels. Alternatively the use of in vitro translated proteins in an in 
vitro cell free reporter system could help determine whether this inhibition 
occurred in vivo.
Analysis of whether HPV could synergise with quercetin exposure in this 
in vitro system using primary human cell lines would be invaluable to determine 
quercetins contribution to oesophageal and gastric cancer. Also other chemicals 
such as ptaquiloside and a-ecdysone which are found in the bracken fern could be 
assayed singly, or in combination, for any synergy with the papillomavirus. The 
use of primary human cell lines would also permit a broader scope of analysis due 
to reagent availability for human systems.
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